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SUMMARY
Since the advent of recombinant DNA technology in the 1970s, various
microbial hosts have been employed for the efficient high-level heterologous
production of a variety of proteins, ranging from enzymes and reagents to
therapeutics and vaccines. More recent microbial hosts to be employed for
these purposes are filamentous fungi, and particularly the genus Aspergillus.
Aspergilli have been associated with industrial processes for many years and
are used in the production of antibiotics, enzymes, citric acid and Oriental foods
and beverages, and thus strains such as Aspergillus niger and Aspergillus
oryzae have been afforded GRAS (Generally Regarded 8s ~afe) status. They
also secrete copious amounts of homologous and heterologous proteins and
are able to perform post-translational modifications effectively. Various proteins
of pharmaceutical interest have been successfully expressed in Aspergillus, but
the potential of these fungi to produce heterologous viral proteins has not been
explored extensively.
In this study, we evaluated the potential of the filamentous fungi A. niger and
Aspergillus awamori as alternative hosts for the heterologous production of
hepatitis B viral proteins. Hepatitis B is a serious, potentially lethal liver disease
that affects 2000 million people world-wide and has a high endemicity in
Southern Africa. Currently there is no effective treatment for viral hepatitis and
thus a mass vaccination strategy is the only solution to curb the spread of the
disease. This kind of vaccination strategy requires a cheap, safe and effective
vaccine and these objectives have been achieved in the development of
recombinant subunit vaccines from yeasts such as Saccharomyces cerevisiae,
Hansenula polymorpha and Pichia pastoris that are commercially available.
The hepatitis B virus envelope consists of a membrane fraction and three
proteins, namely the major (S) protein (encoded by the S gene), the middle (M)
protein (encoded by the preS2S gene) and the large (L) protein (encoded by the
preS1preS2S gene). When produced in the above-mentioned yeasts, the S
protein was shown to spontaneously assemble into pseudoviral particles devoid
of viral DNA, which were then purified and used as vaccine.
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In the present study the Sand preS1preS2S genes from a local isolate of
hepatitis B subtype adw2 were placed under transcriptional control of the
constitutive Aspergillus nidulans glyceraldehyde-3-phosphate dehydrogenase
(gpdA) promoter and the inducible A. niger glucoamylase (glaA) promoter. The
respective viral genes were also fused to the region encoding the catalytic
domain of the highly expressed and secreted A. niger glucoamylase, which
served as a carrier moiety to possibly facilitate viral protein secretion. The
various gene constructs were subsequently transformed to laboratory strains of
A. niger and A. awamori and numerous transformants were obtained. One
A. niger transformant carrying the S gene under control of the gpdA promoter
contained approximately 7 integrated copies of the expression cassette and
produced hepatitis B pseudoviral particles intracellularly at levels of 0.4 mg/I
culture. These levels are approximately ten-fold higher than those initially
obtained from the yeast S.cerevisiae, which showed yields of 0.01 to
0.025 mg/I. None of the other transformants could be shown to produce
recombinant S or L protein and no secretion of viral protein could be
demonstrated. This could be attributed to numerous factors, including vector
copy number, site of integration or proteolytic activity. The most important
insight emerging from this work regarding secretion of heterologous viral protein
was that the addition of a carrier protein hampered, rather than enhanced
secretion of the viral envelope protein, due to the inherent properties of viral
protein assembly.
This work also serves as a "proof of principle", showing that Aspergillus is
indeed a viable alternative host for the production of hepatitis B pseudoviral
particles, and could be investigated further for its potential as host for the
heterologous expression of other viral proteins.
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OPSOMMING
Sedert die ontwikkeling van rekombinante DNA tegnologie in die sewentigerjare
is verskeie mikroorganismes reeds gebruik vir die doeltreffende produksie van
'n verskeidenheid proteïne teen hoë vlakke; onder andere ensieme, reagense,
terapeutiese middels en vaksiene. Onlangs is filamentagtige swamme, veral
van die genus Aspergillus, ontwikkel vir heteroloë proteïenproduksie. Aspergilli
word al vir baie jare in nywerheidsprosesse gebruik, onder andere in die
vervaardiging van antibiotika, ensieme, sitroensuur en sekere Oosterse
voedsel- en drankprodukte. As gevolg van hierdie jarelange gebruik van rasse
soos Aspergillus niger en Aspergillus oryzae, word hulle algemeen aanvaar as
veilig vir menslike gebruik. Hierdie swamme besit veral die vermoë om hoë
vlakke van homoloë en heteroloë proteïene uit te skei en die na-translasie-
modifisering van proteïene korrek uit te voer. Verskeie proteïene van
farmaseutiese belang is al suksesvol in Aspergillus uitgedruk, maar die
potensiaal van hierdie swamme om virale proteïene te vervaardig is nog nie
deeglik ondersoek nie.
Hierdie studie ondersoek die geskiktheid van die filamentagtige swamme
A. niger en Aspergillus awamori om as alternatiewe gashere vir die heteroloë
produksie van hepatitis B proteïene te dien. Hepatitis B is 'n ernstige en selfs
dodelike lewersiekte. Omtrent 2000 miljoen mense wêreld-wyd is met die virus
geïnfekteer en dit is veral endemies in Suiderlike Afrika. Daar is tans geen
doeltreffende behandeling vir virale hepatitis en dus is wêreld-wye
inentingsprogramme die enigste oplossing om die verspreiding van die siekte te
bekamp. Hierdie inentingsstrategie vereis die beskikbaarheid van 'n
bekostigbare, veilige en doeltreffende vaksien. Die rekombinante subeenheid-
vaksiene wat ontwikkel is deur van gashere soos Saccharomyces cerevisiae,
Hansenula polymorpha en Pichia pastoris gebruik te maak, voldoen aan hierdie
vereistes en is kommersieel beskikbaar. Die omhulsel van die hepatitis B virus
bestaan uit 'n membraangedeelte en drie proteïene, naamlik die hoofproteïen
(S) (gekodeer deur die S-geen), die middelproteïen (M) (gekodeer deur die
preS2S-geen) en die grootproteïen (L) (gekodeer deur die preS1preS2S-geen).
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Wanneer die S-proteïen in bo-genoemde giste uitgedruk word, vorm dit
spontaan pseudovirale partikels wat nie virale DNA bevat nie. Hierdie partikels
word dan gesuiwer en as vaksien gebruik.
In hierdie studie is die S- en preS1preS2S-gene, vanaf 'n plaaslike isolaat van
hepatitis B subtipe adw2, onder transkripsionele beheer van die konstitutiewe
Aspergillus nidulans gliseraldehied-3-fosfaat-dehidrogenasepromoter (gpdA) en
die induseerbare A. niger glukoamilasepromoter (glaA) geplaas. Die
onderskeie virale gene is ook aan die koderende gedeelte vir die katalitiese
domein van A. niger glukoamilase gelas om fusieproteïene te vorm.
Glukoamilase word teen hoë vlakke deur Aspergillus vervaardig en uitgeskei en
kan dus moontlik dien as draerproteïen om sekresie van die proteïne te
bevorder. Transformasie van die geenkonstrukte na laboratoriumrasse van
A. niger en A. awamori het verskeie transformante gelewer. Een A. niger
transformant bevattende die S-geen onder transkripsionele beheer van die
gpdA promoter het minstens sewe kopieë van die uitdrukkingskaset in sy
genoom geïntegreer en het hepatitis B pseudovirale partikels intrasellulêr teen
vlakke van 0.4 mg/I swamkultuur vervaardig. Hierdie vlakke is omtrent tien-
voudig hoër as die vlakke van 0.01 - 0.025 mg/I wat S.cerevisiae oorspronklik
opgelewer het. Nie een van die ander transformante het rekombinante S of L
proteïene vervaardig nie en sekresie van virale proteïen kon nie getoon word
nie. Hierdie verskynsel mag te wyte wees aan verskeie faktore insluitende
vektor-kopiegetal, setel van integrasie en proteolitiese aktiwiteit. Die
belangrikste insig uit hierdie studie aangaande sekresie van heteroloë virale
proteïene is dat die koppeling van die virale omhulsel-proteïen aan 'n
draerproteïen sekresie benadeel het, eerder as om dit te bevorder. Hierdie
verskynsel is te wyte aan die inherente geneigdheid van virale omhulsel-
proteïene om 'n kompleks te vorm.
Die studie dien ook as "bewys van beginsel" dat Aspergillus wel 'n werkbare
alternatiewe gasheer vir die produksie van hepatitis B pseudovirale partikels is,
en dat dit verder ondersoek sou kon word as potensiële gasheer vir die
heteroloë uitdrukking van ander virale proteïene.
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"Molecular biology is the art of the inevitable. If you do it, it's
inevitable you will find how it worbs - in the end."
Sydney Brenner
This thesis is dedicated to Gerhard and Ingrid Plliddemann
In loving memory of Harold and Lotte PlOddemann and Karl and Martha Kroll
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PREFACE
This thesis is presented as a compilation of manuscripts. Each chapter is
introduced separately and is written according to the style of the journal to
which the manuscript was submitted.
Chapter 3 "Evaluation of Aspergillus niger as host for virus-like particle
production using the hepatitis B surface antigen as a model" will be submitted to
Journal of Virology.
The South African Provisional Patent (no. 2001/9777) that has been filed
encompassing the work detailed in chapter 3 is provided as an Appendix.
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Chapter 1
Introduction
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1. INTRODUCTION
Hepatitis B is a serious, potentially lethal liver disease caused by the hepatitis B
virus (HBV) and there are an estimated 2000 million HBV carriers in the world
today (Vryheid et aI., 2001). The disease is especially prevalent in
underdeveloped areas of the world, such as Africa, where 60% to 99% of
healthy adults show evidence of exposure to HBV (Moradpour and Wands,
1995; Ayoola, 1988). In South Africa, more than 70% of the population has
been exposed to HBV, with an estimated 10% being carriers of the virus (Tsebe
et al., 2001). Hepatitis B surface antigen proteins have important functions in
the viral life cycle, such as attachment and penetration, envelopment and virus
maturation (Gerlich, 1991). These proteins also spontaneously assemble into
pseudoviral particles devoid of viral DNA and these particles play a role in
neutralising virus-eliminating immune reaction. Thus, these proteins have been
targeted for heterologous expression to produce recombinant vaccines. HBsAg
proteins are encoded by two adjacent regions of the HBV envelope gene,
namely the preS and the S region (Tiollais et aI., 1985). The S gene encodes
the major (S) protein (226 amino acids) which constitutes most of the HBV
envelope. S protein monomers can also spontaneously assemble into
pseudoviral particles of about 22 nm in size. The middle (M) protein is coded
for by the preS2-S gene and contains an additional 55 amino acids at the N-
terminus, while the large (L) protein is encoded by the preS1-preS2-S gene and
is 389 amino acids in size. No effective treatment for this disease currently
exists and an extensive programme of vaccination presents the only solution to
curb the spread of the disease (Kassianides et aI., 1988; Dehoux et aI., 1986).
In order to make a mass vaccination strategy feasible, large amounts of safe,
affordable vaccine must be available. Recombinant DNA methods have
provided an alternative to the blood-origin vaccine obtained from plasma of
chronic carriers and to date, bacteria, yeasts and mammalian cells transformed
with appropriate expression vectors are able to synthesise hepatitis B surface
antigen (HBsAg) for immunisation purposes (Dehoux et aI., 1986; Valenzuela
et aI., 1982; Michel et aI., 1984).
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2Since the 1980's genetic engineering procedures have been developed for the
filamentous fungi, in particular aspergilli (Kinghorn and Unkles, 1994).
Subsequently various heterologous proteins of fungal and non-fungal origin
have been expressed in these fungi (Gouka et a/., 1997; Kinghorn and Unkles,
1994; Verdoes et al., 1995). The use of the yeast Saccharomyces cerevisiae
as heterologous host for the production of pharmaceutical (viral) proteins has
already highlighted limitations, such as low product and biomass yields, lack of
very strong, tightly regulated promoters and hyperglycosylation of glycoproteins
(Romanos et aI., 1992). This initiated a search for alternative heterologous
hosts, and non-Saccharomyces yeasts (e.g. Pichia pastoris, Hansenu/a
po/ymorpha, K/uyveromyces /actis) as well as filamentous Aspergillus species
have gained increasing importance as hosts for the production of eukaryotic
proteins in particular. Several characteristics of filamentous fungal expression
hosts give them potential advantages over S. cerevisiae. These include the
production of fungal proteins (homologous and heterologous) in copious
amounts; their extensive use in the production of enzymes, citric acid and
Oriental foods; efficient post-translational modification of proteins and effective
secretion of heterologous proteins (Harvey and McNeil, 1994; Kinghorn and
Unkles, 1994). Viral protein production in filamentous fungi has not been
extensively evaluated to date, and the hepatitis B viral proteins provide the ideal
basis for such an evaluation. Furthermore, new fungal systems offer
alternatives for the commercial production of proteins already encumbered by
process patent applications involving other systems.
1.1. Aims of the study
This study comprised an investigation into the potential of the filamentous
fungus Aspergillus to produce hepatitis B virus envelope proteins and serve as
a possible alternative vaccine production system. The specific aims of the
study were:
1. Cloning of the hepatitis B S gene encoding the major viral surface antigen
under control of the inducible Aspergillus niger glucoamylase (g/aA)
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3promoter and the constitutive Aspergillus nidulans glyceraldehyde-3-
phosphate dehydrogenase (gpdA) promoter.
2. Cloning of the hepatitis B preS1preS2S gene, encoding the large viral
envelope protein, under control of the inducible A. niger glucoamylase (glaA)
promoter and the constitutive A. nidulans glyceraldehyde-3-phosphate
dehydrogenase (gpdA) promoter.
3. Construction of an in-frame fusion, separated by a dibasic proteolytic
cleavage site, between the catalytic domain of the A. niger glucoamylase
and the Sand preS1preS2S genes, respectively, in order to enhance
secretion of the viral proteins.
4. Transformation of the various expression vectors to laboratory strains of
A. niger and Aspergillus awamori and evaluation of intracellular and
extracellular recombinant viral protein production.
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Chapter 2
Literature Review
Filamentous Fungi: Vaccine factories of the
future?
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52. FILAMENTOUS FUNGI: VACCINE FACTORIES OF THE
FUTURE?
2.1. Introduction
Fungi commonly receive negative attention for their harmful effects, such as
causing disease and food spoilage, and they have proven themselves a force to
be reckoned with for anyone who has ever tried to keep a bathroom mould-free!
Despite all these negative aspects generally associated with fungi, they can
rather be considered as "unsung heroes" with all the benefits that they have
afforded humans. In the last century they have quietly been harnessed for the
production of antibiotics (thereby removing the threat of many a bacterial
infection), enzymes, fermented foods, vitamins, pharmaceuticals and organic
acids, to name just a few (Alexopoulos and Mims, 1979). Filamentous fungi can
now be considered to be "microbial factories", effectively and efficiently
providing us with products we require every day. With the advent of gene
technology, this capability has been further expanded and now fungi are
employed to produce not only homologous, but heterologous proteins as well
(Davies, 1994; Kinghorn and Unkles, 1994; Van den Hondel et al., 1991). The
technology of heterologous protein production by microorganisms was
pioneered in the prokaryotic host Escherichia coli in the 1970s and
subsequently expanded to eukaryotic yeasts, particularly Saccharomyces
cerevisiae (Hadfield et ai., 1993). Today, filamentous fungi, in particular
aspergilli, are emerging as another important eukaryotic host for the cost-
effective production of functional proteins from a variety of sources (Davies,
1994; Van den Handel et ai., 1991). With the increasing demand for vaccines
as a means to control and eradicate disease and the inherent advantages of
filamentous fungi as protein production systems, the evaluation of Aspergillus
for the production of immunogenic viral proteins has emerged as a promising
alternative to the current vaccine production technologies.
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62.2. The fungus Aspergillus
The first person to study the aspergilli was a priest by the name of Micheli in
1729, who published Nova Plantarum Genera in which his microscopical
research on fungi was included, distinguishing stalks and spore heads
(Alexopoulos and Mims, 1979; Raper and Fennell, 1965). He noted that the
spore chains or columns radiated from a central structure to produce a pattern
that suggested the aspergillum (a device used to sprinkle holy water) and thus
he applied the name Aspergillus to the moulds he observed. Species of
Aspergillus belong to the first fungal organisms that were cultivated on artificial
media and studied for their biochemical properties and they are one of the most
common fungi found in man's environment (Samson, 1994). Since ancient
times, Aspergillus species have been used in fermentation of food in Japan and
other Asian countries and the early discovery of their ability to produce organic
acids was made at the turn of the century. By 1928 more than 2000 papers had
been published which in some way concerned aspergilli (Raper and Fennell,
1965).
2.2.1. Taxonomy
Various criteria are employed in the classification and identification of
filamentous fungi. Morphological structures are still important for classification
and Aspergillus species typically produce the aspergillum, a conidiophore with
an aseptate stipe terminating in a vesicle, on which the conidiogenous cells
(phialides and metulae) are borne (Samson, 1994). The phialides produce
conidia in long chains with different pigmentation and ornamentation.
Furthermore, colony colour and diameter, characteristics of the vegetative
mycelium as well as pigments produced provide a basis for classification. More
recently, several new approaches have also been employed in the identification
and classification of aspergilli. These include profiles of secondary metabolites
(Rahbaek et et., 2000), steroid transformation (Mostafa, 1995), isozyme
analysis (Kozlowski and Stepien, 1982; Loudon and Burnie, 1995) nuclear
restriction fragment length polymorphisms (RFLPs) combined with DNA probes
(James et al., 2000), ribosomal banding patterns and mitochondrial RFLPs
(Varga et al., 1994). Polymerase chain reaction (PCR)-based methods that
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gene (Yokoyama et aI., 2001), internal transcribed spacer (ITS) regions of the
ribosomal DNA (Henry et aI., 2000; Kumeda and Asao, 1996; Zhao et aI., 2001)
and the utilisation of sequence-specific DNA primers of RAPD (random
amplified polymorphic DNA) fragments (Mondon et al., 1997). The black
aspergilli (Aspergillus section Nigri, which includes Aspergillus niger and
Aspergillus awamon) have always been an important group in biotechnology
and their taxonomy was based primarily on morphological criteria (Kusters-van
Someren et aI., 1991). This hampered the taxonomy as morphology is
determined by both genetic and environmental factors and morphological
criteria are rather subjective. Furthermore, distinct morphological differences
may be caused by simple mutations and are thus not always reliable for
establishing genetic relationships. The integration of molecular, physiological
and biochemical methods has recently facilitated the understanding of the
classification of aspergilli (Samson and Pitt, 2000). Currently it is accepted that
the genus Aspergillus belongs to the family Trichocomaceae and contains 182
species with eight holomorphic genera accepted as being associated with
Aspergillus anamorphs, namely Chaetosartorya, Emericella, Eurotium,
Fennellia, Hemicarpenteles, Neosartorya, Petromyces and Sclerocleista (Pitt
et al., 2000). Aspergillus and its teleomorphs have been divided into three
subgenera and 15 sections (Peterson, 2000). The biotechnologically important
Aspergillus oryzae belongs to the subgenus Aspergillus, section Flavi, whereas
A. niger and A. awamori are grouped in the subgenus Aspergillus section Nigri
(Peterson, 2000). Aspergillus nidulans is phylogenetically distinct from these
strains and has been grouped in subgenus Nidulantes, section Nidulantes.
2.2.2. Physiology and Life cycle
Fungi of the genus Aspergillus occur in a wide variety of habitats, such as soil,
stored food and feed products and decaying vegetation (Kozakiewicz and
Smith, 1994). They grow readily at temperatures between 15 and 30°C with
some tolerating temperatures as low as 3°C and as high as 65°C. A. niger has
a temperature range of 9 to 60°C with a temperature optimum of 17 to 42°C.
Aspergilli can also tolerate a wide range of pH, with A. niger able to grow over a
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been identified and seven of the eight have been correlated with a specific band
in the electrophoretic karyotype (Debets et al., 1993; Swart et al., 1994). Some
species of Aspergillus exhibit an ascosporic stage, but for most aspergilli the
teleomorph is unknown (Raper and Fennell, 1965). For the anamorph
A. nidulans the teleomorph has been identified and was named Emericella
nidulans and a graphic representation of the life cycle of the holomorph is given
in Figure 1 (Pitt et al., 2000).
Sexual cycle
meiosis
recom bination
---£
~
• nuclear eXChang~
(
hyphal anastomosis heterokaryon
Parasexual cycle
mitosis
haploidisation
mitotic recombination~---..
ascus
Asexual cycle
mitosis
conidiophore
conidium
~
initial c1eistothecium
Figure 1. Life cycle of A. nidulans (Martinelli, 1994).
2.2.3. Industrial uses
For centuries fungi have been found to be both useful and harmful to humans
(Alexopoulos and Mims, 1979). Fungi are the agents responsible for much of
the disintegration of organic matter and as such they affect man directly by
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9destroying food, fabrics, leather and other consumer goods manufactured from
raw materials subject to fungal attack. They cause the majority of known plant
diseases and many diseases of animals and humans. Furthermore, they are
the basis of a number of industrial processes involving fermentation, such as
the fermentation of the cacao bean and the preparation of certain cheeses.
They are employed in the commercial production of many organic acids, some
drugs such as ergometrine and cortisone and some vitamin preparations, and
are responsible for the manufacture of a number of antibiotics, particularly
penicillin and griseofulvin.
2.2.3.1. Citric acid production
Citric acid is the most important organic acid produced by modern
biotechnological means (Bodie et aI., 1994). It is commercially used as an
acidulant in the food and pharmaceutical industries. In the food industry it is
used in foods such as soft drinks, fruit juices, desserts, jams and jellies, candy
and wine. In the pharmaceutical industry iron citrate is used as a source of iron
and citric acid as a preservative for blood. Citric acid is also used in cosmetics
and toiletries as a buffer, for pH adjustment and as an anti-oxidant. It is also
used as a chelating and sequestering agent and citrate and citrate esters are
used as plasticizers (Casida, 1968). At the beginning of the last century, citric
acid could only be obtained commercially from citrus fruits (Johnson, 1954).
Today, however, the product is obtained by fungal fermentation. The
development of citric acid fermentation may be divided into three historical
phases. The first phase started in 1893, with the discovery that certain
Penicillium species produced citric acid. Various attempts were made to utilise
this process commercially and many of these failed due to problems with
contamination, selection of proper organisms, long fermentation time and high
plant construction costs.
In 1917 during World War 1 it was discovered that A. niger is an excellent citric
acid producer, marking the beginning of the second historical phase of citric
acid production. During this phase, citric acid was produced by means of a
surface culture method and since then a large amount of research has
contributed to our knowledge of citric acid fermentation. The third phase was
\..
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inaugurated in 1938 when submerged culture methods supplanted the surface-
culture methods. Advantages of submerged cultures include lower labour cost,
higher yield, shorter time cycle, simpler operation and easier maintenance of
asepsis. The main factors that are especially important for production in a
submerged process include mycelium morphology, medium composition, pH,
aeration and high quality materials used for fermenter construction (Bodie et al.,
1994). The most commonly used substrate for fermentation is beet molasses, a
by-product of the sugar industry containing 10 to 20% sugar. Optimal yields of
citric acid have been observed at sugar concentrations of 10% (w/v) (Xu et al.,
1989). High level accumulation of citric acid by A. niger is induced by a nutrient
deficiency in the form of trace metals or phosphate. Fermentation is carried out
at 28 to 30°C and the citric acid yield is in the order of 60 to 80 g of anhydrous
citric acid per 100 g sugar (Kiel et al., 1981). The inoculant consists of a high
concentration of spores to produce an optimal form of pellet growth. Pellets are
0.1 to 0.5 mm in diameter, consisting of stubby mycelia with many swellings and
with a granulated and vacuolated structure (Calam, 1986). Various strategies
are continuously studied to improve the citric acid yield. One of these was a
study on the effect of C02 on microbial growth (Mcintyre and McNeil, 1997).
Low levels of dissolved CO2were shown to stimulate growth, but at high levels
of CO2 there was a reduced growth rate, thus decreasing biomass
concentration. The morphology of A. niger was also affected by higher CO2
levels in that longer hyphae were present rather than the pellets with short
stubby lateral hyphae, which are commonly accepted to be essential in
achieving high citric acid yields.
2.2.3.2. Enzyme production
The major applications for industrial enzymes are in the manufacture of foods
and beverages, waste-water treatment and the manufacturing of fine chemicals
(Bodie et aI., 1994). The current world market for industrial enzymes is
estimated at US$1.5 billion a year and a significant growth is predicted for the
future (refer to Table 1) (Maister, 2001). Filamentous fungi are sources of about
40% of available enzymes (Archer and Peberdy, 1997). One of the industrially
important enzymes produced by Aspergillus is glucoamylase (EC 23.2.1.3), also
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referred to as amyloglucosidase (Bodie et aI., 1994). This is an exoamylase
that catalyses the release of successive glucose units from the non-reducing
ends of starch by hydrolysing a-1,4-D-glucosidic linkages. The glucose syrup
and alcohol industries are the principal users of glucoamylase for
saccharification of liquefied starch. Aspergilli such as A. niger produce two
forms of glucoamylase, namely GA1 (Mr 85 300) and GA2 (Mr 77 600). Both
forms are glycosylated and are capable of hydrolysing oligosaccharides, but
GA1 hydrolyses starch nearly three times more rapidly than GA2. Both forms of
A. niger glucoamylase are encoded by the single copy glaA gene and secreted
proteases and/or glycosidases are involved in the generation of the different
forms of GA in the culture broth.
Table 1. Global sales (US$ Mio.) of industrial enzymes from 1992 to 1998 and projected to
2009 (Godfrey, 2001).
YEAR GLOBAL SALES (US $ MlO) % CHANGE
1992 500
1993 600 +20
1994 720 +20
1995 780 +8
1996 950 +22
1997 1200 +26
1998 1300 +8
2005 predicted 1700 +5 average
2009 predicted 2250 +8.1 average
Many other important enzymes are produced by aspergilli. a-Amylase is also
used in commercial starch saccharification (Bodie et aI., 1994). Pectinolytic
enzymes are used in the production of fruit juice and wine for increased juice
extraction and juice clarification. Lactase is used as a digestive aid and
proteases are used in the fermentation of wheat, soybeans and rice in the
manufacture of Asian foods and beverages such as shochu, miso and sake, in
beer brewing for haze clarification and in meat tenderisation. Glucose oxidase
is used in the determination of glucose concentrations in body fluids and is also
a component of other diagnostic enzyme kits. Other industrially important
enzymes include catalase, cellulase, lipase, xylanase and phytase. It is clear
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that enzymes from aspergilli are being used in a large variety of industries,
making these fungi essential for our everyday lives.
Thus, with the established industrial importance and fermentation technology,
filamentous fungi, especially Aspergillus species, were attractive hosts for the
development of heterologous protein production systems.
2.3. Development of filamentous fungi as hosts for
heterologous protein production.
To develop a heterologous protein expression system for a particular host a
plasmid is required which contains all the information necessary for expression
of the protein of interest and a transformation method for the host. The basic
components of plasmids are (1) a gene that can be used for the selection of
fungal transformants, (2) transcription elements for expression and, in the case
of secreted proteins, secretion signals to direct protein production outside the
cell and (3) bacterial plasmid sequences that can be used for selection and
propagation of the plasmid in E. coli. Sometimes sequences for selection of
plasmids in yeast or other alternative hosts are also included (Timberlake,
1991).
2.3.1. Selectable markers
Selective markers can be divided into at least three functional groups: genes
that complement pre-existing mutations and lead to prototrophic growth
(auxotrophic markers), genes that provide a new function and lead to drug
resistance or growth on a previously non-utilisable nutrient source (drug
resistance or added-function markers, also referred to as dominant selectable
markers) and DNA fragments that give rise to selectable mutations when
integrated into the genome of the recipient strain at specific locations
(mutagenic markers). Each type of marker has specific uses, and in some
cases it is advantageous to use combinations of markers.
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2.3.1.1. Dominant selectable markers
Dominant selectable markers, also referred to as inhibitor resistance markers,
can be used in transformation of both wild-type and mutant fungal strains and
several of these markers are "broad-host range" markers which can be
employed in different fungal species (Turner, 1994; Van den Handel and Punt,
1991). Most of these markers are based on drug resistance, as reviewed by
Van den Handel and Punt (1991). Drug resistance markers that have been
successfully employed in fungal transformation include genes conferring
resistance to oligomycin, bleomycin, phleomycin, hygromycin and benomyl
(Austin et al., 1990; Dunne and Oakley, 1988; Kolar et al., 1988; Punt et aI.,
1987; Ward et al., 1988). The 0liC3 gene of A. niger encoding an oligomycin-
resistant allele of subunit 9 of the mitochondrial ATP synthetase complex
confers resistance against oligomycin to A. niger recipient strains (Ward et al.,
1988). Similarly the A. nidulans 0liC31 allele confers resistance against the
antibiotic to A. nidulans, however the A. nidulans gene is not able to act as a
marker in A. niger, indicating the species specificity of this marker and thereby
limiting its wide-spread use. Bleomycin and phleomycin are very closely related
classes of metalloglycopeptide antibiotics produced by Streptomyces verticil/us
(Austin et al., 1990). They are cytotoxic because they cause single-stranded
and double-stranded breaks in DNA. The bleomycin and phleomycin
resistance-encoding gene bIe obtained from the bacterial transposon Tn5 has
been used successfully in Neurospora crassa as well as A. nidulans, Penicillium
chrysogenum, Schizophyllum commune and Trametes versicolor when placed
under control of a fungal promoter and terminator (Austin et al., 1990;
Bartholomew et al., 2001; Kolar et al., 1988). Hygromycin resistance is
conferred by the E. coli hygromycin B phosphotransferase gene (hph) (Punt
et aI., 1987). This marker was also placed under control of a fungal promoter
and terminator and used effectively in transformation of fungi such as
A. nidulans, A. niger and the nematode-trapping fungus Arfhrobotrys oligospora
(Punt et al., 1987; Tunlid et al., 1999). In using antibiotic resistance markers,
however, the sensitivity of the host strain to the antibiotic is a critical factor as
some fungi have low sensitivity to some of the antibiotics. For example, at least
1 gIl hygromycin B is required to select for A. nidulans hygromycin B resistant
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transformants (Punt et al., 1987), and P. chrysogenum grows at concentrations
of more than 1 g/I hygromycin B (Kolar et al., 1988). Recently, a homologous
drug-resistant marker gene has been developed for Pleurotus ostreatus (Irie
et al., 2001b). The marker gene CbxR encodes a mutant iron-sulphur protein
subunit of succinate dehydrogenase and confers dominant resistance to a
systemic fungicide, carboxin.
One of the most commonly used dominant markers is the amdS gene from
A. nidulans that encodes the enzyme acetamidase (E.C.3.5.1.4) which
hydrolyses acetamide to acetate and ammonium, permitting utilisation of
acetamide as sole carbon and/or nitrogen source (Hynes, 1972; Hynes, 1973).
It has been widely used as a dominant marker since fungi such as A. nidulans
are insensitive to many antibiotics (Wernars et al., 1985). Caesium chloride is
added to the medium for reduction of background growth (Huge-Jensen et al.,
1989; Kelly and Hynes, 1985). In A. nidulans one copy of the amdS gene is
sufficient for growth on acetamide, however growth on acrylamide is only
possible if several copies of the gene are present (Van den Handel et al., 1992).
The 1.5 kb amdS gene containing three small introns is located on chromosome
III of A. nidulans. Acetamidase production is subject to multiple controls
including nitrogen and carbon catabolite repression and induction by co-amino
acids, acetate and benzoate (Hynes, 1978). Therefore, production of the
enzyme is regulated by several trans-acting regulatory genes affecting specific
control mechanisms, as well as cis-acting regulatory sites closely linked to the
structural genes (Corrick et aI., 1987; Hynes, 1979; Hynes, 1980; Hynes et aI.,
1983). Trans-acting regulatory genes involved in amdS induction by small
molecular weight effectors include amdR (co-aminoacids), facB (acetate) and
amdA (acetate) (Apirion, 1965; Arst, 1976; Hynes and Davis, 1986). The areA
gene is also a major activator involved in nitrogen metabolite repression of
amdS, where the availability of easily metabolisabie nitrogen sources such as
ammonium or glutamine represses amdS expression (Hynes, 1972; Hynes,
1973). Since wild-type strains of A. nidulans do not grow strongly on acetamide
medium it is possible to detect over-producing strains directly by their increased
growth, and so amdS was one of the first genes used as selective marker for
A. nidulans transformations (Hynes and Davis, 1986; Tilburn et al., 1983). This
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marker has since been successfully used to transform various fungi such as
A. niger (Kelly and Hynes, 1985), Trichoderma reesei (Pentilta et al., 1987),
P. chrysogenum (Beri and Turner, 1987; Kolar et aI., 1988) and the plant
pathogen Cochliobolus heterastraphus (Hynes, 1986). The homologous amdS
gene from A. oryzae has also been isolated (Gomi et aI., 1991). Transformation
occurs by homologous or non-homologous integration of vector DNA into the
genome and frequently multiple copies of the vector are present in tandem
repeats (Beri and Turner, 1987; Kelly and Hynes, 1985; Pentllla et al., 1987;
Wernars et al., 1985). It is not known whether multi-copy transformants are
generated by repeated integration events of plasmid monomers or by the
formation of concatamers followed by a single integration event (Hynes, 1986).
However, very high copy numbers of amdS have been shown to cause titration
of trans-acting regulatory proteins, especially the amdR regulatory gene product
(Arst, 1976; Arst et al., 1978; Kelly and Hynes, 1987).
2.3.1.2. Auxotroph complementation
Transformation of nutritional mutants with cloned, wild-type genes requires the
availability of an appropriate, cloned, prototrophic gene and stable, matching
mutant (Turner and Ballance, 1985). In the initial transformation of N. crassa,
the N. crassa qa-2+ gene encoding catabolic dehydroquinase (3-dehydroquinate
hydrolyase, EC 4.2.1.10) required for the catabolism of quinic acid, was used to
obtain transformation of N. crassa qa-2 aram-9 mutants (Case et al., 1979).
The qa-2 gene was first obtained by complementation of an E. coli ara mutation
and subsequently other fungal genes have been isolated in a similar manner
and have been employed as nutritional markers in fungal transformation
(Hynes, 1986). Some of the markers used (e.g. pyrG, niaO and trpC) have
proven to be very useful, since they are functional in several species (Van den
Hondel and Punt, 1991) (refer to Table 2).
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Table 2. Auxotrophic markers used for homologous and/or heterologous transformation of
filamentous fungi.
Marker Species from which Encoded protein First transformed Reference
marker is derived species
acuA Ustilago maydis acetyl-coA synthase U. maydis Hargreaves and
Turner, 1989
acuD Aspergillus nidulans isocitrate lyase A. nidulans Ballance and
Turner, 1986
ade-2 Schizophyllum unknown Phanerochaete Alic et al., 1989
commune chrysosporium
am Neurospora crassa glutamate N. crassa Kinsey and
dehydrogenase Rambosek,
1984
amdS A. nidulans acetamidase A. nidulans Tilburn et al.,
1983
Aspergillus niger Kelly and
Hynes, 1985
Penicillium Beri and Turner,
chrysogenum 1987
argB A. nidulans L-ornithine- A. nidulans John and
carbamoyl-transferase Peberdy, 1984
A. niger Buxton et aI.,
1985
Aspergillus oryzae Gomi et aI.,
1987
Trichoderma reesei Pentillá et al.,
1987
facA P. chrysogenum acetyl-coenzyme A P. chrysogenum Gouka et al.,
synthetase 1993
inl N. crassa unknown N. crassa Akins and
Lambowitz,
1985
leu Mucor circinelloides unknown M. circinelloides Van Heeswijck
and Roncero,
1984
met A. oryzae unknown A. oryzae limura et aI.,
1987
met-2 Ascobolus immersus homoserine-O-trans A. immersus Goyon and
acetylase Faugeron, 1989
niaD A. nidulans nitrate reductase A. nidulans Malardier et al.,
1989
Fusarium Malardier et al.,
oxysporum 1989
P. chrysogenum Whitehead
et aI., 1989
niaD A. niger nitrate reductase A. niger Campbell et al.,
1989; Unkles
etaI., 1989a
A. nidulans Campbell et al.,
1989
A. oryzae Campbell et al. ,
1989
P. chrysogenum Campbell et al. ,
1989;
Whitehead
et aI., 1989
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Table 2. Continued.
Marker Species from which Encoded protein First transformed Reference
marker is derived species
niaO A. oryzae nitrate reductase A. oryzae Unkles et aI.,
A. nidulans 1989b
A. niger
P. chrysogenum
niaO P. chrysogenum nitrate reductase P. chrysogenum Gouka et al.,
1991
nic-1 N. crassa unknown N. crassa Akins and
Lambowitz,
1985
Nit1 Fusarium oxysporum nitrate reductase F. oxysporum Garcia-Pedrajas
and Roncero,
1996
pkiA A. nidulans pyruvate kinase A. nidulans De Graaff et al.,
1988
pm A. nidulans proline catabolism A. nidulans Durrens et a/.,
1986
pyr-3 U. maydis dihydroorotase U. maydis Banks and
Taylor, 1988
pyr-4 N. crassa orotidine-5'-phosphate A. nidulans Ballance et a/.,
decarboxylase 1983
Aspergillus flavus Woloshuk et al.,
1989
pyr-6 U. maydis orotidine-5'-phosphate U. maydis Kronstad et al.,
decarboxylase 1989
pyrG Aspergillus awamori orotidine-5'-phosphate A. awamori Gouka et al.,
decarboxylase 1995
pyrG A. nidulans orotidine-5'-phosphate A. nidulans Oakley et aI.,
decarboxylase 1987a
pyrG/A A. niger orotidine-5'-phosphate A. niger Goosen et al.,
decarboxylase 1987;Van
Hartingsveldt
et aI., 1987
A. nidulans Goosen et al.,
1987
A. oryzae Mattern et aI.,
1987
pyrG A. oryzae orotidine-5'-phosphate A. oryzae De Ruiter-
decarboxylase A. niger Jacobs et al.,
1989
pyrG Aspergillus parasiticus orotidine-5'-phosphate A. parasiticus Skory et a/.,
decarboxylase 1990
pyrG M. circinelloides orotidine-5'-phosphate M. circinelloides Benito et aI.,
decarboxylase 1992
pyrG Claviceps purpurea orotidine-5'-phosphate C. purpurea Smit and
decarboxylase A. niger Tudzynski, 1992
pyrG Solorina crocea orotidine-5'-phosphate A. nidulans Sinnemann
decarboxylase etaI., 2000
pyroA A. nidulans unknown A. nidulans Van den Hondel
and Punt, 1991
qa-2 N. crassa catabolic N. crassa Case et aI.,
dehydroquinase 1979
qUTE A. nidulans catabolic A. nidulans Da Silva et al.,
dehy_droquinase 1986
riboB A. nidu/ans unknown A. nidulans Oakley et a/.,
1987b
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Table 2. Continued.
Marker Species from which Encoded protein First transformed Reference
marker is derived species
sC1 A. nidulans ATP sulphurylase A. nidulans Buxton et al.,
1989
sA A. nidulans phosphoadenosyl A. nidulans Turner, 1994
phosphosulphate
reductase
trp-1 Cochliobolus trifunclional enzyme A. nidulans Turgeon et aI.,
heterostroph us of tryptophan 1986
biosynthesis*
tro-t Coprinus cinereus trifunctional enzyme C. cinereus Binninger et al.,
of tryptophan 1987
biosynthesis*
tro-t S. commune trifunctional enzyme S. commune Munoz-Rivas
of tryptophan etal., 1986
biosynthesis* C. cinereus Casselton and
De la Fuente
Herce, 1989
tro-t N. crassa trifunctional enzyme N. crassa Kim and
of tryptophan Marzluf, 1988
biosynthesis*
trp-3 N. crassa tryptophan synthetase N. crassa Vollmer and
Yanofsky, 1986
trpC A. nidulans trifunctional enzyme A. nidulans Yelton eta!.,
of tryptophan 1984
biosynthesis* A. niger Goosen et al.,
1989
trpC A. parasiticus trifunctional enzyme A. nidulans Horng et al.,
of tryptophan 1989
biosynthesis*
trpC P. chrysosporium trifunctional enzyme C. cinereus Casselton and
of tryptophan De la Fuente
biosynthesis* Herce, 1989
trpC P. chrysogenum trifunctional enzyme P. chrysogenum Picknett et aI.,
of tryptophan 1987; Sanchez
biosynthesis* et aI., 1987
A. nidulans Picknett et al.,
1989
ura3 T. reesei orotidine-5'-phosphate T. reesei Berges and
decarboxylase Barreau, 1991
ura5 T. reesei orotate T. reesei Berges and
phosphoribosyl Barreau, 1991
transferase
ura-5 Podospora anserina orotidylic acid P. anserina Begueret et aI.,
pyrophosphorylase 1984
*encodes for glutamine arnidotransferase, Indoleglycerolphosphate synthetase and
phosphoribosylanthranilate isomerase
The most common selection systems based on complementation include use of
the cloned trpC, argB, niaD and pyrG genes, as these were the earliest markers
where mutant recipient strains were already available (John and Peberdy, 1984;
Johnstone, 1985; Turner, 1994; Unkles et aI., 1989b). The trpC gene
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complements mutants lacking phosphoribosylanthanilate isomerase activity and
was isolated from A. nidulans by complementation of an E. coli trpC mutant
(Yelton et aI., 1983). The A. nidulans argB gene encodes ornithine carbamoyl
transferase (E.C.2.1.3.3.), an enzyme involved in arginine biosynthesis, and
was cloned by complementation of the yeast arg3 mutation (Berse et al., 1983).
This gene has been used to transform argB- mutants of A. nidulans, A. niger,
A. oryzae and T. reesei (Buxton et al., 1985; Gomi et al., 1987; John and
Peberdy, 1984; Pentilla et al., 1987). In the nitrate assimilation pathway, the
niaO gene codes for the nitrate reductase apoprotein (EC 1.6.6.8). This gene
has been cloned from fungi including A. nidulans, A. niger and A. oryzae and
has been employed in the transformation of various fungal species (Malardier
et aI., 1989; Unkles et aI., 1989b; Unkles et aI., 1989a). The pyrG gene codes
for the enzyme orotidine-5'-phosphate decarboxylase (EC4.1.1.23) which
catalyses the final enzymatic step in the de novo biosynthesis of uridine
monophosphate (UMP) (Benito et aI., 1992). Therefore, pyrG- mutants are
auxotrophic for uracil or uridine (Goosen et aI., 1987). The equivalent N. crassa
pyr-4 gene was first used to successfully transform a pyrG- A. nidulans strain,
demonstrating that a gene from one euascomycete can function in another
(Ballance et al., 1983). Subsequently, the pyrG genes of fungi such as A. niger,
A. nidulans, A. oryzae, A. awamori, Claviceps purpurea, Mucor circinelloides
and Solorina crocea have been isolated and employed in the development of
transformation systems (Benito et al., 1992; De Ruiter-Jacobs et al., 1989;
Goosen et aI., 1987; Gouka et et., 1995; Mattern et aI., 1987; Oakley et al.,
1987a; Sinnemann et aI., 2000; Smit and Tudzynski, 1992; Van Hartingsveldt
et al., 1987;). The popularity of these genes as selective markers is due to (1)
their early cloning in the development of fungal transformation systems, (2) the
ready availability of the corresponding mutant strains, and (3) the simplicity and
dependability of selection schemes for transformants (Timberlake, 1991).
Markers such as pyrG and niaO are also attractive markers for developing a
gene transfer system in poorly characterised fungal species, since the required
mutants can be isolated by positive selection (Van den Hondel and Punt, 1991).
In the case of pyrG they can be isolated by resistance to 5-fluoro-orotic acid
(Goosen et al., 1987; Mattern et aI., 1987; Smit and Tudzynski, 1992; Van
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Hartingsveldt et al., 1987) and in the case of niaO, by resistance against
chlorate (Gouka et al., 1991; Unkles et aI., 1989a).
2.3.1.3. Mutagenic Markers
In yeast and some filamentous fungi, plasmids carrying DNA fragments from the
recipient species often integrate into the chromosome by homologous
recombination (Timberlake, 1991). This integration often leads to loss of gene
function and can sometimes be used for selection of the integration event and
also transformation. For example, integration of an internal fragment of the
A. nidulans pyrG gene will lead to loss of orotidine-5'-phosphate decarboxylase,
which can be selected for by resistance to 5-fluorootic acid, as described above.
2.3.2. Promoters
For efficient heterologous expression, the gene of interest must be flanked by
transcription control sequences that are functional in the host organism (Van
den Hondel et a/., 1991). S. cerevisiae promoters have generally not been used
successfully to drive gene expression in filamentous fungi, which implies that
transcription control sequences probably differ fundamentally from the
corresponding sequences of S. cerevisiae (Hynes and Andrianopoulos, 1989;
Van den Hondel et a/., 1991). In filamentous fungi consensus TATA-boxes
have been found in very few fungal promoters. Some genes possess TATA-like
sequences at the expected position, while others simply have an AT-rich region
30-100 bases upstream of the transcription start point. Sequences related to
the CAAT consensus have also been described. For a review see Ballance,
1986; Ballance, 1991 and Jeenes et a/., 1991. In some cases, remarkably short
(± 50 bp) upstream sequences can initiate transcription precisely in filamentous
fungi, which may explain why transcriptional signals appear to transfer so
readily between filamentous fungi (Hamer and Timberlake, 1987; Punt et aI.,
1990; Van den Hondel et aI., 1991). Various promoters from filamentous fungi
have been isolated which include constitutive and regulated promoters (refer to
Table 3) (Van den Hondel et aI., 1991). One of the strongest inducible
promoters available to date is the alcohol dehydrogenase I (aIcA) promoter,
which shows low expression on glucose, but is strongly induced by ethanol or
Stellenbosch University http://scholar.sun.ac.za
21
threonine under glucose depleted conditions (Devchand et aI., 1989; Gwynne
et a/., 1989; Hintz and Lagosky, 1993). Other regulatable strong promoters
include the glucoamylase (glaA) promoter of A. niger, A. oryzae and
A. awamori; the Taka-amylase A gene promoter (amyB) of A. oryzae and the
A. awamori 1,4-I3-endoxylanaseA (exIA) promoter (Fowler et aI., 1990; Gouka
et a/., 1996a; Hata et a/., 1992; Kanemori et a/., 1999; Nunberg et aI., 1984).
The g/aA and amyB promoters are all inducible by starch or maltose and
repressed by xylose or glycerol, while the exlA promoter is strongly inducible by
D-xylose.
Table 3. Fungal promoters used for heterologous protein production.
Organism Promoter Encoded protein Typea Heterologous Hosts Reference
Aspergillus amyA a-amylase I A. awamori Korman et al., 1990
awamori amyB a-amylase I A. awamori Korman et al., 1990
exlA 1,4-~- I A. awamori Gouka et aI., 1997a;
endoxylanase A Van Gemeren et al.,
1996;
gdhA glutamate C A. awamori Moralejo et al., 1999
dehydrogenase
glaA glucoamylase I A. awamori Dunn-Coleman et al.,
1991
Aspergillus nidulans Dunn-Coleman et al.,
1991
Aspergillus niger Archer et al., 1990a
A. nidulans alcA alcohol I A. nidulans Gwynne et al., 1987;
dehydrogenase Ward et al., 1992b
aleC alcohol I A. nidulans Upshall et aI., 1987
dehydrogenase
amdS acetamidase I A. nidulans Turnbull et al., 1989;
Turnbull et al., 1990
A. niger Turnbull et al., 1990
gpdA glyceraldehyde-3- C A. awamori Moralejo et al., 1999
phosphate Aspergillus ficuum Mullaney et al., 1988
dehydrogenase
Aspergillus giganteus Wnendt et al., 1990
A. nidulans Puntetal., 1991b;
Roberts et al., 1989
A. niger Archer et al., 1990a ;
Punt et al., 1991b;
Roberts et al., 1989
Aspergillus oryzae De Ruiter-Jacobs
et aI., 1989
Cladosporium fulvum Oliver et al., 1987;
Roberts et al., 1989
Claviceps purpurea Van den Hondel et aI.,
1991
Cryphonectria Churchill et al., 1990
parasitica
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Table 3. Continued.
Organism Promoter Encoded protein Typea Heterologous Ho sts Reference
A. nidulans gpdA glyceraldehyde-3- C Curvularia lunata Osiewacz and Weber,
phosphate 1989
dehydrogenase Fusarium culmorum Van den Handel et al.,
1991
Laccaria laccata Barrett et al., 1990
Leptosphaeria Farman and Oliver,
maculans 1988
Penicillium Kolar et al., 1988
chrysogenum
Penicillium roque forti Van den Hondel et al.,
1991
Pseudocercosporel/a Blakemore et al., 1989
herpotrichoides
Schizoph yl/um Mooibroek et al., 1990
commune
Septoria nodorum Cooley et al., 1988
Tolypocladium Calmels et al., 1991
geodes
Trichoderma Van den Hondel et al.,
hamatum 1991
Trichoderma Herrera-Estrella et al.,
harzianum 1990
Trichoderma viride Herrera-Estrella et al.,
1990
Trichosporon Glumoff et al., 1989
cutaneum
oliC ATPase subunit 9 C A. nidulans Ward,1991
pgk 3- C A. nidulans Streatfield et al., 1992
phosphoglycerate
kinase
tpiA triosephosphate C A. nidulans Upshall et al., 1987
isomerase
trpC tryptophan C A. nidulans Hamer and
biosynthesis Timberlake, 1987; Kos
enzyme et al., 1988
C. parasitica Churchill et al., 1990
A. niger adhA alcohol C A. nidulans Upshall et al., 1987
dehvdrocenase I
aphA acid phophatase I A. niger MacRae et al., 1993
A. nidulans MacRae et al., 1993
glaA glucoamylase I A. niger Fowler et al., 1990;
Jeenes et al., 1993
Ustilago maydis Smith et al., 1990
A. nidulans Cullen et al., 1987;
Gwynne et al., 1987
A. awamori Faus et al., 1998
god glucose oxidase I A. nidulans Whittington et al., 1990
gpdA glyceraldehyde-3- C A. niger Van den Hondel and
phosphate Punt, 1991
dehydrogenase A. nidulans Van den Handel and
Punt, 1991
oliC ATPase subunit 9 C A. niger Ward et al., 1988
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Organism Promoter Encoded protein Typea Heterologous Ho sts Reference
A. niger pe pectin esterase I A. niger Khanh et al., 1991
pelA pectin lyase I A. niger Gysler et aI., 1990
pg polygalacturonase I A. awamori Ruttkowski et al., 1991
A. niger
pkiA pyruvate kinase C A. nidulans Bartling et al., 1996
A. niger Bartling et al., 1996
pkiA pyruvate kinase C A. awamori Bartling et al., 1996
A. oryzae agdA a-glucosidase I A. oryzae Minetoki et al., 1995
amyA a-amylase I A. oryzae Christensen et al.,
1988; Huge-Jensen
et aI., 1989
A. niger Jeenes et al., 1991
amyB Taka-amylase A I A. nidulans Kanemori et al., 1999
A. oryzae Takashima et aI., 1998
glaA glucoamylase I A. oryzae Hata et al., 1992;
Tsuchiya et aI., 1993
Cephalo- isp isopenicillin N C C. parasitica Churchill et al., 1990
sporium synthetase
acremonium
Neurospora jHubulin p-tubulin C C. parasitica Churchill et al., 1990
crassa am glutamate C N. crassa Kinnaird and Fincham,
dehydrogenase 1983
P. chrysogenum oliC ATPase subunit 9 C P. chrysogenum Bull et al., 1988
pcbC isopenicillin N ID P. chrysogenum Cantwell et al., 1990
synthetase A. awamori Moralejo et al., 1999
Pleurotus sdi1 component of the C P. ostreatus Irie et aI., 2001a
ostreatus mitochondrial
respiratory chain
Penicillium vaoA vanillyl-alcohol I A. niger Benen et al., 1998
simplicissimum oxidase
Rhizomucor mprA aspartyl protease I Mucor circinelloides Dickinson et aI., 1987
miehei
Acremonium AlpA alkaline protease C A. chrysogenum lsogai et al., 1991
chrysogenum cesB B2 esterase C A. awamori Moralejo et al., 1999
S. commune Gpd glyceraldehyde-3- C Trametes versicolor Bartholomew et al.,
phosphate 2001
dehydrogenase
Trichoderma cbh1 cellobiohydrolase I T. reesei Harkki et al., 1989;
reesei Nyyssënen et al.,
1993; Uusitalo et al.,
1991
A. nidulans Berka and Barnett,
1989
eg1 endogIucanase I A. nidulans Berka and Barnett,
1989
U. maydis hsp heat shock I C. parasitica Churchill et al., 1990
promoter
Saccharomyces gpd glyceraldehyde-3- C A. oryzae Hahm and Batt, 1990
cerevisiae phosphate-
dehydrogenase
a - • D.C - constitutive, I - inducible, secondary metabolism
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The A. niger g/aA promoter has been studied using green fluorescent protein
(GFP) as a reporter, as well as with the aid of deletion analyses (Fowler et a/.,
1990; Santerre Henriksen et a/., 1999). These studies revealed that the
promoter is induced to high levels when the fungus is grown on starch or
maltose, to intermediate levels when grown on glucose, but that it is repressed
in the presence of xylose (Santerre Henriksen et a/., 1999). The promoter
region is 1966 bp and two regions essential for transcription have been
identified. Region I (between position -318 and -562) is required for high-level
expression and region II (which lies within the first 214 bp upstream of the
translation initiation site) directs low-level expression and is the minimum region
that can act as a promoter (Fowler et a/., 1990). Putative binding sites for the
protein that mediates carbon catabolite repression (CREA) have also been
identified (Archer and Peberdy, 1997; Kelly, 1994). The A. niger g/aA promoter
can function in other ascomycetes (such as A. nidu/ans), as well as in the
basidiomycete Usti/ago maydis (Smith et al., 1990).
The most commonly used constitutive promoter is the gpdA promoter from
A. nidu/ans (Punt et al., 1988). Glyceraldehyde-3-phosphate-dehydrogenase
(GPO) is a key enzyme in glycolysis and gluconeogenesis and in A. nidu/ans up
to 5% of the soluble cellular proteins consists of GPO (Punt et aI., 1990). This
indicates that the expression signals of the gpdA gene are very strong, making
this an ideal promoter for heterologous expression. Promoter studies of the 1.3
kb region upstream of the ATG using a /acZ fusion strategy revealed two
elements (at position -650 and -250) which act as transcription activation
elements (Punt et a/., 1990; Punt et a/., 1995). A third element (a C + T- rich
region directly upstream from the transcription start point) was shown to be
involved in correct initiation of transcription.
Vectors have also been developed carrying various reporter genes to facilitate
the analysis of promoter fragments as well as the identification of novel genomic
fragments with strong promoter activity, which could have applications in the
high-level expression of heterologous proteins (Ozeki et a/., 1996; Punt et a/.,
1991a; Roberts et al., 1989; Van Gorcom et a/., 1985; Van Gorcom et a/., 1986;
Van Gorcom and Van den Hondel, 1988).
Stellenbosch University http://scholar.sun.ac.za
25
2.3.3. Secretion signals
A minimum requirement for secretion of proteins is that a sequence encoding a
secretory signal peptide is included in the expression cassette (Van den Hondel
et al., 1991). This signal peptide is necessary for the translocation of a
polypeptide across the membrane of the endoplasmic reticulum, the first step in
the protein secretion pathway. Studies have shown that signal peptides do not
contain certain recognition amino acid sequences that are necessary for
secretion, rather the physical characteristics of the leader peptide are important
(Jarai, 1997). Although a signal sequence from a protein in one species usually
functions to direct secretion of that protein in an organism of a different species,
secretion efficiency is often lower (Moir and Mao, 1990). Therefore host
secretion signals are mostly employed for secretion of heterologous proteins in
filamentous fungi. One of the most commonly used secretion signals is the
A. niger glucoamylase secretion signal. Glucoamylase is secreted at high
levels by various Aspergillus species (Van den Hondel et al., 1992). Other
secretion signals that have been employed include the a-amylase signal
peptide from A. oryzae (Hellmuth et al., 1995), and the signal sequences from
the A. niger acid phosphatase (MacRae et al., 1993), polygalacturonase II and
pectin lyase (Bartling et al., 1996). In some cases secretion vectors have also
been constructed containing entire genes or N-terminal sequences of efficiently
secreted homologous enzymes to aid the secretion of heterologous proteins by
fusion to these sequences (Gouka et al., 1997b; Jeenes et al., 1993; Spencer
et al., 1998). This aspect is discussed in detail elsewhere (section 4.1.5.).
Briefly, for this gene fusion strategy mainly the A. niger or A. awamori
glucoamylase genes have been used (Gouka et al., 1997b). Other genes that
have also been employed for gene fusion strategies to improve secretion
include the T. reesei cellobiohydrolase I, A. awamori a-amylase and the
A. oryzae Taka-amylase genes (Gouka et al., 1997b; Harkki et al., 1989;
Korman et al., 1990). Since both A. nidulans and A. niger have been shown to
exhibit an endoproteolytic activity equivalent to that of the yeast KEX2 protease,
a yeast KEX2-like cleavage site is generally introduced between the
homologous secretion sequence and the heterologous gene to facilitate the
cleavage of the heterologous protein from the secretory sequences
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(Broekhuijsen et al., 1993; Contreras et al., 1991; Jarai, 1997). There have also
been cases where the signal peptide of a vertebrate gene itself has been used
successfully and cleaved correctly from the mature protein, for example human
tissue plasminogen activator and hen egg white lysozyme (Archer et al., 1990a;
Upshall et aI., 1987). This indicates that the signal cleavage enzymes and
recognition signals of vertebrates, filamentous fungi and insects can be
compatible, in contrast to the general failure of mammalian signal peptides in
yeast (Davies, 1994).
2.3.4. Terminators
The mechanism of transcription termination and polyadenylation in filamentous
fungi is unknown (Van den Hondel et al., 1991). Filamentous fungal mRNAs
tend to have heterogeneous 3' ends with several apparent polyadenylation
sites, sometimes resulting in mRNA transcripts of varying lengths (Kleene et al.,
1987; Mullaney et aI., 1985). The higher eukaryotic polyadenylation signal
AATAAA is seen intact or degenerate preceding polyadenylation sites in some
fungal genes, but is more often absent (Clements and Roberts, 1986; Hata
etaI., 1991; Mullaney etaI., 1985). Transcription termination and
polyadenylation is however important to achieve optimal levels of mRNA and
therefore all expression cassettes contain termination regions, often originating
from the same gene as the promoter region (Davies, 1991).
2.3.5. DNA Transformation Methods
DNA transformation of a filamentous fungus was first achieved with N. crassa in
1979 (Case et aI., 1979). The method was adapted from the yeast spheroplast
transformation method of Hinnen and co-workers and involved the glusulase-
mediated spheroplasting of germinated conidia in the presence of sorbitol as
osmotic stabiliser. DNA uptake was mediated by polyethylene glycol (PEG)
4000 and CaCI2. The mechanism by which cellular membranes become
competent for DNA uptake is not known, but PEG induces protoplast fusion and
calcium chloride precipitated DNA may be internalised along with membrane
during this process (Johnstone, 1985; Timberlake and Marshall, 1989).
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Since this first transformation experiment, the protocol has been adapted to
transform various filamentous fungi including A. nidulans (Ballance et al., 1983;
Tilburn et al., 1983; Yelton et al., 1984), A. niger (Buxton et al., 1985; Kelly and
Hynes, 1985), T. reesei (Pentilla et al., 1987) and P. chrysogenum (Beri and
Turner, 1987). For an overview of filamentous fungi which have been
transformed see Ballance, 1991. All these procedures involve removal of the
cell wall of germinated spores or hyphae with lytic enzymes (most commonly
Novozym 234, an enzyme preparation from Trichoderma harzianum primarily
consisting of glucanases and chitinase), in the presence of osmotic stabilisers,
followed by co-precipitation of DNA with Ga2+ and polyethylene glycol. In some
protocols MgS04 has been employed in the preparation of protoplasts for
transformation in order to facilitate separation of protoplasts from mycelial
debris (Tilburn et al., 1983). In this medium, protoplasts vacuolate and become
less dense than the solution, allowing their purification by centrifugation:
mycelial debris forms a pellet at the bottom of the centrifuge tube while the
protoplasts float (Johnstone, 1985). Various combinations of lytic enzymes
(Novozym 234, helicase, f3-glucuronidase, driselase) and osmotic stabilisers
(sorbitol, sucrose, KGI, NaGI) have been used by different workers, and for each
laboratory and organism it is necessary to establish appropriate protocols
(Ballance et al., 1983; Jeenes et al., 1991; Tilburn et al., 1983; Yelton et al.,
1984). There does not seem to be a great deal of difference in transformation
frequency between these methods, all achieving about 10-100 transformants
per microgram DNA. In some protocols the nuclease inhibitor aurintricarboxylic
acid is added to the DNA prior to transformation as it was found to increase
transformation frequencies by approximately 2 to 5 fold (Ward et al., 1988).
Electroporation of protoplasts has also been employed as an alternative to
PEG-mediated transformation (Ward et al., 1989).
Transformation methods that do not require protoplasting have subsequently
been developed. A lithium acetate-mediated method has been developed for
N. crassa where germinated conidia are treated with lithium acetate and then
incubated with DNA (Dhawale et al., 1984). This is a relatively rapid, simple
and reliable method and transformation frequencies are comparable to those
obtained with protoplasting methods. Other transformation methods include
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biolistic nuclear transformation (Armaleo et al., 1990) and Agrobacterium
tumefaciens-mediated transformation (De Groot et al., 1998). Using
Agrobacterium, both hyphal tissue and conidia can be transformed and when
this technique was employed for transformation of A. awamori conidia,
transformation frequencies improved up to 600-fold as compared with the
conventional protoplasting technique (De Groot et al., 1998). Other fungi that
have been successfully transformed using Agrobacterium include A. niger,
Fusarium veneta tum, T. reesei, Colletotrichum gloeosporioides, N. crassa and
the mushroom Agaricus bisporus, indicating that this technique can be very
useful, especially for species that are recalcitrant to transformation by other
means.
Various factors that may influence DNA transformation frequency include carrier
DNA, incubation period, incubation temperature, PEG molecular weight, PEG
concentration, addition of cations and purity and concentration of transforming
DNA (Wernars et al., 1985). The most important of these is the purity of the
vector DNA. In transformation of A. nidulans a non-linear relationship was
observed between the number of transformants and the amount of vector used.
A minimum of 2 IJg vector was required for transformation and the number of
transformants increased exponentially with an increasing amount of DNA up to
10 IJg. At higher concentrations the relationship became linear and above
50 IJgtransformation frequency dropped, possibly due to impurities in the DNA
preparations. Cotransformation is also an efficient process in filamentous fungi
and the cotransformation frequency of unlinked sequences can equal that of
covalently linked genes (Wernars et al., 1987). Cotransformation can be used
for introduction of genes for which direct selection is not possible.
2.3.6. Transformation Events
Transformed plasmids may be maintained extrachromosomally or be integrated
into the genome of the recipient strain at homologous or heterologous sites and
the copy number may vary from one to many copies (Timberlake, 1991).
Abortive transformants can occur and in filamentous fungi sometimes up to 90%
of the initially observed colonies remain very small and are incapable of further
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growth upon subculture (Turner and Ballance, 1985). This may result from
transient expression without stabilised integration.
2.3.6.1. Integration
In most filamentous fungi, stable transformants result from various types of
recombinational interaction between transforming DNA and the chromosome of
the recipient strain (Turner, 1994). Circular vector DNA can become integrated
into the genome, but in some species linearisation of vector DNA prior to
transformation increases transformation frequency and the proportion of
homologous recombinations (Berka et aI., 1990; Frederick et al., 1989; Miller
et a/., 1985; Paietta and Marzluf, 1985). Mechanisms of fungal recombination
and integration are reviewed by Orr-Weaver and Szostak (1985). In general
three types of integration events can occur: Type I, integration of the vector by
homologous recombination; type II, ectopic integration of the vector by non-
homologous recombination; and type III, gene replacement (Case et aI., 1979;
Van den Hondel and Punt, 1991). For most homologous selectable markers,
homologous interactions (type I and III integrations) predominantly occur,
resulting in gene conversion or integration of the whole vector sequence
(Ballance and Turner, 1985; Campbell et al., 1989; Dunne and Oakley, 1988;
Yelton et al., 1984). However, in some cases type II transformants are
preferentially found, e.g. in A nidulans with the trpC gene (Ballance and Turner,
1985; Yelton et a/., 1984) and with the amdS gene (Wernars et al., 1985). The
most striking feature of transformation of Aspergillus is that integration shows
no dependence on extensive homology between the transforming DNA and the
host chromosomal sequences (Ballance and Turner, 1985). Plasmids can
integrate into the genome by single crossover events (Tilburn et al., 1983;
Yelton et al., 1984). Alternatively, plasmid co-integrants can form by
homologous recombination of a number of plasmid molecules prior to
chromosomal recombination, resulting in integration of multiple plasmid copies
arranged in head to tail arrays (Wernars et al., 1985). Integration of a single
plasmid molecule can also be followed by integration of additional plasmids to
form tandemly repeated arrays, and different integration events result in
different levels of expression (Tilburn et al., 1983). The ratio of homologous to
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heterologous (ectopic) integration varies according to the plasmid used and the
species and genetic strain being transformed (Timberlake, 1991;Wernars et al.,
1985). For example, A. nidulans shows about 70% homologous integration
(Tilburn et ai., 1983; Yelton et ai., 1984). Heterologous, seemingly random
integration is presumably favoured with plasmids containing low amounts of
DNA homology to the target genome. However, even with plasmids having no
known homology with the target genome, small stretches of target-plasmid DNA
identity could provide nucleation sites to initiate homologous recombination
reactions. If these sites are small (e.g. 6-bp sequence), integration would be
expected to occur at many genomic locations, thus approximating random
integration. Targeting to a homologous sequence can also be improved by
cutting and linearising the vector within the homologous sequence or by using a
plasmid containing an internal restriction fragment from the gene to which
integration is to be targeted (Streatfield et al., 1992; Timberlake, 1991).
However, even with this strategy, integration does not occur solely at the
targeted site. The type of integration is dependent on the strain used for
transformation (Wernars et al., 1985). For example, in one A. nidulans strain
transformed with a vector containing the amdS gene, most of the transformants
showed integration of one copy of the vector at the partially deleted amdS gene,
whereas in another strain tandem integration of multiple copies at non-
homologous sites occurred.
Integrated plasmids of homothallic fungi such as A. nidulans and A. niger are
generally mitotically stable in that they are stably maintained during vegetative
growth and through the asexual reproductive cycle (even after 100 days of
growth on non-selective medium), but show meiotic instability through the
sexual cycle (Mohr and Esser, 1990; Tilburn et ai., 1983; Wernars et ai., 1985).
Tandemly repeated sequences are frequently lost after sexual reproduction
cycles in A. nidulans (Kelly and Hynes, 1987; Tilburn et ai., 1983; Yelton et ai.,
1983). However, most economically important filamentous fungi lack a sexual
phase, thus with many species the behaviour of inserted DNA sequences in
meiosis is irrelevant (Timberlake and Marshall, 1989). In some cases it has
proved possible to rescue the transforming DNA integrated into the
chromosome by making use of cos sites present in the original vector utilising a
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technique called cosmid rescue, where the DNA is packaged into viral particles
(Yelton et aI., 1985). Integrated vectors can also be recovered by digestion with
restriction enzymes, followed by circularisation with T4 DNA ligase and
subsequent transformation of E. coli (Ballance and Turner, 1985; Yelton et al.,
1984). It is often also possible to recover plasmids by transforming E. coli with
untreated transformant DNA, even when the plasmid has been shown to
integrate into a chromosome (Ballance and Turner, 1985). There seems to be a
limited degree of "pop-out", or reversal of the integration event, leading to a very
low amount of free molecules, which are however not able to replicate
autonomously (Ballance, 1991).
2.3.6.2. Autonomous replication
In single-celled yeasts, selection can be stringent enough to ensure that only
plasmid-bearing cells continue to divide, but in coenocytic filamentous fungi, the
flow of nutrients along the hyphae will allow division of piasmidiess nuclei,
resulting in a heterokaryon (Buxton and Radford, 1984). However, replicative
plasmids are more suited for gene expression studies. They have the
advantage over integrative systems in that transformation rates are high, the
context of the expressed gene is free from effects of different chromosomal
integration sites, the risk of rearrangement accompanying integration is
eliminated and copy number is dependent only on the selective system
(Aleksenko et el., 1996b).
To develop autonomously replicating vectors there are five potential sources of
replication origins: (1) native nuclear plasmids, (2) DNA viruses,
(3) mitochondrial DNA, (4) mitochondrial plasmids and (5) chromosomal DNA
(Gems et al., 1991; Johnstone, 1985). Plasmids such as the freely replicating
yeast episomal plasmid shuttle vectors based on the naturally occurring 2-l-lm
plasmid of S. cerevisiae have not been found in the filamentous fungi and the 2-
um replication origin does not function in these fungi (Gems et al., 1991). A
native plasmid-like DNA inducing senescence has been identified in the
ascomycete Podospora anserina which could be developed as a vector for
gene transfer, but no such DNA molecules have thus far been identified in other
ascomycetes (Tudzynski et al., 1980). Also, no native DNA viruses have been
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found in Aspergillus species, which might supply "replicons" suitable for
autonomous replication (Johnstone, 1985). Mitochondrial DNA sequences from
Aspergillus amstelodami and A. nidulans that have replicative activity in
S. cerevisiae were isolated and incorporated into integrative transformation
vectors (Beri et al., 1988). Although the A. nidulans sequence enhanced
transformation frequency, neither of the ARS-containing plasmids were
mitotically stable in A. nidulans and no freely replicating plasmids were
detected. Three mitochondrial plasmid DNAs have been isolated from
N. crassa and when ligated to E. coli vectors one of these was found to
replicate autonomously in both N. crassa and E. coli (Stohl and Lambowitz,
1983). Similarly hybrid bacterial-mitochondrial plasmids exhibiting autonomous
replication have been constructed for the fungus P. anserina (Stahl et al., 1982).
These are, however, exceptions. It has not proved possible to develop such
vectors for other ascomycetous fungal species, possibly due to differences in
the organisation of origins of replication between species (Jeenes et aI., 1991).
The best-known chromosomal elements that support replication of
extrachromosomal plasmids in yeasts are the autonomous replicating
sequences (ARSs) which are chromosomal origins of bidirectional replication
(Aleksenko and Clutterbuck, 1997). Among filamentous fungi, an ARS has only
been successfully isolated from zygomycetous fungi like M. circinelloides and
from the basidiomycete U. maydis, however the autonomous replicating
plasmids carrying these sequences were found to be mitotically unstable in both
these fungi (Tsukuda et al., 1988; Van Heeswijk, 1986). More than 100
independent clones that had replicative activity in yeast were isolated from an
A. nidulans genomic library, however only one (designated ANS1 for Aspergillus
nidulans sequence 1) enhanced Aspergillus transformation frequency 50 to 100
fold (Ballance and Turner, 1985). ANS1-bearing vectors replicate while
retaining high recombinogenic potential and undergo reversible integration into
the chromosome, but do not promote autonomous replication (Aleksenko and
Clutterbuck, 1997; Ballance and Turner, 1985). When a genomic library of
A nidulans was constructed in A nidulans, a 6.1 kb fragment designated AMA 1
(autonomously maintained in Aspergillus) was isolated (Gems et aI., 1991).
Vectors carrying this fragment exhibit 2000-fold enhanced transformation
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frequency of A. nidulans, are maintained in free form at 10 to 30 copies per cell,
are rarely transferred between nuclei and are not integrated into the fungal
chromosome. The AMA 1 sequence consists of an inverted repeat of a
sequence that has other isolated copies throughout the genome (Aleksenko and
Clutterbuck, 1996). These sequences (mobile Aspergillus transformation
enhancers or MATEs) share a high degree of sequence similarity and exhibit
some features characteristic of mobile elements. The nucleotide sequence
does not encode any extended polypeptides but contains ARS-consensus
matches and a multiply repeated "Spe" motif, which may be described as a
symmetrically duplicated topoisomerase I recognition site. The two long perfect
inverted repeats (MATE elements) are necessary for efficient plasmid
replication (Aleksenko et al., 1996a). In vivo rearrangements of plasmids
containing the AMA 1 replication-promotion element have been reported and
AMA 1 plasmids were also shown to recombine efficiently with co-transforming
DNAs to form autonomously replicating co-integrates (Gems et al., 1995; Gems
and Clutterbuck, 1993). Concatenation occurs by end-to-end ligation of linear
molecules, together with homologous or non-homologous recombination of
linear and/or circular molecules (Aleksenko, 1994). This recombination of the
autonomously replicating plasmids during co-transformation is a phenomenon
generated entirely by the conditions of transformation, i.e. protoplasting, DNA
uptake and regeneration (Gems et et., 1995). After this period a plasmid is
structurally stable in vegetative mycelium for many generations. However,
during sexual reproduction, autonomous plasmids exhibit increased
recombination, which results in both plasmid concatenation and integration into
the chromosome. The AMA 1 sequence has been shown to function as an
origin of replication not only in A. nidulans, but also in A. niger, A. oryzae,
P. chrysogenum and Penicillium canescens (Aleksenko et al., 1995; Fierro
et al., 1996; Gems et et., 1991). Other chromosomal elements that can
promote autonomous replication are telomeric sequences (Javerzat et el.,
1993). Linear plasmids containing two inverted stretches of human telomeric
repeats transformed A nidulans at frequencies characteristic of autonomously
replicating vectors, however replication of telomeric plasmids is never as
efficient as that of circular AMA 1 plasmids (Aleksenko and Ivanova, 1998).
Fungal sequences containing telomeric elements that promote autonomous
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replication of linear plasmids have also been isolated (Javerzat et al., 1993;
Poplawski et al., 1997; Powell and Kistler, 1990).
Although a variety of tools (transformation procedures, dominant and
auxotrophic markers, transcriptional elements) have been developed for the
genetic engineering of filamentous fungi, particularly aspergilli, the availability
and application is still somewhat limited when compared to the tools available
for yeasts such as S. cerevisiae, P. pastoris and H. polymorpha. This may be
directly attributed to the greater degree of complexity of the multicellular
filamentous fungi when compared to the unicellular yeasts.
2.4. Heterologous protein production in Aspergillus
There has been considerable commercial interest in exploiting filamentous
fungi, especially aspergilli, as hosts for heterologous protein production
(Kinghorn and Unkles, 1994). Aspergilli have the ability to secrete copious
amounts of their own enzymes, which can be as much as 25 g/I of
glucoamylase by A. niger. Through their history of industrial application in the
production of antibiotics, enzymes, citric acid and oriental alcoholic beverages,
fermentation and cultivation procedures, conditions and equipment has been
established. A. oryzae has been used for more than 2000 years in the
production of koji, a complex enzyme preparation for the production of soy
sauce, miso and sake (Barbesgaard et aI., 1992). It has also been employed in
Europe since the beginning of the 20th century to produce enzymes for baking
and brewing. Cultivation took place in open trays, releasing massive amounts
of conidia into the environment, but without adverse effect to the population. No
proven carcinogenic metabolites have been identified in A. oryzae and
aflatoxins are not formed although it belongs to the section Flavi (Barbesgaard
et al., 1992; Peterson, 2000). This group of mycotoxins is produced exclusively
by other members of the section Flavi, notably A. flavus, Aspergillus nominus
and Aspergillus parasiticus. A. niger is known to occur naturally in foods and is
commonly present in products such as rice, seeds, nuts, olives and dried fruits
(Coenen et al., 1998). As mentioned previously it also has a long history (since
1919) in the industrial production of enzymes and citric acid. In the US, enzyme
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preparations from A. niger have had a GRAS (Generally Regarded As Safe)
status since 1973 and there is no evidence that industrial strains used are able
to produce toxins. Detailed safety evaluations and toxicity tests of various
homologous and heterologous enzyme preparations from A. niger and
A. oryzae have clearly indicated that there are no reasons for safety concerns in
the human consumption of these products (Barbesgaard et aI., 1992; Coenen
et aI., 1998; Greenough et aI., 1996; Lane et al., 1997). Therefore, the fungi
A. niger and A. oryzae also have been granted GRAS status by the United
States Food and Drug Administration, making them acceptable hosts for the
production of recombinant proteins of pharmaceutical interest.
2.4.1. Factors affecting heterologous protein expression
When employing Aspergillus as a host for the production of heterologous
proteins, various factors influence the level of protein yield as well as the
integrity and functionality of the protein:
2.4.1.1. Site of integration
Transformation of filamentous fungi with recombinant DNA frequently results in
non-specific integration of the molecule into the chromosome, as already
described. A common feature of this process is the duplication of the integrated
DNA, producing multiple copies of the target gene (Verdoes et aI., 1993).
Although it can be generally said that increasing the copy number will result in
improved yields, there appears to be no strict correlation between the two (e.g.
Christensen et aI., 1988; Fowler et aI., 1990; Finkelstein et aI., 1989; Punt et aI.,
1991b; Verdoes et al., 1994b). This was also found to be the case in the
expression of hepatitis B viral proteins in Aspergillus (Paper 1 and 2, this
thesis). The most likely explanation is that the DNA is integrating into regions of
the chromosome which are transcribed with different efficiencies (Verdoes
et aI., 1994b). Nucleosome positioning can either restrict or provide access of
transcription factors to their recognition sequences in promoters and is therefore
a powerful element of control in gene expression (Archer and Peberdy, 1997).
This problem can be overcome by using site-directed integration vectors,
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resulting in gene replacement or integration into a non-essential gene which is
known to be highly expressed (Gouka et al., 1995; Van Gemeren et al., 1996).
2.4.1.2. Transcriptional control
Several strong promoters from highly expressed genes are currently being
exploited for the expression of recombinant genes, as has been discussed in
section 2.2. Strategies for optimising the production of proteins have to ensure
that transcription levels do not limit protein yields. The most straightforward
approach to transcriptional enhancement has been to alter gene dosage, for
example, glyceraldehyde-3-phosphate dehydrogenase overproducing strains
were constructed containing 9 copies of the gpdA gene (Hanegraaf et al., 1991)
and glucoamylase overproducing strains of A. niger were constructed carrying
around 20 copies of the glaA gene (Verdoes et al., 1993; Verdoes et al.,
1994b). However, introduction of more copies led to reductions in
glucoamylase levels due to gene rearrangements (Verdoes et aI., 1994a). One
important factor affecting heterologous protein expression in this regard is
regulatory factor limitation (Verdoes et aI., 1995). Limitation at the level of the
amount of regulatory factors available has been observed for the
overexpression of several fungal genes, including glaA (Verdoes et al., 1994a),
genes involved in laetarn and co amino acid catabolism (Kelly and Hynes, 1987),
and genes involved in alcohol metabolism (Davies, 1991). Specific trans-acting
regulatory proteins regulate expression of these genes. The regulatory proteins
are limiting when multiple copies of these gene promoters are employed to
direct expression of heterologous genes in transformants carrying multiple
copies of the expression vector. If the regulatory factors have been identified,
these limitations can be overcome by increasing the expression level of the
gene encoding the limiting regulatory factor through the introduction of
additional copies of this gene (Davies, 1991; Kelly and Hynes, 1987).
In general, with a few exceptions, the transcription of recombinant genes is not
limiting in filamentous fungi and the majority of eukaryotic mRNAs are relatively
stable in the cytoplasm (Jeenes et aI., 1991). Five structural features of mRNA
have been shown to strongly influence this stability: (i) the 5' 7-methylguanosine
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triphosphate cap, and (ii) the 3'-poly A tail, both of which have a protective
function on mRNA stability; (iii) the mRNA length, which sometimes negatively
regulates mRNA stability; (iv) posttranscriptional base modifications, such as
methylation of adenine residues or the conversion of adenines to inosines; and
(v) mRNA-stabilising or destabilising sequences (Gouka et ai., 1996b).
2.4.1.3. Intron splicing
The majority of filamentous fungal genes sequenced contain introns, ranging in
size from 48 bp to 398 bp (Ballance, 1991; Clements and Roberts, 1986; Gomi
et al., 1991). In higher eukaryotes, the majority of genes contain introns, which
can be several kilobases in size, whereas in yeasts introns are very much the
exception and tend to be relatively short (a few hundred bases or less)
(Ballance, 1986). Filamentous fungal genes appear to be somewhere in
between in this respect. Sequences at the 5' and 3' splice site are highly
conserved and are similar to those observed in yeast and in higher eukaryotes,
though both yeast and filamentous fungi lack the pyrimidine-rich stretch which
precedes the 3' splice site in higher eukaryotes. There are also sufficient
differences between the conserved sequences of introns in yeasts and
filamentous fungi. Therefore, some yeasts fail to splice fungal introns.
However, filamentous Ascomycete genes are to a large extent interchangeable,
indicating that the intron splice signals are conserved. For example, the
A. nidulans amdS gene contains three introns, but is functional in various
heterologous hosts, such as A. aryzae, A. niger, P. chrysagenum and T. reesei
(Beri and Turner, 1987; Gami et al., 1991; Kelly and Hynes, 1985; Pentiua et al.,
1987). Therefore, fungal genes can be expressed in a heterologous host
without the prior removal of introns. However, filamentous fungi have not been
shown to remove introns from mammalian genes.
2.4.1.4. Codon bias
All organisms tend to favour a subset of codons and this bias is generally most
marked in highly expressed genes (Ballance, 1991). Thus different genes in the
same genome have related codon preference rules and it seems clear that
certain codons are optimal for the translation system in a particular organism
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(Sharp and Cowe, 1991). These "optimal" codons are those that are
recognised most efficiently by the most abundantly available tRNA species and,
just as the optimal codons vary among species, so do the anticodon sequences
and relative abundance of different tRNAs. The codons are translated at
different rates and the rate of polypeptide chain elongation will influence the
efficiency with which ribosomes are utilised, affecting the growth rate of the cell
and thus providing the basis for a selective advantage of optimal codons in
highly expressed genes. This implies that genes which are strongly expressed
are more biased towards optimal codons than genes expressed at a lower level
and this leads to the conclusion that, in addition to the regulatory flanking
elements of a structural gene, the coding sequence itself contains crucial
information with regard to expression levels of a gene (Bennetzen and Hall,
1981; Hoekema et aI., 1987). In filamentous fungi the degree of bias varies,
being particularly marked in N. crassa and less so in A. nidulans (Ballance,
1986). The preferred codons are similar in all ascomycete filamentous fungi for
which genes have been sequenced. There is a preference for codons ending in
pyrimidines, or where this is not possible, codons ending in G. In both genera
there is a tendency to avoid usage of codons ending in A. This is also seen in
S. cerevisiae (Bennetzen and Hall, 1981), though there are several cases
where the codons preferred by S. cerevisiae, e.g. GAA for Glu and AGA for Arg,
are different from those preferred by filamentous fungi, where GAG is preferred
for Glu and GGU or CGC for Arg (Ballance, 1986). In highly expressed or
constitutive genes in Aspergillus there is generally a preference for G or C in the
third codon position (Clements and Roberts, 1986; Gomi et al., 1991; Lloyd and
Sharp, 1991). Only 10 of the codons identified as being optimal for A. nidulans
are among the 22 optimal codons in S. cerevisiae (Lloyd and Sharp, 1991;
Sharp and Cowe, 1991). Interestingly, the codon dialects in these two species
are at least as divergent, if not more divergent, than those of E. coli and
S. cerevisiae (Lloyd and Sharp, 1991). In mammalian genes, the percentage of
A-ending codons is low, with G- and C-ending codons prevailing, corresponding
more closely to the codon strategy of Aspergillus, than that of yeast and
bacteria (De Boer and Kastelein, 1986). However, mammalian viruses (SV40,
adenovirus, hepatitis) differ again from their hosts with A-ending codons being
exceptionally frequent. Codon usage in A. nidulans is summarised in Lloyd and
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Sharp, 1991. Codon usage may influence the translation of heterologous
genes, although this has not been investigated in any detail in filamentous fungi.
Codon preference was examined in the expression of Cyamopsis tetragonoloba
a-galactosidase in A. awamori (Gouka et a/., 1996b). Full-length mRNA was
not detected from the wild-type gene, but was detected when the codon
preference was altered to that of S. cerevisiae, suggesting that mRNA stability
had been affected due to the presence of rarely used codons, possibly resulting
in temporary translation arrest and subsequent degradation of the transcript.
Therefore, the codon context of a heterologous gene may influence the yield of
a protein where mRNA is produced at high levels (Romanos et al., 1992). This
may be more likely to occur in minimal growth medium when the cell produces a
wide variety of biosynthetic enzymes, encoded by genes containing rare
codons. Highly efficient translation of cloned mammalian or other heterologous
genes may thus require careful comparison of codon usage of the gene in
relationship to the codon preference of the host cell. Also, an understanding of
the role of the coding sequence in controlling gene expression is required to
achieve an expression level of heterologous genes in Aspergillus that is
equivalent to that of homologous genes (Gomi et al., 1991). Therefore the
construction of a synthetic gene with a codon usage optimised for Aspergillus
species might improve the translation efficiency in some proteins, resulting in
increased protein levels.
2.4.1.5. Secretion
Many proteins of biotechnological importance produced in filamentous fungi are
secreted because it makes the product easier and cheaper to purify (Archer and
Peberdy, 1997). Continuous fermentation can then be employed, because cell
lysis to recover an intracellular product is unnecessary. Continuous
fermentation reduces product loss which can occur due to inefficient lysis or
internal proteolysis during intracellular product recovery, and facilitates product
purification (Jeenes et al., 1991; Smart, 1991). Also, possible toxic effects of
intracellular product build-up are reduced and, by passing through the secretory
pathway, processing events such as glycosylation and proteolytic maturation
can occur to yield correctly folded, fully active molecules. However, there are
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some disadvantages to secreting heterologous proteins into the growth
medium. Several fungal strains secrete a wide array of proteases that can
degrade the product (Van den Hombergh et al., 1997c). Furthermore, many
fungi also produce large amounts of organic acid, resulting in a low pH (pH 1.5-
2.0 in some cases), which can alter the structure of certain proteins or lead to
increased sensitivity to acid proteases active in the culture broth (Jeenes et al.,
1991). Although homologous proteins such as secreted filamentous fungal
gene products (both homologous and heterologous) can often attain levels
measured in gIl, secreted proteins derived from non-fungal sources tend to give
yields measured in mgll (Jeenes et al., 1991). Thus, for these proteins the
secretory pathway may present a bottleneck. Intracellular compartmentalisation
of recombinant proteins appears to be less of a problem in filamentous fungi
than in S. cerevisiae or E. coli, indicating that many of the problems of
expression are due to the secretion pathway or the extracellular environment.
To identify possible bottlenecks in the secretory pathway, the processes
involved in secretion need to be elucidated. The protein secretion pathway
processes in filamentous fungi do not essentially differ from those in yeast and
mammalian cells (Moir and Mao, 1990) and are reviewed by Gouka et al.
(1997b). Essentially, co-translational entry of a protein into the lumen of the
endoplasmic reticulum (ER) with concomitant processing of the N-terminal
signal peptide is followed by translocation through the ER lumen to membrane-
bound vesicles and targeting to the Golgi compartment. In the Golgi
compartment processes such as glycosylation and processing occur and finally
the protein is transported to the cell wall, again in vesicles, and is secreted into
the extracellular medium through the fusion of the vesicles with the hyphal
membrane. The precise location of protein secretion is under debate, but
occurs primarily at the hyphal tips (Gordon et al., 2000a; Gordon et al., 2000b).
The wall at the hyphal tips is newly synthesised and may be more porous than
elsewhere, thereby facilitating secretion.
Studies on protein secretion in fungi have shown that in most cases the
presence of a fungal (or non-fungal) sequence encoding a secretion signal is
sufficient to promote secretion of a protein into the culture fluid (Brandhorst and
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Kenealy, 1995; Punt et al., 1991b; Punt et al., 1994; Van den Hondel et al.,
1992). However, in some cases the heterologous gene is fused to the 3' end of
a highly expressed and efficiently secreted fungal gene, such as glucoamylase,
as described by Gouka et al. (1997a). Fusion can be effected to the complete
fungal gene or to a truncated gene (Tsuchiya et aI., 1994). For these gene
fusion strategies, the A. niger or A. awamori glucoamylase (glaA) genes have
been mainly employed, resulting in improved levels of secreted bovine
prochymosin (Ward et al., 1990), porcine pancreatic phospholipase A2 (Roberts
et aI., 1992), human interleukin-6 (Contreras et aI., 1991), hen egg-white
Iysoszyme (Jeenes et al., 1993) and human lactoferrin (Ward et al., 1992a).
The production increase varies from 5 to 1000-fold, depending on the protein,
resulting in levels varying from 5 mg!1 to 250 mg!1. A similar gene fusion
strategy was therefore also employed to possibly direct and enhance secretion
of the hepatitis B virus major (S) and large (L) proteins by A. niger (Paper 2, this
thesis). However, in this case the strategy was unsuccessful, probably due to
the underlying mechanisms of viral protein assembly (Huovila et aI., 1992;
Prange and Streeck, 1995; Paper 2, this thesis).
Apart from glaA gene fusions, fusion constructs utilising the A. awamori (X.-
amylase (Korman et aI., 1990) and the A. oryzae Taka-amylase!glucoamylase
(Tsuchiya et aI., 1994) have also been successful in Aspergillus. The success
of this strategy can be attributed to the structure of these carrier enzymes. The
glucoamylases can be divided into three domains: an N-terminal catalytic
domain, a C-terminal starch-binding domain and a flexible O-glycosylated linker
region that separates the two domains (Archer, 1994). The C-terminal starch-
binding domain can be efficiently replaced by the heterologous protein
(Broekhuijsen et aI., 1993; Jeenes et aI., 1993; Ward et aI., 1995), although
fusions to full-length glucoamylase have also been successful (Contreras et al.,
1991; Roberts et al., 1992; Ward et al., 1990). The positive effect of the fusion
is probably caused by the fact that the linker region permits the catalytic domain
and the rest of the fusion protein to fold independently. In general, the N-
terminal fungal protein is believed to serve as a carrier, improving the
translocation of the protein into the ER, to aid folding and to protect the
heterologous protein from degradation. The fusion protein is then cleaved
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further along the secretory pathway, resulting in the secretion of the separate
proteins. Cleavage occurs either by autocatalytic processing by an unknown
fungal protease (Baron and Tiraby, 1992; Nyyssënen et aI., 1993; Roberts
et aI., 1992; Tsuchiya et aI., 1994; Ward et aI., 1990) or by a KEX2-like
protease, for which a dibasic amino acid recognition site had been introduced
specifically into the fusion protein (Broekhuijsen et aI., 1993; Calmels et al.,
1991; Contreras etaI., 1991; Mikosch etal., 1996). The latter has proven an
effective method of obtaining correctly processed mature heterologous proteins
because an effective kexin-like maturase has been identified in A. niger (Jalving
et aI., 2000). However, the sequences upstream and downstream of the KEX2
site affect the fidelity of the cleavage, with more faithful processing occurring
when the downstream sequence is less prone to helix formation (Spencer et al.,
1998).
2.4.1.6. Chaperones
In the secretory pathway, many proteins (collectively known as chaperones) are
involved in the transport of secretory proteins by membrane translocation and
vesicular transport from the endoplasmic reticulum (ER) via the Golgi apparatus
to the cell surface. Only a few genes encoding such proteins involved in the
secretory pathway of aspergilli have been isolated to date (Punt et aI., 1998).
These proteins are all resident in the ER lumen and are encoded by the srpA
(Thompson et aI., 1995), pdiA (Ngiam et aI., 1997), tigA (Jeenes et aI., 1997),
prpA (Wang and Ward, 2000), sarA (Punt et aI., 1994) and bipA (Van Gemeren
et aI., 1997) genes. The pdiA, tigA (Jeenes et aI., 1997) and prpA (Wang and
Ward, 2000) genes all encode protein disulphide isomerases which possess
disulphide-bond exchange activities and, together with other chaperone
proteins, are required for proper folding of soluble ER proteins (Jeenes et aI.,
1997;Wang and Ward, 2000).
BiP (encoded by the bipA gene) is a chaperone protein first identified in the ER
of mammalian cells, which belongs to the HSP70 class of stress-inducible
proteins and is a homologue of the S. cerevisiae Kar2p (Normington et al.,
1989). In mammalian cells it was shown to bind transiently to nascent proteins,
but permanently to misfolded proteins whose transport from the ER is blocked.
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Therefore BiP has been afforded a dual role in preparing normal proteins for
export from the ER by presenting them to POI and other catalysts of polypeptide
folding, and acting as quality control monitor which binds and retains
unassembled or misfolded proteins in the ER where they are degraded (Kim
et al., 1992; Knittier et al., 1995). In normal cells, the concentration of
chaperones is likely to be sufficient for proper folding and assembly of secretory
proteins. However, in expression systems where there is a greater flux of
proteins being translocated into the ER, the folding, assembly and secretion
machinery may become saturated, leading to improperly folded structures or
protein aggregates which are not secreted (Ngiam et aI., 2000). Both POI and
BiP transcription levels increase in response to stress (Van Gemeren et al.,
1997; Wang and Ward, 2000). Higher levels of prpA transcript levels were
found in A. awamori producing bovine prochymosin (Wang and Ward, 2000)
and bipA expression was induced in recombinant A. niger strains
overexpressing glucoamylase and human interleukin-6 (IL-6), respectively, and
in recombinant A. awamori strains overexpressing single-chain antibody
fragments (scFv4715) (Punt et al., 1998). To overcome the secretion
bottleneck, overexpression of BiP and/or POI could increase the yield of
secreted heterologous protein and this has proven successful in S. cerevisiae
expressing bovine prochymosin (Gouka et al., 1997b; Harmsen et al., 1996).
However, overexpression of BiP did not improve yields of IL-6 or scFv4715 from
Aspergillus, nor did the overexpression of POIA improve yields of hen egg white
lysozyme in A. niger (Ngiam et aI., 2000; Punt et aI., 1998). In fact, in some
cases the overexpression of chaperones negatively affects heterologous protein
expression. This phenomenon was observed when BiP was overexpressed in
an H. polymorpha strain expressing A. niger glucose oxidase (Van der Heide
et al., 2002). BiP overexpression also significantly reduced recombinant
manganese peroxidase production by A. niger (Conesa et aI., 2002). With
increased understanding of the transcriptional regulation of the chaperone
proteins and their role in the secretory pathway, they will however play a key
part in improving heterologous protein production by filamentous fungi.
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2.4.1.7. Glycosylation
Glycosylation is one of several important events associated with the post-
translational modification of proteins and plays an important role in protein
folding, stability and function (Sorensen et al., 1996; Wang et al., 1996). It is
perceived that this process is a bottleneck at several levels, which affects
biosynthesis and secretion of homologous and heterologous glycoproteins. An
understanding of the glycosylation of proteins is important when using
filamentous fungi as hosts for heterologous protein production as the diversity in
the composition of glycans associated with proteins could have major
consequences with respect to their antigenicity and functionality (Speake et al.,
1980). Many commercially important eukaryotic proteins are glycosylated
(Jeenes et al., 1991). Carbohydrate structures of varying complexity are
attached to the protein via N-glycosidic linkage to the asparagine residue in the
sequence Asn-X-SerlThr or via O-glycosidic linkage, mainly to serine or
threonine.
Like yeasts and mammalian cells, filamentous fungi are capable of both N- and
O-linked glycosylation with varying carbohydrate structures (Archer, 1994;
Kornfeld and Kornfeld, 1985; Neustroevet al., 1993). The early events of N-
glycan synthesis take place in the endoplasmic reticulum and are identical in
yeasts, plants and higher eukaryotes (Maras et al., 1997b). This is also true for
fungi and the glycosyltransferase enzymes involved in the initial stages of the
N-linked protein glycosylation pathway have been identified in A. niger (Speake
et al., 1980; Wallis et al., 1999). A common precursor oligosaccharide (namely
Glc3MangGlcNAc2) is transferred to Asn residues in nascent proteins still
associated with the ribosome (Kornfeld and Kornfeld, 1985; Kukuruzinska et al.,
1987; Long and Rudick, 1979). Further processing occurs by removal of three
glucose (Glc) residues and one mannose (Man) residue. The synthesis
pathways then diverge between yeast and higher eukaryotes: another three
Man residues are removed in the latter, resulting in a Man5GlcNAc2
oligosaccharide. This N-glycan then serves as an acceptor substrate for the
first glycosyltransferase involved in complex carbohydrate formation, namely
GlcNAc-transferase I. In yeast, however, large high-Man oligosaccharides are
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formed by addition of Man residues by various mannosyltransferases
(Kukuruzinska et aI., 1987). In filamentous fungi, N-glycans seem to be further
processed by removal rather than addition of Man residues, which is closer to
the situation prevailing in higher eukaryotes (Aleshin et aI., 1992; Chiba et al.,
1993; Evans et aI., 1990; Limongi et aI., 1995; Maras et aI., 1997a; Svensson
and Larsen, 1983; Turnbull et aI., 1990; Upshall et al., 1987). In fact, the
presence of an acceptor substrate for GlcNAc-transferase I on certain
glycoproteins from various Aspergillus and Trichoderma species has been
reported (Chiba et al., 1993; Maras et aI., 1997a). There may be differences in
the selectivity for the various types of sugar residues, the capacity to add some
types of residues (e.g. sialic acid) is absent and a tendency to add large
numbers of mannose residues to the core backbone has occasionally been
observed. For example a high mannose N-linked structure was found in
recombinant A. niger pectate lyase expressed in A. nidulans (Colangelo et al.,
1999b) and in recombinant endopolygalacturonase I from A. niger (Colangelo
et al., 1999a). However, the "hyperglycosylation" that has been a major
problem in S. cerevisiae appears to be less of a problem in filamentous fungi.
Examples of this include human lactoferrin, the insect glycoprotein Bm86 and
human tissue plasminogen activator. Lactoferrin is a glycosylated protein
expressed and secreted by glandular epithelial cells and is found in high
concentrations in milk of most species, functioning as protection against
microbial infection and in the regulation of immune function and cellular growth
promotion 0Nard et aI., 1997). Murine lactoferrin expressed in A. awamori was
biologically active and indistinguishable from native human breast milk
lactoferrin regarding size, immunoreactivity and glycosylation. The insect
glycoprotein Bm86, a cell surface glycoprotein from cells of the digestive tract of
the cattle tick Boophilus microplus, when expressed in A. niger and A. nidulans
was also glycosylated to a similar extent as the native glycoprotein (Turnbull
et aI., 1990). In the case of human tissue plasminogen activator (t-PA)
expressed in A. nidulans the fungus was capable of mimicking the differential
glycosylation of the single chain forms leading to a doublet seen when the
protein is secreted from mammalian cells (Kinghorn and Unkles, 1994; Upshall
et aI., 1987). There is also no hyperglycosylation and this is in strong contrast
to the t-PA produced in S. cerevisiae which is extensively hyperglycosylated
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(Lemontt et ai., 1985; Upshall et aI., 1987). Regarding fungal enzymes, a
comparison between the glycosylation patterns of phytase from A. niger and a
recombinant phytase showed that the oligosaccharides released from native
and recombinant phytase gave the same glycosylation pattern (Panchal and
Wodzinski, 1998) and this was also the case in recombinant Coprinus cinereus
peroxidase produced in A. oryzae (Limongi et al., 1995). Expression of the
hepatitis B virus S protein in A. niger also resulted in a product similar in size to
the native protein (24 kDa), thereby indicating the absence of
hyperglycosylation (Paper 1, this thesis).
Strategies to overcome possible hyperglycosylation problems include the in
vitro conversion of the carbohydrate structure of heterologous proteins
produced by fungi to mammalian-type oligosaccharides (Maras et aI., 1997b).
This strategy was successfully employed to convert high-mannose
carbohydrates on T. reesei cellobiohydrolase I to mammalian-type hybrid
structures and could be employed for heterologous mammalian proteins. In
yeast, the use of glycosylation mutants defective in mannan biosynthesis
proved effective to reduce hyperglycosylation (Innis, 1989). This approach has
not been used in filamentous fungi, but could be replicated.
In some cases overglycosylation can be desirable, as was found with
heterologous Aspergillus kawachi glucoamylase and calf chymosin produced in
A. awamori (Archer, 1994; Goto et ai., 1997). The addition of a glycosylation
site to the glucoamylase resulted in an enzyme with higher digestibility of raw
corn starch and higher stability in response to heat and extreme pH (Goto et al.,
1997). Introduction of an additional N-glycosylation site to chymosin led to a
product with at least three-fold improved production levels, however with a
reduction in specific activity (Archer, 1994).
2.4.1.8. Proteases
Proteolytic degradation is one of the major factors influencing the yield of
secreted proteins, especially heterologous proteins where yields rarely reach
the gram-per-litre level of many homologous enzymes (Archer and Peberdy,
1997; Van den Hombergh et aI., 1997c). Degradation can occur during the
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secretion process and after secretion in the culture fluid as a result of host cell
proteases (Jarai, 1997). Many filamentous fungi secrete considerable amounts
of proteolytic enzymes, some of which are of interest in industrial applications,
such as soy sauce production, sake brewing and milk coagulation in cheese
manufacturing (Cheevadhanarak et al., 1991; Gomi et al., 1993; Thompson,
1991). Analysis of the Aspergillus proteolytic spectrum revealed the presence
of a number of aspartic proteases, alkaline and semi-alkaline serine proteases
and serine carboxypeptidases (Jarai, 1997; Van den Hombergh et al., 1997c).
Refer to Figure 2.
Four extracellular proteases with acid pH optima have been purified from
A. niger culture filtrates (Dal Degan etaI., 1992; Inoue etaI., 1991; Krishnan
and Vijayalakshmi, 1985; Krishnan and Vijayalakshmi, 1986; Van den
Hombergh et al., 1994). These include two aspartyl proteases, PEPA and
Extracellularendeprotease
Intracellularendeprotease-{
PEPA
-rPepSin_ PEPEAspartyl Non-pepsin PEPB Extracellularendeprotease
--{
PEPC Intracellularendeprotease
r-Subtilisin
PEPD Extracellularendoprotease
Proteases- Serine_
{
PEPF Extracellularexoprotease
_Serinecarboxy PEPG Extracellularexoprotease
CPY Intracellularexoprotease
'--Metallo --Thermolysin-type -PEPH Extracellularendeprotease
Figure 2. The proteolytic system of A. niger (Van den Hombergh et al., 1997c).
PEPS, and two serine carboxypeptidases, PEPF (or CPOII) and PEPG (or
CPOI). Aspergillopepsin A (PEPA) seems to be responsible for the majority of
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extracellular acidic activities, while PEPB is a non-pepsin type acidic
endopeptidase (Berka et al., 1990; Gomi et al., 1993; Inoue et al., 1991). The
pepA, pepB and pepF genes have been shown to be regulated by nitrogen and
carbon catabolite repression, environmental pH and the presence of exogenous
protein (Jarai and Buxton, 1994; Van den Hombergh et al., 1994). A. niger also
has a metalloprotease, PEPH (Van den Hombergh et al., 1997c), and an
alkaline protease, PEPD, which is an extracellular subtilisin-type serine
protease (Jarai et al., 1994a). A. nidulans, however, produces at least three
neutral or alkaline extracellular proteases, which are produced in response to
carbon-, nitrogen-, or sulphur-limiting conditions (Cohen, 1973a; Cohen,
1973b). A gene, designated prtA, encoding one of these alkaline extracellular
serine proteases has been isolated (Katz et al., 1994). In contrast to A. niger,
only one gene (designated prtB) has been isolated encoding an acid protease
homologous to the A. niger aspergillopepsin (Van Kuyk et al., 2000).
In A. niger the proteases with acidic pH optima predominate, exhibiting the
highest activity at low pH (Bartling et al., 1996; Mattern et al., 1992; Van den
Hombergh et al., 1997b). However, in A. nidulans neutral and alkaline
proteases playa more important role and acid proteases are weakly expressed,
which was indicated by the high levels of alkaline protease (prtA) expression
and low levels of acid protease (prtB) expression observed in A. nidulans (Van
Kuyk et al., 2000). These differences may reflect differences in the physiology
of the two species. A. niger rapidly acidifies the growth medium, whereas
external alkalinisation occurs in A. nidulans. However, extracellular protease
expression increases significantly upon derepression with respect to carbon
and/or nitrogen source in both A. niger and A. nidulans. The molecular basis for
these transcriptional control mechanisms has been elucidated with the cloning
of three wide-domain regulatory genes, creA, areA and pacC. The creA gene
encodes a negative regulator protein (CREA) that mediates carbon catabolite
repression (Kelly, 1994), the areA gene encodes an activator protein (AREA)
needed to alleviate nitrogen metabolite repression (Kudla et al., 1990) and the
pacC gene encodes a pH regulator protein which is only active at an alkaline pH
and acts as an activator of alkaline target genes and a repressor of acid target
genes (Tilburn et al., 1995). Consensus recognition motifs for CREA and AREA
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have been identified in the promoter regions of the A. niger pepA, pepB and
pepF genes and mutations in the areA, creA and pace genes resulted in
reduced transcriptional levels of all extracellular proteases (Jarai and Buxton,
1994; Van den Hombergh et al., 1997c).
Intracellular proteases can also be found in Aspergillus and thus far three
proteases that are homologous to yeast vacuolar proteases have been cloned
from A. niger. The PEPC protease is a subtilisin-type serine endoprotease
homologous to the yeast vacuolar proteinase B (PRB1), PEPE is a pepsin-type
aspartyl endoprotease homologous to the yeast vacuolar pep4 gene product
and CPY is a serine carboxypeptidase (Jarai et aI., 1994b; Van den Hombergh
et aI., 1997c). These proteases are constitutively expressed and are probably
involved in non-specific protein degradation and turnover, as well as in the
activation of the precursors of several vacuolar enzymes (Jarai et aI., 1994b).
Various strategies have been employed to address the problem of proteolytic
degradation of heterologous protein products. Many protease-encoding genes
have been cloned and used to provide specific protease deletion strains and
protease-deficient mutants have also been produced (Archer and Peberdy,
1997). Disruption of the gene encoding the major extracellular acid protease
PEPA in A. awamori and A. niger reduced extracellular proteolytic activity to
approximately 20% of that of the wild type (Berka et al., 1990; Mattern et aI.,
1992). Expression of chymosin in an A. awamori pepA deletion strain resulted
in improved levels of extracellular chymosin production (Ward et aI., 1993).
Proteolytic activity of a pepB deletion strain, however, was only reduced to 94%
of that of the wild-type (Van den Hombergh et aI., 1997b). Deletion of pepE
resulted in reducing the total intracellular proteolytic activity to 32% (Van den
Hombergh et aI., 1997b). An A. niger strain lacking pepA, pepB and pepE was
subsequently constructed and protease activity in this strain was reduced to 7%
of that of the wild-type strain. This strain showed higher levels of A. niger pectin
lyase production than the single or double protease mutants constructed and
can be used to further optimise homologous and heterologous gene expression
(Van den Hombergh et aI., 1997b).
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Several protease-deficient UV mutants of A. niger have also been isolated and
characterised (Mattern et al., 1992; Van den Hombergh et al., 1995; Van den
Hombergh et al., 1997a). These mutants have varying levels of proteolytic
activity ranging from 80% to as little as 1-2% of that of the parental wild-type
strain and contain mutations in structural and/or regulatory genes involved in
proteolysis. When one of these strains was used to express human interleukin-
6 and porcine phospholipase A2, respectively, active recombinant protein was
secreted in both cases (Broekhuijsen et al., 1993; Roberts et al., 1992). An
A. nidulans mutant with reduced levels of extracellular proteases has also been
isolated with the mutations affecting the levels of alkaline protease gene mRNA,
as well as altering the expression of other proteases (Katz et al., 1996).
Another strategy to construct protease deficient mutants is the antisense control
strategy (Zheng et al., 1998). By expressing the antisense RNA of the
structural gene of carboxypeptidase (CPase), an A. oryzae mutant was isolated
which showed (CPase) levels of 30% of that of the wild-type strain. Using this
mutant as a heterologous protein expression host, a stable, higher level of
human lysozyme expression could be obtained, compared with the wild type.
Mutagenesis has also been employed to yield strains that acidify the medium
less, thereby preventing induction of acid protease expression and degradation
of heterologous protein products (Gordon et al., 2000b). This kind of protease
deficient, non-acidifying strain is commonly used in the expression of
heterologous proteins, particularly non-fungal proteins, and was also utilised for
the expression of hepatitis B viral proteins (Paper 1, this thesis; Paper 2, this
thesis; Gordon et al., 2000b; Wiebe et al., 2001). In general, a mutagenesis-
based selection programme with classical genetic strain improvement coupled
to the cloning and targeted disruption of certain protease genes can provide a
selection of host strains with diverse protease spectra and low proteolytic
activity which can be employed in heterologous protein expression (Jarai,
1997).
Yield reduction of target heterologous proteins can be due not only to co-
secreted proteases, but due to intracellular degradation (Gouka et al., 1996a)
and the release of intracellular proteases from hyphaI disruption in older
cultures (Archer et al., 1992). Proteolytic activity can also be reduced by
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growing cultures of recombinant Aspergillus strains in buffered media containing
glucose as the carbon source at high concentrations to prevent depletion of
preferred carbon source and acidification or alkalinisation of the medium with
concomitant protease induction (Bartling et al., 1996). Some problems with
proteolysis may also be overcome by the inclusion of protease inhibitors in the
growth media, but this is unlikely to be a cost-effective measure (Archer and
Peberdy, 1997).
Apart from addressing the above-mentioned factors affecting heterologous
protein production levels, other strategies for the improvement of protein
production include random mutagenesis (MacKenzie et al., 2000), DNA-tagged
mutagenesis involving restriction enzyme-mediated integration as a mutagen
(Yaver et aI., 2000), and physiological optimisation through temperature or
substrate adjustments (MacKenzie et al., 1994). Although considerable
progress has been made concerning the understanding of protein
overproduction, it should be considered that overcoming limitations at, for
example, the level of transcription will probably reveal new limitations at other
levels concerning cell physiology and protein secretion. Also, protein secretion
in filamentous fungi has proven to be very expensive in relation to energy
consumption. Therefore extensive protein overproduction may affect cell
physiology which could in turn affect gene expression and genetic stability
(Verdoes et al., 1995). In conclusion, the factors influencing heterologous
protein yield are complex and include biochemical and biophysical properties of
the protein itself; its influence on, and modification of, the host's own cellular
functions and the choice and deployment of those sequences that are
necessary for efficient transcription and translation. Therefore optimisation
strategies must be individually designed and assessed for each heterologous
protein production system.
2.4.2. Heterologous proteins produced in Aspergillus
Since the development of molecular-biological techniques opened new ways to
use filamentous fungi for the production of homologous and heterologous
proteins, many fungal and non-fungal proteins have been expressed with
varying success (Gouka et al., 1997b; Kinghorn and Unkles, 1994; Verdoes
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et al., 1995). A large market exists for recombinant enzymes in various
industries, including the animal feed, glucose syrup, alcohol, wine, brewing,
baking, fruit juice and dairy industries and this is reviewed by Archer (2000),
Archer and Peberdy (1997), Bennett (1998) and Bodie et al. (1994). Some
bacterial and fungal enzymes of commercial importance that have been
produced by recombinant aspergilli are summarised in Table 4.
Table 4. Enzymes expressed in Aspergillus.
Enzyme Source Expression Production levels Reference
host
Acid phosphatase Aspergillus A. awamori 24.2 U Piddington et aI.,
awamori 1993
Acid protease Aspergillus oryzae A. oryzae 5236 Ulg dry Gomi et al., 1993
mycelium
Alkaline protease A. oryzae A. oryzae 41529 Ulg substrate Cheevadhanarak
et aI., 1991
a-Amylase Barley Aspergillus 60 mgll Juge et al., 1998
niger
a-L-Arabino- A. niger A. niger 2.48 Ulml Flipphi et al.,
furanosidase 1993
~spergillus 2.64 Ulml Flipphi et aI.,
nidulans 1993
Aspartic proteinase Rhizomucor A. oryzae 3.3 gIl Christensen
miehei et aI., 1988
A. awamori 1.97 gIl Ward et al., 1993
Catalase A. niger A. niger 11 Ulmg protein Fowler et aI.,
1993
Chloroperoxidase Caldariomyces A. niger 10 mgll Conesa et al.,
fumago 2001
Cutinase Fusarium solani A. awamori 30 -70 mgll Van Gemeren
pisi et ai., 1996
Endoglucanase Cel/ulomonas fimi A. nidulans -20 mgll Gwynne et al.,
1987
1,4-~-Endoxylanase A. awamori A. awamori 58 kUlml Hessing et al.,
1994
~6-Fatty acid Morlierella alpina A. oryzae NR Sakuradani
desaturase et ai., 1999
a-Galactosidase A. niger A. niger NR Den Herder
et ai., 1992
Glucoamylase A. niger A. awamori 4.6 gil Finkelstein et al.,
1989
A. niger 7.5 gIl Finkelstein et ai.,
1989
A. nidulans 1.2 gil Devchand et al.,
1989
Glucoamylase A. oryzae A. oryzae 29.4 Ulml Hata et ai., 1991
Glucose oxidase A. niger A. niger 13.8 Ulmg protein Whittington
A. nidulans 5.4 U/mq protein et ai., 1990
a-Glucosidase A. niger A. nidulans 18 mU/mg protein Nakamura et al.,
1997
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Table 4. Continued.
Enzyme Source Expression Production levels Reference
host
~-Glucosidase Trichoderma A. oryzae Co-expressed, Takashima et al.,
Cellobiohydrolase reesei several hundred mgll 1998
Endoglucanase cellulases
~-1,4-Endoglucanase T. reesei A. niger 138 Ulml Rose and Van
Zyl,2002
Laccase Coprinus cinereus A. oryzae 8 -135 mgll Yaver et aI.,
1999
Myceliop hth ora A. oryzae 11 - 19 mg/I Berka et al.,
thermophila 1997
Pycnoporus A. niger 70 mg/I Record et al.,
cinnabarinus 2002
Trametes villosa A. oryzae NR Yaver et aI.,
1996
Lignin peroxidase Phanerochaete A. niger Enzyme inactive Conesa et al.,
chrysosporium 2000
Lipase Thermomyces A. oryzae 2.1 relative lipase Yaver et aI.,
lanuginosa units/ml 2000
Manganese peroxidase P. chrysosporium A. niger 100 mg/I Conesa et al.,
2000
A. oryzae 5 mg/I Stewart et al.,
1996
Manganese peroxidase Pleurotus eryngii A. nidulans 148.5 U/mg protein Ruiz-Duenas
et aI., 1999
Pectate lyase Erwinia carotovora A. niger 0.4 mg/I Bartling et al.,
A. nidulans 2.0 mg/I 1996
A. awamori 0.8 mQ/1
Pectin lyase A A. niger A. niger NR Harmsen et al.,
1990
Pectin methyl esterase A. niger A. niger 45 U/mg protein Khanh et aI.,
1991
Phenol oxidase Acremonium A. awamori 0.6 g/I Gouka et aI.,
murorum 2001
Phytase A. awamori A. awamori 328.9 U Piddington et al.,
1993
Polygalacturonase I A. niger A. nidulans 510 U/ml Bussink et al.,
1992a
Polygalacturonase II A. niger A. niger 88 U/ml Bussink et aI.,
1990; Bussink
et al., 1992b
Polygalacturonase C A. niger A. nidulans 33 U/ml Bussink et aI.,
1992a
Taka amylase A. oryzae A. oryzae 12 g/I Christensen
et aI., 1988
Triglyceride lipase R. miehei A. oryzae 8810 U/mg protein Huge-Jensen
et aI., 1989
Vanillyl-alcohol oxidase Penicillium A. niger NR Benen et aI.,
simplicissimum 1998
Xylanase A. awamori A. awamori 58 kU/ml Hessing et al.,
1994
A. awamor A. niger 140 kU/ml Verdoes et aI.,
1995
T. reesei A. niger 480 U/ml Rose and Van
Zvl,2002
NR - Not Reported
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In addition to the expression of fungal enzymes, many studies on heterologous
gene expression have concerned the genes of higher eukaryotes using the
expression hosts A. nidulans, A. niger and A. awamori for commercial reasons
(Van den Hondel et a/., 1991). High level heterologous protein production
facilitates the study of the structure and/or biological function of a protein.
Where the availability of a certain protein may be erratic, expression in a
microbial host can fulfil demand and pharmaceutically important proteins that
were previously only obtained from biological samples such as serum can be
obtained more easily with less risk of contaminating biological agents such as
viruses. Some of the proteins from non-fungal higher eukaryotes that have
been expressed in Aspergillus are summarised in the following section:
2.4.2.1. Chymosin
Chymosin, sometimes referred to as rennin, is a gastric aspartyl protease
extracted from the fourth stomach of unweaned calves (Ward, 1989). This 35.6
kDa enzyme is used commercially for milk clotting during the cheese-making
process because it specifically cleaves K-casein and is readily heat inactivated,
preventing the degradation of the whey fraction. The first filamentous fungal
host used to express bovine chymosin was A. nidulans (Cullen et al., 1987).
Chymosin is naturally secreted as a zymogen precursor (prochymosin) and the
amino terminal propeptide is autocatalytically cleaved at low pH. The gene
encoding prochymosin was placed under transcriptional control of the A. niger
glucoamylase gene and various fusion constructs with glucoamylase were also
made to enhance secretion. Secretion of chymosin enzymatically and
immunologically indistinguishable from bovine chymosin was achieved with all
the constructs transformed to A. nidulans. With the success of chymosin
expression in A. nidulans, the commercially important species A. oryzae and
A. awamori were subsequently employed for high-level expression (Tsuchiya
et al., 1993; Ward et al., 1990). Significant increase in yield was obtained using
A. awamori as host with the prochymosin cDNA fused to the entire A. awamori
glaA gene with levels reaching 140 mg active chymosin per liter culture (Ward
et a/., 1990). One problem that was identified as a factor contributing to low
yields was the production by A. awamori of the extracellular aspartyl protease,
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aspergillopepsin, which degraded the secreted chymosin (Dunn-Coleman et al.,
1991). The yield was therefore further improved to 250 mgll by deletion of the
native aspartyl protease gene (pepA) and commercial levels of chymosin of 1
gil were subsequently achieved in A. awamori by random mutagenesis of this
protease deficient strain (Dunn-Coleman et aI., 1991). Chymosin was also
successfully expressed and secreted by A. oryzae under control of the native
glucoamylase gene promoter, however levels were lower than those achieved
with A. awamori, reaching 150 mglkg wheat bran in commercially used solid-
state culture (Tsuchiya etaI., 1993; Tsuchiya etaI., 1994). The strains of
A. awamori producing commercially viable amounts of chymosin were
evaluated with extensive biochemical and toxicological tests (detailed in Ward,
1989) and cheese-making trails were conducted with the conclusion that this
chymosin constitutes a safe and effective alternative to chymosin obtained from
calves (Ward, 1991). Recombinant chymosin is now the first heterologous
fungal product that has the approval of the United States Food and Drug
Administration for commercial use (Kinghorn and Unkles, 1994). Various
reviews outline the further details of this "success story" (Archer, 1994;
Kinghorn and Unkles, 1994; Ward, 1989;Ward, 1991).
2.4.2.2. Lysozyme
Lysozyme is a 14.5 kDa enzyme that catalyses the hydrolysis of the
~-1,4-glycosidic bonds of the polysaccharide of bacterial cell walls and has
applications as a safe anti-bacterial, anti-inflammatory and even anti-tumoral
drug (Baron and Tiraby, 1992; Tsuchiya et aI., 1992). Human lysozyme and
hen egg-white lysozyme (HEWL) have been successfully expressed in
Aspergillus (Archer et al., 1990a; Tsuchiya et al., 1992). Human lysozyme was
expressed in A. oryzae under control of the Taka-amylase A gene (amyB) gene
promoter, with transformants secreting active human lysozyme at levels of 1.2
mgll (Tsuchiya et al., 1992). HEWL was initially expressed in A. niger under
control of the A. awamori glaA promoter and the A. nidulans gpdA promoter
(Archer et aI., 1990a). Secretion was directed by the native HEWL secretion
signal peptide, which was correctly processed by A. niger. Lysozyme levels up
to 12 mgll were secreted when expression was controlled by the starch-
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inducible glaA promoter and 1 mgll when controlled by the constitutive gpdA
promoter. The specific activity of the recombinant protein was identical to that
of authentic hen egg-white lysozyme and the protein was correctly folded.
Strategies to improve HEWl production included increasing the copy number of
the transforming vector, buffering the growth medium, optimisation of culturing
conditions and fusion of HEWl to the A. niger glaA gene (Archer et al., 1990b;
Jeenes et al., 1994; MacKenzie et al., 1994). HEWl secretion was improved by
optimising the levels of ammonium chloride and sodium phosphate buffer in the
medium and maximal levels were found at culturing temperatures of 20 to 25°C
in rich medium containing soya milk (MacKenzie et aI., 1994). Cultures
incubated at 30 to 3rC showed faster growth with a more rapid acidification of
the medium and lower levels of HEWL. These results suggested that protease
activity, perhaps from more rapid autolysis reduced the levels of HEWL. The
lower growth temperature may also enhance protein folding and passage
through the secretory pathway. Implementing these optimisation strategies led
to levels of 30 to 60 mgll secreted HEWL. Further optimisation of the growth
conditions in fermentation studies, influencing mycelial morphology led to yields
of up to 1 gil (Archer et aI., 1995; Wongwicharn et al., 1999). However, some
strain instability has been observed in HEWl-producing A. niger strains grown
in glucose-limited chemostat culture where the generation of morphological
mutants was pH dependent, demonstrating the importance of preserving
adequate stock cultures of new transformants and avoiding sub-culturing as
much as possible (Mainwaring et al., 1999).
2.4.2.3. Human interleukin-6
The cytokine human interleukin-6 (hll6) is a 23 kDa secreted glycoprotein with
antiviral and B-cell proliferative properties (Kinghorn and Unkles, 1994). The
biologically active protein was first successfully expressed in A. nidulans under
control of the A. niger glaA promoter (Carrez et al., 1990). Secretion was
facilitated by both the native hll6 secretion signal and the glucoamylase
secretion signal, with the fungal secretion signal proving to be more efficient.
A. nidulans transformants secreted up to 25 IJg hll6/1 into the medium and the
recombinant protein was similar in size to the native hll6 and was not
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glycosylated. Subsequently production in A. nidulans was improved by fusing
the hll6 gene to the entire A. niger glaA gene through a spacer peptide
containing a KEX2-like protein processing signal (Contreras et al., 1991). This
approach resulted in 250 times more mature hll6 with expression levels
reaching 5 mgll. A. niger and A. awamori have also been successfully
employed to produce this protein (Broekhuijsen et al., 1993; Gouka et al.,
1997a). Initially, no recombinant hll6 could be detected from A. niger
transformants and this was attributed to extracellular proteases (Carrez et al.,
1990). Subsequently, a protease-deficient A. niger transformed with several
copies of a glucoamylase-hl l6 fusion construct under control of the constitutive
A. nidulans gpdA promoter produced 15 mg/l recombinant protein
(Broekhuijsen et al., 1993). In the case of expression in A. awamori, hll6 was
fused to the catalytic domain of glucoamylase and placed under control of the
inducible A. awamori 1,4-~-endoxylanase A (exlA) promoter (Gouka et al.,
1997a). Transformants carrying a single copy of the expression vector secreted
5-10 mg hll6/1, which compared favourably with levels obtained from multicopy
A. nidulans and A. niger transformants.
2.4.2.4. Human interferon a-2
Interferon a-2 is used to treat viral disease and acts by lowering viral load by
reducing viral replication (Kassianides et al., 1988). The main source of the
protein is human serum, making its purification extremely expensive and
difficult. Biologically active human interferon a-2 was secreted from A. nidulans
by placing the gene under the transcriptional control of the tightly regulated
promoters of the A. nidulans alcA or the A. niger glaA gene (Gwynne et al.,
1987). Optimisation of the translation initiation sequence and direct fusion of
the synthetic signal peptide to the mature interferon protein sequence yielded
levels of 1 mgll secreted interferon in shake flasks on minimal medium.
2.4.2.5. Human tissue plasminogen activator
Tissue plasminogen activator (t-PA) is a complex, large, secreted serine
protease consisting of two chains (67 kDa and 30 kDa), which is important in
the dissolving of blood clots (Upshall et al., 1987). It is used therapeutically for
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the treatment of myocardial infarction, thrombosis, pulmonary embolism and
stroke, and with low serum levels of t-PA it is necessary to obtain this protein
through a recombinant source (Wiebe et aI., 2001). The protein contains
multiple cysteine residues which are involved in the formation of disulphide
bonds and there are three N-linked glycosylation sites which have been shown
to be utilised in mammalian systems. Production of this protein in A. nidulans
under control of the A. nidulans tpiA promoter resulted in a correctly processed,
secreted, active protein that was not hyperglycosylated (Upshall et a/., 1987).
The highest levels of t-PA secreted into the culture medium were 100 I-Ig/I.
However, utilising the A. nidulans ethanol induced alcC gene promoter or the
A. niger alcohol dehydrogenase (adhA) gene promoter resulted in transformants
producing levels of 1 mg/I t-PA. For production in A. niger, a protease-deficient
strain was utilised and t-PA was fused to the catalytic domain of the native
glucoamylase protein and placed under control of the constitutive A. nidulans
gpdA promoter or the inducible A. niger glaA promoter (Wiebe et aI., 2001). t-
PA was produced in quantities of 12 to 25 mg/I, and although it was present in
the two-chain form, most of the protein was not active or had low specific
activity compared with human melanoma t-PA. The reasons for this were
unclear, but possible factors influencing activity were the (His), tag employed
for purification purposes, incorrect glycosylation or aberrant processing. There
was also evidence that t-PA was degraded by extracellular proteases during
fed-batch cultivation, despite the fact that a protease-deficient strain was
utilised.
2.4.2.6. Lactoferrin
Human lactoferrin (hLF) is a 78 kDa iron-binding glycoprotein present in milk,
other exocrine secretions and the secondary granules of polymorphonuclear
granulocytes (Ward et a/., 1992b). The functions proposed for lactoferrin
include protection against microbial infection, cellular growth promotion and
regulation of intestinal iron homeostasis. Initial heterologous expression studies
were performed in A. nidulans and, under control of the alcA promoter, 5 mg/I
hLF was produced of which approximately 30% was secreted into the culture
medium. The recombinant protein was indistinguishable from native hLF with
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respect to size and immunoreactivity and was functional by the criterion of iron-
binding capacity. Subsequent expression in A. oryzae under control of the
native a-amylase promoter yielded levels of 25 mgll active, correctly processed
protein with appropriate N-glycosylation (Ward et aI., 1992a). Commercial
levels of hLF have since been obtained from A. awamori in excess of 2 gIl by
employing the glucoamylase fusion strategy combined with a classical strain
improvement programme (Ward et aI., 1995). This recombinant hLF was intact,
biologically active in terms of its ability to bind iron and human enterocyte
receptors and glycosylated to the same extent as the native hLF (Sun et aI.,
1999; Swarts et aI., 2000; Ward et a/., 1995). The protein was found to function
as a potent broad spectrum antimicrobial protein and could have potential
nutritional and therapeutic applications (Ward et a/., 1995). Similarly, murine
(mouse) lactoferrin has also been successfully expressed in A. awamori and will
be an invaluable tool to address both the species specificity of lactoferrin action
and to further clarify the in vivo biological role of this protein (Ward et al., 1997).
2.4.2.7. Porcine pancreatic phospholipase A2
Porcine pancreatic phospholipase A2 has been extensively studied as a model
enzyme for protein engineering and efficient heterologous protein production of
this enzyme can provide sufficient quantities for structure-function studies
(Roberts et a/., 1992). To this end, the cDNA gene encoding porcine pancreatic
prophospholipase A2was cloned into an A. niger expression vector downstream
of the glaA promoter region. Detectable PLA2was however only obtained when
an in-frame fusion to the entire glaA gene was made and a protease-deficient
(pepk) A. niger strain was used. This strain secreted up to 10 mgll correctly
processed, enzymatically active PLA2.
2.4.2.8. Cattle tick cell-surface glycoprotein
The cell surface glycoprotein 8m86 from cells of the digestive tract of the cattle
tick B. microplus has been shown to elicit a protective immunological response
against the ectoparasite in vaccinated cattle, but is difficult to isolate in sufficient
quantities (Turnbull et aI., 1990). Thus, this 83 kDa protein was expressed and
secreted in A. nidulans and A. niger by using the A. nidulans amdS promoter
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and the native Bm86 secretion signal. Bm86 was secreted from both
Aspergil/us strains as a soluble protein that was glycosylated to a similar extent
as the native glycoprotein. No intracellular Bm86 was detected and the highest
levels were obtained from A. nidulans which secreted up to 1.8 mg/I
recombinant Bm86.
2.4.2.9. Antibody fragments
The high affinity and specificity of monoclonal antibodies for a particular
antigen, as well as the possibility for "infinite" production, have made them a
valuable tool for the pharmaceutical industry and medical or other research
(Frenken et al., 1998). The high cost and limited availability and stability of
monoclonal antibodies has however limited their application. These limitations
could be overcome by the large-scale heterologous production of stable
antibodies or antibody fragments such as single chain Fv (scFv). Various
expression cassettes encoding the scFv-LYS D1.3 fragment were constructed
for heterologous expression in A. awamori, utilising the A. niger glaA and
A. awamori exlA promoters and signal sequences. Production levels of 10 mg/I
were obtained for both promoter systems. This level could be improved to 50
mg/I when the protein was fused to the first 514 amino acids of glucoamylase.
The recombinant protein was correctly processed and contained some O-linked
glycosylation. Subsequent expression of other scFv fragments has shown
varying success, indicating that certain scFv fragments are more easily
degraded than others in the Aspergillus mycelium and/or culture medium.
However, fed-batch fermentations of a recombinant A. awamori producing scFv-
4715 consistently yielded production levels of 200 mg/I, indicating that this
approach is likely to deliver a process of large-scale, cost-effective production of
scFv fragments.
2.4.2.10. Thaumatin
Thaumatin is an intensely sweet protein isolated from the fruit of the tropical
plant Thaumatococcus daniel/i, native to Western Africa (Zermanek and
Wasserman, 1995). In contrast to other sweeteners, thaumatin is very heat and
acid stable, occurs naturally and does not disturb the balance of the amino acid
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pool in the body after digestion and these unique properties could make it highly
attractive to the food industry as an intense sweetener and flavour enhancer. It
is also safe for diabetics and toxicological studies have established its safety as
a food additive. This protein has therefore been expressed in A. oryzae and
A. awamori (Faus et aI., 1998; Hahm and Batt, 1990). For expression in
A. oryzae, the thaumatin II cDNA was placed under transcriptional control of the
S. cerevisiae glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter and
secretion was directed by the native plant signal sequence (Hahm and Batt,
1990). In this case, the S. cerevisiae gpd promoter was properly recognised
and regulated by A. oryzae and an immunoreactive 22 kDa protein
indistinguishable from mature thaumatin was present in the culture medium at a
concentration of 50 ng/ml. In A. awamori thaumatin expression was directed by
the A. niger glaA promoter and the thaumatin cDNA was fused in-frame with the
complete A. awamori glucoamylase gene (Faus et aI., 1998). Laboratory
fermentations of recombinant A. awamori strains carrying this expression
cassette yielded secreted thaumatin concentrations of 5-7 mg/1. This production
level was further improved by using an A. awamori strain deficient in
aspergillopepsin (PEPA); employing two strong fungal promoters, the
A. awamori gdhA promoter and the A. nidulans gpdA promoter; constructing
double transformants with different expression cassettes and utilising a
synthetic gene encoding thaumatin with fungal codon usage (Moralejo et al.,
1999). This optimised transformant gave expression levels of nearly 100 mg/I in
fermentors and has potential application at the commercial scale.
2.4.2.11. Human B2-microglobulin
Class I human leukocyte antigens (HLA) bind peptides that result from cleavage
of intracellular antigens (O'Herrin et aI., 1996). The HLA molecule is a
heterodimer consisting of the noncovalent association of a polymorphic heavy
chain (a chain) and a soluble 12 kDa P2-microglobulin (P2m). The trimeric
complex (a chain, P2m and antigenic peptide) provides the context for
recognition of peptides by cytotoxic T lymphocytes. A readily available supply
of HLA class I components would be useful for assembly studies and peptide
screening. Thus the P2m has been expressed in A. nidulans using the
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A. awamori glaA promoter. In 60-liter fermentations, 117 I-Ig/Iof recombinant
132mwas secreted into the culture medium which was biochemically similar to
that obtained from human urine, and effectively interacted as a subunit of class I
MHC molecules. This successful expression of biologically active 132msuggests
that fungal systems might be useful for the production of other active
components of the HLA class I MHC complex.
2.4.2.12. Human mucus proteinase inhibitor
Human mucus proteinase inhibitor (MPI) is a serine antiproteinase of leukocyte
elastase, chymotrypsin-like proteinases and trypsin (Mikosch et al., 1996). The
inhibitor is produced locally by mucosal cells, including those of the respiratory
tract, where its principal physiological function is probably protection of the
airway epithelium from attack by elastase. MPI therefore has applications as a
therapeutic agent in destructive lung diseases such as pulmonary emphysema
or cystic fibrosis and has also been shown to have antiretroviral activity, which
may contribute to the infrequent oral transmission of HIV-1. In its biologically
active conformation the 14 kDa protein is highly disulphide bonded. MPI was
expressed in A. niger by utilising the promoter, signal sequence and first 514
amino acids of the A. niger glaA gene, creating an in-frame fusion to the human
mpi gene via a linker containing a KEX2-like processing site. Recombinant
A. niger secreted up to 3 mg/I MPI into the medium, which was correctly
processed and folded properly. Recombinant MPI retained full inhibitory activity
against chymotrypsin and leukocyte elastase.
Some other non-fungal proteins expressed in A. niger include bovine
enterokinase (5 mg/I) (Svetina et al., 2000) and bovine pancreatic trypsin
inhibitor (10 to 20 mg/I) (MacKenzie et al., 1998), where some molecules were
however aberrantly processed. Expression of the E. coli enterotoxin subunit B
gene in A. nidulans resulted in mature peptide that was, however, retained in
the endoplasmic reticulum (Turnbull et al., 1989).
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2.4.3. Future directions for the Aspergillus expression system
The results described in the previous section indicate that although
considerable progress has been made in the development of Aspergillus for the
production of complex mammalian proteins, not all problems have been
resolved. However, the utility of this host for effective expression of mammalian
proteins has been proven with the numerous successes that have been
achieved. However, despite the apparent success of expressing higher
eukaryotic proteins in Aspergillus, the potential of this host to produce another
pahrmaceutically important group of proteins, namely viral proteins, is largely
unknown. Only one report has been published in a Chinese journal of the
production of hepatitis B surface antigen (HBsAg) in Aspergillus foetidus (Liu
et al., 1990). No other reports have been found to date detailing the production
of viral proteins in Aspergillus. The inherent advantages and potential of the
system, however, warrant an investigation into the capability of this fungal host
as a viral protein production system.
2.5. The Hepatitis B Virus
The first report of what must have been hepatitis B was that of LOrman who
reported on an epidemic of hepatitis that occurred in shipyard workers in
Bremen following vaccination against small pox with glycerinated lymph of
human origin in 1883 (Purcell, 1994; Zuckerman, 1975). The first step in the
identification of the hepatitis B virus was made in 1963 by Baruch S. Blumberg
who observed an antibody that reacted with an antigen present in the blood of
an Australian aborigine infected with hepatitis, and he thus called this antigen
the Australia antigen (Krugman, 1985; Tiollais and Buendia, 1991). This
antigen was then later (in 1968) identified as the hepatitis B virus surface
antigen (HBsAg) (Tiollais and Buendia, 1991). In 1970, Dane and colleagues
first identified the so-called Dane particle under the electron microscope, thus
visualising the complete viral particle for the first time (Krugman, 1985).
2.5.1. Prevalence of hepatitis B
Since serological tests for the detection of hepatitis B virus (HBV) infection were
first applied in the mid-1960s, the incidence of hepatitis B progressively
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increased until the mid-1980s (Purcell, 1994). To date, hepatitis B is a
widespread and serious liver disease and can be considered a global health
problem with an estimated 2000 million HBV carriers in the world today (Figure
3) (Vryheid et al., 2001). Even though there is a highly effective vaccine
available, between 200 000 and 300 000 people acquire HBV infection each
year in the United States alone (Maddrey, 2000). Approximately 5% to 10% of
infected patients become long-term carriers of the virus. According to some
estimates, of the more than 350 million people world-wide that are chronically
infected with HBV, 25% to 40% will die from liver cirrhosis or primary
hepatocellular carcinoma associated with the virus (Nowak et ai., 1996; Vryheid
et al., 2001). At least one million deaths per year world-wide may be attributed
to HBV-induced and associated liver diseases (Vryheid et al., 2001). The
problem is most prominent in developing countries with 95% of chronic carriers
residing in the developing world (Ayoola, 1988). In Southeast Asia and tropical
Africa, chronic carriers of the virus represent 10% or more of the population,
whereas they make up less than one percent in North America and western
Europe. It is estimated that there are about 50 million HBV carriers in Africa
alone with 60% to 99% of healthy African adults showing evidence of exposure
to HBV.
With regard to southern Africa specifically, in a study performed in Swaziland in
1983 and in Namibia in 1985, 82.6% and 98.9%, amongst those tested showed
exposure to HBV, respectively (Ayoola, 1988). In South Africa, more than 70%
of the population has been exposed to HBV, with an estimated 10% being
carriers (i.e. HBsAg positive) of the virus (Tsebe et ai., 2001). The carrier rate
differs regionally, with higher rates of infection in rural areas (5-10%) than urban
areas «5%). In Western industrialised countries, high-risk populations consist
of persons in direct contact with chronic carriers or with their blood samples
(nurses, doctors, dentists), recipients of blood or blood products
(haemophiliacs, patients receiving blood transfusions or dialysis treatments),
prison inmates, intravenous drug abusers, homosexuals and persons with
multiple sex partners. However, in Africa all susceptible groups (i.e. those who
are negative for HBV markers) are at high risk of infection, with the highest risk
occurring among children (Ayoola, 1988; Garrison and Baker, 1991; Tiollais and
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Buendia, 1991). A pre-immunisation survey conducted in South Africa in 1999
indicated HBsAg carriage of 8.9% in 1-year-olds, increasing to 12.8% in 3-year-
olds and rising to 15.7%by the age of 6 years (Vardas et al., 1999).
HBV is also a highly infectious virus. In the far East, viral transmission occurs
most frequently from an infected mother to her infant (Hino et al., 2001).
However, this mode of transmission is of little significance in Africa. Active
infection is unusual during early infancy, because of protective maternal
antibodies passively transferred. Clearance of such antibodies occurs within
the first year and thereafter most African children are infected. Amongst African
adults, blood transmission of HBV is of minor significance, rather scarification,
tattooing, blood-sucking vectors, sexual intercourse and uncontrolled injections
Geographic Pattern of Hepatitis B Prevalence, 1997
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Figure 3. Geographic distribution of chronic hepatitis B infection world-wide, shown as hepatitis
B surface antigen prevalence. World Health Organisation (Maddrey, 2000).
have been incriminated in transmitting HBV (Ayoola, 1988). All these, however,
contribute a small proportion of HBV transmission, as the majority of infections
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occur in early childhood, and this is also the case in South Africa (Vardas et al.,
1999). The virus can also spread rapidly within a family or small community,
because it can be found in blood, saliva and semen (Tiollais and Buendia,
1991). In fact, the epidemiology of HBV is very similar to that of Acquired
Immunodeficiency Syndrome (AIDS), but HBV is far more contagious than
AIDS. HBV is therefore primarily a disease of infants in developing nations,
whereas in Western countries it is mostly confined to adults. This fact has very
important consequences for future vaccination strategies in that in the Third
World, mass vaccination is necessary, but in Western countries only high-risk
population groups need to be protected. Therefore, in accordance with
recommendations made by the World Health Organisation (WHO), 110
countries had introduced the HBV vaccine into their Expanded Programme on
Immunisation (EPI) by April 2000 (Tsebe et al., 2001) (Refer to Figure 4). Of
these, only 8 are African countries, despite the high prevalence of HBV infection
on this continent. South Africa integrated the HBV vaccine into the EPI in April
1995 and this has already shown a positive impact in the elimination of HBsAg
carrier rate in children <5 years (Aspinall and Kocks, 1998; Hino et al., 2001;
Tsebe et al., 2001) .
.....
, I~.
Cl None
- Infant
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)
Figure 4. Countries using hepatitis B vaccine in their national immunisation system, 2000
(WHO).
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2.5.2. Subtypes of the Hepatitis B Virus
The HBsAg possesses a number of antigenic subdeterminants (Holland, 1985;
Peterson et ai., 1982). The a determinant is common to all HBV isolates,
regardless of geographical origin or clinical source. It has a highly conserved
amino acid sequence and is exposed on the surface of the HBV particle
(Holland, 1985; Howard and Allison, 1995). The a determinant is thus regarded
as a group-specific determinant (Eble et ai., 1987). Variations in the primary
structure of the a determinant have been described and were shown to
markedly change the antigenic structure of HBsAg (Tonekaboni-Seddigh et ai.,
2000). Apart from this group-specific determinant, the HBsAg also contains
either the d or y determinant and either the w or r determinant (Eble et al.,
1987). These are the type-specific determinants and it was found that
variations at amino acid sites 122 and 160 alone defined the dly or wir
variations, respectively (Eble et a/., 1987; Magnius and Norder, 1995). The 5'
end of the preS1 region of ad subtypes also contains an additional sequence of
33 bp or 12 bp compared with ay subtypes (Tiollais et ai., 1985). There are
therefore four major antigenic types of HBsAg, namely adw, ayw, adr or ayr.
Subdivision of the w determinant into four subdeterminants and the
identification of the q determinant has led to sérological classification of HBsAg
into 9 categories (or subtypes), namely ayw1, ayw2, ayw3, ayw4, ayr, adw2,
adw4, adrq+ and adrq- (Holland, 1985; Magnius and Norder, 1995). It is
generally accepted that this heterogeneity reflects genetic differences between
hepatitis B viruses of different subtypes (Eble et ai., 1987). Thus, sequence
data of viral genomes can be used to trace routes of infection, to reconstruct the
phylogenetic history of viruses and to delimit genetic subtypes (Hu and
Peterson, 1988). Genetic classification based on the comparison of complete
genomic sequences has defined 6 genomic groups (genotypes) of HBV,
designated A, B, C, 0, E and F. A review of the subtypes contained in these
groups as well as their distribution is given by Magnius and Norder (1995) and
summarised in Table 5.
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Table 5. Geographical distribution of HBV genotypes and subtypes (Magnius and Norder,
1995).
Hepatitis B Genomic Group Subtype Areas of high prevalence
A adw2
ayw1
adw2
ayw1
adw2
B
C
North-western Europe, sub-Saharan Africa
Central Africa
Indonesia, China
Vietnam
East Asia
adrq+ Korea, China, Japan
adrq- Polynesia
o
ayr
ayw2
ayw3
ayw4
adw4q-
E
F
Vietnam
Mediterranean area
India
West Africa
American natives, Polynesia
2.5.3. The Disease
Hepatitis B is a liver disease that can manifest itself in various ways. After a
two- to six-month incubation period, HBV infection can lead to acute hepatitis
and liver damage, causing abdominal pain, jaundice, elevated levels of certain
enzymes in the blood, inflammation and other symptoms (Ganem and Varmus,
1987; Tiollais and Buendia, 1991). Many individuals experience mild or no liver
injury and the disease remains permanently asymptomatic. Viral replication
does not appear to be cytosolic, rather variation in the severity of liver damage
can be attributed to differences in host immune response (Ferrari et a/., 1996;
Ganem and Varmus, 1987). Usually, a patient with acute hepatitis will recover
completely as primary infection is mostly self-limited, with a prompt, vigorous
and broad-based cellular immune response resulting in clearance of viral
antigens and infectivity from liver and blood and the development of lasting
immunity to re-infection (Ganem and Varmus, 1987; Grob, 1998; Moradpour
and Wands, 1995). However, 5% to 10% of individuals do not resolve primary
infection, but develop a persistent, usually life-long, hepatic infection, possibly
due to a weak immune response and thus become chronic HBV carriers
(Ganem and Varmus, 1987; Grob, 1998; Tiollais and Buendia, 1991).
Generally, it is from these chronic carriers that the virus is spread and also most
of the mortality resulting from HBV infections occurs from chronic rather than
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acute disease (Ganem and Varmus, 1987). Some chronic carriers are healthy,
having limited liver damage and no symptoms (Tiollais and Buendia, 1991).
Others acquire chronic persistent hepatitis, sometimes causing fatigue. In the
worst cases, chronic active hepatitis develops which can lead to cirrhosis of the
liver and finally hepatocellular carcinoma (HCC), a primary liver cancer, which
usually does not develop until after a 30- to 50-year latency period. In fact, the
hepatitis B virus is second in importance only to tobacco as a known human
carcinogen. It is this association, amongst other aspects, that has fuelled the
study of the structure and molecular biology of the virus.
2.5.4. Treatment of Hepatitis B
Therapy of HBV carriers can aim to either inhibit viral replication or enhance
immunological responses against the virus or both (De Clercq, 1999; Nowak
et al., 1996). Various drugs have been developed for the treatment of viral
hepatitis, such as the nucleoside analogue (-)-2'-deoxy-3'-thiacytidine
(Iamivudine). Lamivudine has potent inhibitory effects on HBV replication in
vivo and was effective in lowering viral levels, but as soon as the drug is
withdrawn, the virus returns. Other experimental drugs include suramin,
acyclovir and adenine arabinoside (which causes a reduction in hepatitis B DNA
polymerase levels) and many others, however some of these drugs were
associated with severe and unacceptable toxicity or caused side-effects (De
Clercq, 1999; Tabor, 1988). In fact, so far, none of the marketed antiviral drugs
have been found to be effective for the treatment of viral hepatitis. Researchers
have therefore studied the human immune system for clues as to the treatment
of viral hepatitis. Recovery from hepatitis B virus infection is dependent on the
integrated activities of the patient's interferon and immune systems (Thomas,
1988). Viral antigens are seen on the surface of the hepatocyte and the
antigens, in association with the class I major histocompatibility complex (MHC)
proteins, make the cell a target for cytotoxic T-cell lysis. In the early stage of
acute HBV infection, alpha-interferon (alpha-IFN) is produced, resulting in the
increase of MHC expression on hepatocytes and the activation of a series of
enzymes which lead to inhibition of viral protein synthesis (McClary et al.,
2000). Recombinant a-IFN was thus produced recombinantly and used in the
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treatment of chronic HBV infection and was shown to induce complete
remissions in certain HBV carriers (Dusheiko et aI., 1988; Kassianides et a/.,
1988; Perez et a/., 1988). While alpha-IFN can be toxic when given in high
doses and does show substantial side-effects, it has been shown to be a
promising therapy (Kassianides et a/., 1988; Thomas, 1988). Other therapies
include the use of beta-IFNs, gamma-IFNs, interleukin II and combinations
thereof which mainly play a role in stimulating and amplifying the immune
response (De Clercq, 1999; Gómez et al., 1988; McClary et al., 2000; Ohta
et a/., 1988; Thomas, 1988). For example, it has been demonstrated that the
use of a combination of lamivudine and a-IFN is more effective than either
monotherapy (Maddrey, 2000). However, HBV will often recur after cessation of
therapy and thus, preventative measures such as vaccination strategies are still
the only real solution to the problem of HBV.
2.5.5. Structure of the virus
The hepatitis B Virus (HBV) is a small (440A) DNA virus classified in the family
Hepadnaviridae (hepatropic DNA viruses), genus Orthohepadnavirus (Huovila
et a/., 1992; Purcell, 1994). HBV has a double-walled structure consisting of
two concentric protein coats (Figure 5) (Tiollais and Buendia, 1991). The
envelope, or outer coat, contains three proteins, designated major (S), middle
(M) and large (L) protein, respectively. One virion contains 300 to 400 major
protein molecules and 40 to 80 middle and large protein molecules (Tiollais
et aI., 1985). The viral particle also has a host-derived lipid composition
consisting of phospholipids (principally phosphatidyl choline), free and esterified
cholesterol and small quantities of triglycerides (Ganem and Varmus, 1987).
The capsid, or inner coat also known as the core, is made up of a single core
protein species that surrounds and interacts with the viral DNA.
The HBV genome is a partially double-stranded, relaxed-circular DNA molecule
of only 3.2 kilobases (kb) in length, making it the smallest of any animal DNA
virus yet encountered (Seeger and Mason, 2000). The DNA molecule displays
two remarkable asymmetries that set it apart from all other viral chromosomes:
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1. The two base-paired strands are not identical in length, i.e. one strand is
longer than the other. The full-length strand is complementary to the viral
mRNAs and, by convention, is designated as the minus strand. The shorter
complementary strand, which can vary in length at the 3' position, is thus the
plus strand.
2. The minus strand DNA contains proteins covalently linked to the 5' terminus,
whereas the plus strand contains an oligonucleotide attached to the 5'
terminus.
These asymmetries are a result of the replicative mechanism of the genome (for
a review see Ganem and Varmus, 1987).
2.5.6. Genomic organisation
The HBV genome is a miracle of compactness, consisting of only four open
reading frames (ORFs) all encoded by minus-strand DNA and coding for four
genes, namely the S, C, P and X genes which show extensive overlapping
(refer to Figure 5) (Ganem and Varmus, 1987; Tiollais and Buendia, 1991).
Regulatory sequences controlling the production of viral proteins as well as the
replication cycle are also situated in these coding sequences.
• Gene S. This gene codes for the major envelope protein (sometimes called
the small protein [S]) and includes all the specifications for hepatitis B
surface antigen (HBsAg) (Tiollais and Buendia, 1991). Upstream of this
ORF is an in-phase reading frame with two conserved in-phase ATG
codons, dividing this upstream sequence into two regions, namely the preS1
and preS2 region. These regions are involved in the synthesis of the other
envelope proteins: the middle protein (M) is encoded by preS2 and the S
gene and the large protein (L) is encoded by preS1, preS2 and the S gene.
• Gene C. This gene encodes the capsid protein and is also preceded by a
short preC region encoding a hydrophobic peptide involved in viral particle
assembly.
• Gene P. Parts of all the other genes make up this gene and it is believed to
encode the viral polymerase (Mr-90 ODD), which possesses a reverse
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Figure 5. Schematic structure of HBV particle and genomic organisation. The ORFs for
preS1preS2S, preS2S, preC/C, P and X are indicated with the encoded polypeptides. The
outer circle depicts the viral transcripts with the common polyadenylation site (Caselman, 1996).
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transcriptase activity and is essential to viral replication (Ganem and
Varmus, 1987; Tiollais et aI., 1985; Tiollais and Buendia, 1991). In addition
to its catalytic role for viral genome synthesis, the P protein also plays a role
in encapsidation (Jeong et al., 2000).
• Gene X. This gene covers the cohesive ends of the viral DNA strands and
its protein product (HBx) of 145 to 154 amino acids (depending on the
subtype) acts as a transcriptional transactivator of the HBV core gene
promoter (Reifenberg et aI., 1999; Tiollais and Buendia, 1991). HBx is also
involved in host cellular signal transduction pathways, playing a role in the
deregulation of cell growth, and is therefore associated with development of
liver oncogenesis (Rahmani et aI., 2000; SchlOter et al., 1994).
It is interesting to note the remarkable parsimony underlying the coding
organisation of the viral genome: every nucleotide in the genome is in at least
one coding region, 50% of the sequence can be read in more than one frame
and even within a frame multiple ATG codons are sometimes used to give rise
to multiple related proteins (Ganem and Varmus, 1987).
2.5.7. Synthesis and assembly of viral proteins
Electron microscopy of partially purified preparations of HBV from human serum
reveals three types of viral particles (Ganem and Varmus, 1987) (Figure 6):
1. 43 nm double-shelled particles, called Dane particles, which represent the
intact virion.
2. 20 to 22 nm spheres, usually present in 103- to 106-fold excess over virions
and termed the hepatitis B surface antigen (HBsAg) (Peterson, 1987).
3. Filaments of 20 to 22 nm in diameter and with variable length.
The latter two contain no viral DNA and are called subviral particles. The
protein composition of the filaments is identical to that of the complete virion,
while the spherical particles contain the major and middle proteins in about the
same ratio as in the virion, but with at least 20 times less of the large protein
(Tiollais et al., 1985). To understand the dynamics of the formation of these
various particles it is important to explore viral synthesis and assembly.
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Subviral sphere
(pseudoviral particle)
Subviral filament
Dane particle
Figure 6. Electron micrograph of serum containing the three distinct morphological forms of the
hepatitis B viral particles. Magnification: 252 OOOx(Zuckerman, 1975).
In the life cycle of HBV, the synthesis of viral proteins is tightly regulated at the
transcriptional and translational level (Tiollais and Buendia, 1991). Within the
nucleus of the hepatocyte, the single-stranded region of the viral DNA is
completed and the genome is converted into a supercoiled DNA molecule,
referred to as the covalently closed circular (CCC) DNA (Fallows and Goff,
1996). In contrast to retroviruses, the hepadnaviral genome is not integrated
into the host cell chromosome (Mason et aI., 1983; Tagawa et a/., 1986).
Instead, the unintegrated molecules of CCC DNA serve as template for
transcription. However, various linear forms of viral DNA resulting from abortive
or inefficient replication have been identified in infected liver cells. These DNA
molecules then participate in nonhomologous recombination with cellular DNA
thereby integrating into the host genome, sometimes resulting in chromosome
translocation which has been associated with hepatocarcinogenesis (Meyer
et a/., 1992; Yang and Summers, 1999).
Each of the HBV genes has one or more promoters regulating its activity and
these promoters are in turn regulated by one or both of the viral enhancer
elements that are located upstream of the core promoter (Seeger and Mason,
2000). Two major mRNA molecules exist, namely a 2.1-kb mRNA and a 3.5-kb
mRNA (Tiollais et a/., 1985) (Refer to Figure 5). The 2.1-kb mRNA covers the
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preS2 region, gene S and gene X. The 3.5-kb mRNA is actually longer than the
complete genome and contains a terminal repeat of about 100 nucleotides. It
encodes the capsid protein and the viral polymerase (Tiollais and Buendia,
1991). A third transcript of 2.4-kb has also been identified and this serves as
the mRNA for the expression of the pre-S1 protein (Ganem and Varmus, 1987;
Masuda et ai., 1990) and a 0.8 kb X-mRNA transcript was demonstrated after
transfection of cell lines with HBV DNA (Caselman, 1996). Transcription is
generally attributed to host RNA polymerases, probably RNA polymerase II, and
no splicing events occur (Ganem and Varmus, 1987; Tiollais et al., 1985). In
fact, HBV S transcripts contain a region known as the posttranscriptional
regulatory element (PRE), which allows for the export of HBV S transcripts
without these transcripts becoming spliced and thus activates their transport
from the nucleus to the cytoplasm without any effects on transcriptional initiation
or cytoplasmic RNA stability (Huang and Yen, 1995).
2.5.7.1. The Major Protein
The S gene promoter directs constitutive expression of the S gene and it is also
the protein product of this gene that is present in the highest amounts (Tiollais
et al., 1985). The S protein consists of 226 amino acids and is present in both
unglycosylated form (24 kDa) and N-glycosylated form (27 kDa) (Huovila et al.,
1992). As mentioned, the 22 nm subviral particle consists almost solely of this
protein with approximately 100 monomers making up the particle (Ganem and
Varmus, 1987). The monomers are extensively cross-linked by interchain
disulphide bonds and the intact particle is highly immunogenic. It has been
postulated that these "dummy particles" serve to absorb neutralising antisurface
antibodies during progression of infection as these non-infectious particles are
produced in excessive amounts (50-300 mg HBsAg/1of serum). The assembly
of this particle occurs in an intermediate compartment between the ER and the
Golgi apparatus (Huovila et ai., 1992; Roingeard et ai., 1990). The 226-amino
acid sequence of the S protein is sufficient for the mobilisation of cellular lipids
(which make up about 25% of the particle mass) needed for subviral particle
assembly, self-assembly of the 100 protein molecules, intracellular transport
and secretion of the lipoprotein complex (Prange et al., 1995a). The Sprotein
Stellenbosch University http://scholar.sun.ac.za
76
is initially synthesised as a transmembrane polypeptide and the membrane
translocation process does not involve cleavage of N-terminal amino acids.
Both translocation and export of the protein can proceed in the absence of any
other viral gene products (Eble et a/., 1987).
The primary structure of the S protein can be divided into three hydrophobic and
two hydrophilic regions (Berting et a/., 1995; Eble et a/., 1986). The
aminoterminal part (residues 11 to 29) is able to insert into the ER membrane,
thus mediating the translocation of the upstream part of the protein into the ER
lumen and this region is thus called signal I (Berting et a/., 1995; Eble et a/.,
1987). A second section, called signal II (residues 80 to 98), also inserts into
the ER membrane and mediates translocation of the downstream sequences
(Figure 7). Both signal sequences contain several conserved structural
features, including a hydrophobic domain followed by specific charged residues
(Eble et a/., 1987). The third hydrophobic area is the C-terminus of the protein
and it projects into the ER lumen and is not completely in a transmembrane
configuration as it can induce antibody response (Berting et a/., 1995; Eble
et a/., 1987). Two further membrane spanning domains have been proposed,
based on model building, but have not been examined experimentally
(Ostapchuk et a/., 1994). Deletion of the major hydrophobic domain (N-terminal
100 aa) completely abolishes the ability to form particles and removal of amino
acids 21 to 80 decreases the ability to form particles, and the particles formed
are correspondingly smaller (Araki et a/., 1990). The first hydrophilic region
(residues 120 to 160) forms the HBV-specific determinant "a" and projects into
the ER (Berting et a/., 1995). The Asn found in this region (Asn-146) is the only
one of the multiple potential glycosylation sites used and the initial glycosylation
events occur in the ER. The potential glycosylation sites at Asn-3 and Asn-59
are not used, but it is unknown whether this reflects their failure to enter the
lumen or whether they are in a conformation unfavourable for glycosylation
(Eble et a/., 1987). Eight cysteins are also located in this region which may play
a role in intramolecular or intermolecular disulphide bridge formation. The
second hydrophilic domain (residues 30 to 80) also contains conserved cysteins
which are essential for secretion of 22 nm particles.
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Within one hour of polypeptide formation, the polypeptide chains embedded in
the ER membrane in this way undergo a conformational change and/or
aggregation making them no longer susceptible to protease action (Simon et a/.,
1988). Newly synthesised S protein is translocated across to the lumen of the
ER where disulphide-linked dimers are rapidly formed (Huovila et a/., 1992).
After the transport of dimers to a post-ER/pre-Golgi compartment, the formation
of oligomer erosslinks occurs and thus the subviral particle matures by budding
into this post-ER/pre-Golgi compartment (Huovila et al., 1992; Prange and
Streeck, 1995). The particles are then rapidly exported from the cell via the
constitutive pathway of vesicular transport and the Golgi where further
modification of the oligosaccharides occurs (Simon et a/., 1988). All of the
oligosaccharides on the secreted HBsAg lipoprotein particles are of the N-linked
complex type (Huovila et a/., 1992).
2.5.7.2. The Middle and Large Proteins
Like the S protein, the middle (281 amino acids) and large (389 or 400 amino
acids depending on the subtype) proteins are also found in two forms, either
glycosylated at Asn-146 of the S sequence or unglycosylated at this site
(Prange and Streeck, 1995). The M protein is also glycosylated at Asn-4. Thus
the M protein is present in two forms, one of 33 kDa, containing only one glycan
and one of 36 kDa, containing 2 glycans (Tiollais et a/., 1985). The L protein is
42 kDa (glycosylated) or 39 kDa (non-glycosylated) in size. The M protein is
efficiently secreted in a similar manner to the S protein with the preS2 region on
the luminal side of the ER (Prange et a/., 1995a) (Figure 7). The L protein is,
however, not easily secreted. It has also been shown that both Mand S are
found in the virion and subviral lipoprotein particles, while L is found almost
exclusively in the virion. The hypothesis has been made that the virion
incorporates the dimeric forms of the glycoprotein before they exit from the ER
while the excess Sand M dimers are transported to the intermediate
compartment in which maturation to lipoprotein particles occurs (Huovila et a/.,
1992). The L protein is essential for virion formation and some L protein can
also be found in the filamentous form of the subviral particles (Prange and
Streeck, 1995; Prange et a/., 1995a). The entire preS region of the L protein is
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generally not translocated across the ER membrane, but is situated on the
cytosolic side where the N-terminus of the L protein is co-translationally
myristoylated (Ostapchuk et ai., 1994; Prange and Streeck, 1995). However,
the L protein can have a dual topology, playing a role in both envelopment of
viral nucleocapsids and also taking part in binding to the host cell (Berting et al.,
1995). The preS1 domain of the L protein is initially located on the cytosolic
side of the ER, but substantial alteration in the transmembrane conformation
occurs posttranslationally, yielding two topologically different populations. Thus,
on the complete virions 50% of the L proteins expose the preS1 domain on the
surface of the virions (Figure 7). It has thus been hypothesised that the dimers
associate in such a way as to form a hydrophilic channel to transport the
hydrophilic preS1 domain from the lumen of the budded particles to the surface.
Finally, transactivating functions have also been attributed to viral proteins
translated from 3'-truncated HBV preS/S sequences (Caselman et ai., 1997).
For example, deletion of that least 87 C-terminal amino acids of the M protein
results in the generation of the transactivating form, which then acts as a
pleiotropic activator of various cellular promoters and thereby plays a role in
hepatocarcinogenesis (Caselman et ai., 1997; SchlOter et ai., 1994).
2.5.7.3. The Core Protein
Transcription of the C gene promoter seems to be inducible, with a
transcriptional enhancer element 450 bp upstream of the C gene promoter
(Ostapchuk et al., 1994). This element exhibits a preferred activity in human
hepatocytes. The 21 kDa core protein has an extremely basic segment at the 3'
end which shows DNA-binding activity and HBV core antigens accumulate
predominantly in the nucleus (Ganem and Varmus, 1987; Ostapchuk et al.,
1994). The core protein has also been shown to interact with the viral
polymerase and this interaction is required for several steps in genome
replication and encapsidation (Koschel et al., 2000; Lott et ai., 2000). In some
cases, the preeore sequences are also expressed and these proteins are
proteolytically processed and secreted into the medium, forming the 50-
called"e" antigen which can be found circulating in the blood during HBV
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Figure 7. Hypothetical model of the three hepatitis B surface proteins. "Liver" indicates the
hepatocyte binding site and "HSA", the human serum albumin binding site. The amino-terminus
of the large protein is bound at Gly2 to myristic acid. I, II: Signal sequences. A mannose-rich
glycosidic group is attached to Asn4 of the middle protein and a complex glycoside is present in
approximately half of the S domain (Gerlich et al., 1990).
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infection (Ganem and Varmus, 1987; Ostapchuk et aI., 1994). The core protein
also has the ability to assemble into nucleocapsids independently of any other
viral gene products and these nucleocapsids are resistant to cytotoxic
T-Iymphocyte-induced apoptosis (pasquetto et aI., 2000). Two separate
regions of the core polypeptide are exposed on the surface of core particles and
thus provide targets for interaction with the envelope components (Seeger and
Mason, 2000). The budding of the complete virion is triggered by interactions of
the cytoplasmic nucleocapsid with the preS region of the L transmembrane
envelope protein (Ostapchuk et aI., 1994).
2.5.8. Functions of the viral envelope proteins
As has been mentioned, the S protein is the predominant constituent of the viral
envelope and plays a primary role in the assembly of the viral particle (Prange
and Streeck, 1995). The M protein has been found in higher concentrations in
the DNA-containing HBV particles (virions) than in the subviral particles and the
L protein is found almost exclusively in complete virions with low levels of L
protein occurring in the filamentous subviral particles (Pontisso et al., 1989;
Prange et al., 1995a). This suggested a role for these proteins in infectious
HBV particle assembly or function (Pontisso et aI., 1989). The preS2 domain of
the M protein possesses a polymerised human serum albumin (pHSA) binding
site (localised to amino acid residues 126 to 140) and plays a role in attachment
of HBV to hepatocytes using pHSA, which also has an affinity for liver cells, as
a linker molecule (Heerman et aI., 1988; Petit et et., 1992). This is a species-
specific process and HBV binds only to human and other primate serum
albumin (Ganem and Varmus, 1987; Gerlich, 1991). The L protein, apart from
being absolutely necessary for virion formation, also plays a role in viral
attachment to hepatocytes with an attachment site situated on the preS1
domain from amino acid 21 t047 (Gerlich, 1991; Paran etaI., 2001; Prange and
Streeck, 1995). This site is the HBV hepatocyte receptor (HBV Hep-R) binding
site and attaches directly to liver plasma membranes via an 80-kDa protein
receptor (Petit et al., 1992; Pontisso et al., 1989; Ryu et al., 2000). However,
the number of S proteins on the HBV envelope is much higher than that of
preS1 domains and they probable playa role in attachment by forming multiple
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contacts with the cell membrane (Paran et a/., 2001). This binding, however, is
probably unstable, but is stabilised by the subsequent interaction of the preS1
epitope with its corresponding receptor. The L protein also regulates the
nuclear pool of covalently closed circular viral DNA (Prange et a/., 1995a). The
preS amino acid sequences are the least conserved coding sequences among
different hepadnaviruses and have thus been implicated in host range
determination. It was shown that the species-specificity of hepadnaviral
infection is determined at the level of virus entry and is governed by the preS
domain of the viral L protein (Ishikawa and Ganem, 1995). Variations in the
preS regions could be a means of evading the host immune system (Tiollais
et a/., 1985). The S protein may also playa direct (e.g. by mediating membrane
fusion) or indirect (e.g. by allowing proper display of the preS sequences) role in
viral entry (Ishikawa and Ganem, 1995).
For more detailed information on hepatitis B virus biology including replication,
transcription, translation, encapsidation, infection and mechanisms of
hepatocarcinogenesis see Caselman, 1996; Fallows and Goff, 1996; Ganem
and Varmus, 1987; Seeger and Mason, 2000.
2.6. Hepatitis B Vaccines: Heterologous Expression of
Hepatitis B Surface Antigens
Since the first successful vaccination against an infectious disease (smallpox)
by Edward Jenner in 1796, the science of vaccinology has developed
immensely from the classical use of whole-cell vaccines, consisting of killed or
attenuated pathogens, to new vaccines based on the subunit principle and,
most recently, nucleic acid vaccines (Dertzbaugh, 1998; Gregoriadis, 1998;
Hilleman, 2000; Liljeqvist and Stahl, 1999).
Prevention of hepatitis B was initially based on passive immunoprophylaxis
through administration of serum immune globulin derived from pooled human
serum and containing antibodies against hepatitis A virus and a varying degree
of antibodies against HBV (Garrison and Baker, 1991). Significant
advancement in the prevention of hepatitis B was made with the development of
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vaccines. The history of hepatitis B vaccine development is summarised in
Table 6 (Greenberg, 1993).
Table 6. History of hepatitis B vaccine development (Greenberg, 1993; Tsebe et a/., 2001).
Date Event
1883
1950s-1960s
1965
1970s
1982
1984
1986
1988
1989
1991
2000
First recognised outbreak of HBV infection in Germany
Krugman described two types of viral hepatitis
Blumberg discovered the Australia antigen (HBsAg)
Dane particle, HBV antigens and antibodies characterised
Plasma-derived vaccine available for high risk groups
Screening of high risk pregnant women recommended
Recombinant vaccine produced by Merck Sharp Dohme licensed
Universal screening of all pregnant women recommended
Recombinant vaccine produced by Smith Kline Biologicals licensed
Universal childhood immunisation recommended
110 Countries implemen t routine childhood immunisation
To date, various hepatitis B vaccines have been developed using a variety of
immunogens (Kobayashi et al., 1992):
1. First-generation hepatitis B vaccines: HBV surface antigen (HBsAg) small
particles from healthy carriers.
2. Second-generation hepatitis B vaccines: yeast-derived HBsAg Sprotein
particles.
3. Third-generation hepatitis B vaccines: yeast or mammalian cell-derived
HBsAg M protein-containing particles.
There is also constant ongoing research to improve the existing vaccines and/or
make them more cost effective.
2.6.1. Plasma-derived vaccines
Hepatitis B was first transmitted to laboratory animals (chimpanzees) in the
1970s (Purcell, 1994). The virus does not grow in cell culture so that a
conventional source antigen was not available (Hilleman, 1987). Although, at
the time, HBV had never been isolated and serially propagated in cell culture in
any practical system, the first hepatitis B vaccine was licensed in the United
States of America in 1981 (Purcell, 1994). This unique vaccine, which proved
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to be safe and highly efficacious, was prepared from viral envelope protein (i.e.
the 22 nm subviral particle) that was purified from the plasma of chronically
infected individuals (Couroucé et a/., 1988; Gibas et a/., 1988; Taylor and
Stevens, 1988). Vaccines produced in this way from human sources were
formalin-inactivated and required highly technical purification procedures (Barr
et a/., 1989; Valenzuela et al., 1985). With the availability of this vaccine, a
hepatitis B immunisation strategy was developed in the United States in the
1980s, targeting groups at high risk of HBV infection (Katkov and Dienstag,
1995). The vaccine was, however, limited in production by the available supply
of acceptable carrier plasma and the need to inactivate any infectious agents
that might also be present (Barr et al., 1989; Hilleman, 1987). A necessary part
of the production process included a prolonged innocuity test in increasingly
scarce chimpanzees (Stephenne, 1988). Furthermore, the principal source of
HBsAg-positive plasma for the manufacture of vaccine was from the same
population that subsequently was at high risk of contracting AIDS (Purcell,
1994). Thus, despite the overwhelming evidence for its safety, the plasma
vaccine was used less than expected due to fear of transmission of HIV by the
vaccine (Hilleman, 1987). In addition, the supply of antigen was so restricted
and expensive that the vaccine was generally only available to particular high-
risk groups, thus not being a solution to the wide-spread problem in third world
countries (Barr et al., 1989; Kitano et a/., 1987). Also, the prevailing strategy of
targeting hepatitis B vaccine to specific high-risk groups was shown to be
ineffective in reducing the frequency of HBV in the US, suggesting the necessity
for more wide-spread immunisation programmes (Katkov and Dienstag, 1995).
This, however, required a safe, inexpensive vaccine. For these reasons, yeast
recombinant vaccine was developed (Hilleman, 1987).
2.6.2. Yeast-derived recombinant S protein subunit vaccines
The recombinant yeast hepatitis B vaccine represents the world's first viral
subunit vaccine, the first licensed vaccine to prevent human cancer and the first
recombinant-expressed vaccine (Hilleman, 2000). It has removed all the
obstacles facing the use of plasma-derived vaccines and dramatically altered
the scale of vaccination that can now be undertaken (Barr et al., 1989). In fact,
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this vaccine is now routinely used in the 110 countries that have employed the
routine childhood immunisation strategy recommended by the WHO in 1991
(Tsebe et al., 2001).
Development of the recombinant subunit vaccine started when Valenzuela and
co-workers reported the cloning of the hepatitis B viral genome in E. coli and
deduced the complete primary structure of the HBsAg (the main antigenic
component of the viral envelope) from the DNA sequence (Valenzuela et aI.,
1979). High level production of HBsAg-related immunogenic material was,
however, not achieved in bacteria (Valenzuela et aI., 1982). Despite many
efforts, production of vaccines in E. coli has not succeeded because, in E. coli
cells, the HBsAg gene product seems to be either unstable or to cause effects
deleterious to the host, or both (Miyanohara et al., 1983). Therefore,
Valenzuela and co-workers examined yeast as an alternative host system and
constructed an autonomously replicating plasmid containing the S gene under
the control of the AOH1 promoter, which they transformed to S. cerevisiae
(Valenzuela et aI., 1982). The protein was successfully synthesised in yeast
and spontaneously assembled with yeast lipids and carbohydrates into particles
having properties similar to the 22 nm particles secreted by human cells (Sato
et al., 1995; Valenzuela et al., 1982) (Figure 8). The yield was 10 to 25 I-Ig
HBsAg/1cells. The yeast-derived particles are more variable in size than the
plasma-derived particles and, unlike the plasma-derived particles, they do not
contain significant quantities of a higher molecular weight glycoprotein. Despite
these differences in size and glycosylation, the yeast-derived particles were
immunoreactive with anti-HBsAg antibodies, which bind to a conformational
determinant that is dependent on the integrity of disulphide bridges present
within the viral envelope protein (Waters et aI., 1987). Subsequently, various
other groups also expressed the HBV S protein in S. cerevisiae. Expression of
the S gene under control of the constitutive S. cerevisiae 3-phosphoglycerate
kinase (PGK) gene promoter yielded 50 I-Ig immunoreactive HBsAg/1 cells
(Hitzeman et aI., 1983). Miyanohara and co-workers constructed a yeast
expression vector carrying the S gene of HBV (subtype adr) under control of the
repressible yeast acid phosphatase promoter which they transformed to
S. cerevisiae (Miyanohara et al., 1983). They also obtained immunogenic virus-
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like particles at 2.8 mg HBsAg/1. The adw subtype S gene was cloned and
expressed by McAleer and co-workers with similar results (McAleer et al.,
1984). The yeast-derived antigen was shown to be at least as antigenic as the
Figure 8. Negatively stained HBsAg particles isolated from recombinant yeasts. x280000.
Bar=50 nm. Inset: x465000. Bar=20 nm. Note subunit structures with pores (arrows)
(Yamaguchi et a/., 1998).
antigen purified from human plasma and animals vaccinated with the adw
subtype vaccine were also protected against both subtype adr and ayw
challenge. All the above expression systems did not employ yeast secretion
signals and no secretion of the particles takes place from S. cerevisiae
(Biemans et al., 1992). The S protein, however, contains internal uncleaved
signal sequences that direct portions of the molecule across the ER membrane.
The majority of the S protein was then also found in dilated ER structures
suggesting that further transport along the secretion pathway is blocked.
Particle formation then occurs in the ER. The absence of N-linked
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oligosaccharide on the yeast-derived S protein might provoke aberrant
formation of disulphide bonds and thus cause the formation of aggregates that
accumulate in the ER. These aggregates might be difficult to transport to the
Golgi complex owing to size constraints. Thus the particles remain intracellular,
however, the possibility exists that, to a limited extent, HBsAg may be secreted
across the plasma membrane into the periplasm. Chen and co-workers
attempted to express HBsAg in the secretion pathway of S. cerevisiae by using
the a-factor leader sequence (Chen et al., 1995). However, the yeast did not
secrete the protein and the growth rate of transformants was inhibited, giving
swollen, division-inhibited cells. This toxicity may be due to the complexity of
the secretory pathway. The toxicity could be overcome by reducing the
ammonium sulphate concentration in selective medium, but it is doubtful
whether this will be viable in large-scale production of the antigen. Unlike
HBsAg derived from human plasma, the yeast antigen is held together by
noncovalent interactions (Wampler et ai., 1985). During in vitro purification
some disulphide bonds form spontaneously between the antigen subunits,
resulting in particles composed of a mixture of monomers and disulphide-
bonded dimers. The fully disulphide-bonded form resembling the plasma-
derived surface antigen particle is then obtained by treatment with thiocyanate.
Ultrastructure analysis of S. cerevisiae-derived HBsAg particles showed that
they are spherical to slightly ovoid with a mean diameter of 27.5 nm and consist
mainly of many subunits each 4 nm in diameter with a minute central pore
(Yamaguchi et ai., 1998). In contrast, human HBsAg particles appear mostly
spherical consisting of 3 nm subunits and have a mean diameter of 21.2 nm.
This difference in size is apparently due to molecular differences in polypeptide
structure.
Studies were also performed on the scale-up of recombinant hepatitis B
production. Controlled fed-batch fermentation comparing three recombinant
S. cerevisiae strains expressing the S gene under control of the alcohol
dehydrogenase (ADH1), acid phosphatase (PH05) and glyceraldehyde-3-
phosphate dehydrogenase (GPO) promoters, respectively, revealed that the
highest HBsAg levels (3-10 mg/L) were obtained from the strain with the
constitutive GPO promoter (Hsieh et ai., 1998). A fed-batch cultivation method
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based on the production kinetics of batch culture enhanced HBsAg production
ten times more than in batch culture (Gu et ai., 1991). However, in the scale-up
of this culture to 9 L, ethanol accumulation occurred at a late stage and was not
reutiiised, inhibiting further growth. Subsequently, a continuous culture study of
the expression of HBsAg was undertaken (Fu et al., 1996). These studies
showed that S gene expression varies inversely with growth rate and plasmid
copy number was stable and independent of dilution rate. The S monomers
were shown to dimerize in less than two minutes, but dimer oligomerisation and
lipoprotein budding occur over a longer time scale (160 minutes). It seems that
a constant ratio of excess S monomer to HBsAg particle may exist and that
growth rate, in itself, does not affect the degree of HBsAg particle accumulation.
In fact, excess level of monomer appears to act as driving force for the
generation of lipoprotein particles.
In 1986 this research eventually culminated in the commercial production of two
S. cerevisiae-derived hepatitis B vaccines based on expression of the S gene,
namely Recombivax-HB (Merck Sharp and Oohme) and Engerix-B (SmithKline-
Beecham) (Manyike et al., 1992; Panda et al., 1991). Recombivax-H B
represents the first licensed vaccine of any kind produced by recombinant
technology and thus established the precedent for new vaccines to be made
using this methodology.
2.6.3. Vaccines containing middle and large proteins
The preS regions contain important antigenic determinants. This was shown by
the fact that antibodies against preS occur during the resolving of HBV
infections; preS sequences appear to augment the immunogenicity of S
sequences in normally non-responding animals; and preS occurs on the surface
of the virus and may be involved in attachment of the virus to target cells
(Peterson, 1987; Yap et al., 1995).
Therefore the Mand L proteins have also been targeted for expression in
S. cerevisiae.
Stellenbosch University http://scholar.sun.ac.za
88
2.6.3.1. The M Protein
As has been mentioned previously, the preS2 domain binds to polymerised
human serum albumin (pHSA) and may play a role in binding of the virus to
hepatocytes (Gerlich et aI., 1990). Antibodies to the polyalbumin receptor
elicited by a vaccine carrying the preS2 region may thus directly interfere with
the binding of HBV to hepatocytes and further prevent the initial step of infection
(Valenzuela et al., 1985). Studies showed that the preS2 region is, in fact,
significantly more immunogenic than the S region, eliciting antibodies 400 times
more efficiently (Itoh et aI., 1986; Milich et aI., 1985; Valenzuela et aI., 1985).
The preS2 region contains two immunodominant regions and anti-preS2
antibodies recognise typical linear epitopes and do not distinguish between
native or denatured preS2 proteins (Meisel et aI., 1994). Also, the preS2 region
appears capable of generating T cell helper activity that can function to induce
production of antibodies to the S region as well as the preS2 region, thereby
circumventing S region non-responsiveness (Milich et al., 1985). Hepatitis B
viruses are also highly mutagenic because of errors in reverse transcription,
which can result in variable specificity of surface antigens (Hilleman, 1995). All
this evidence pointed to the fact that inclusion of the preS2 region could
augment the effectiveness of future HBV vaccines. To this end, S. cerevisiae
was transformed with plasmids carrying the preS2 region as well as the S gene.
The M protein (encoded by preS2-S) has been expressed independently by
several laboratories since 1985 (Gerlich et al., 1988; Jacobs et al., 1989;
Valenzuela et al., 1985). Kitano and co-workers (1987) transformed
S. cerevisiae with a plasmid containing the sequence for the M protein of HBV
subtype adr under control of the glyceraldehyde-3-phosphate dehydrogenase
(GPD) promoter (Kitano et al., 1987). The resultant M protein accumulated as
particles of 20 to 30 nm and formed inclusion bodies in the S. cerevisiae cells.
Initially, it was found that the preS2 region was especially sensitive to
proteolysis, however this could be solved by modifying certain base sequences
or by using a protease-deficient (pep4) yeast host strain (Kitano et al., 1987;
Langley et al., 1988). Two other groups performed similar experiments and
obtained recombinant S. cerevisiae strains expressing the HBV M protein
Stellenbosch University http://scholar.sun.ac.za
89
(Imamura et a/., 1987; Langley et aI., 1988). The preS2 gene products obtained
from the yeasts assembled into the spherical forms, showed pHSA binding
activity and reacted with antibodies specific for epitopes within the preS2 region.
In S. cerevisiae, the M protein is translocated across the ER membrane,
however no further processing by the yeast secretory apparatus occurs (Jacobs
et a/., 1989). Thus, the M protein product is probably situated in the ER lumen,
with some possible translocation to the Golgi. However, when a proteinase
resistant preS2-S gene was fused to the chicken-lysozyme signal peptide and
placed under control of the GPO promoter, S. cerevisiae was able to secrete
HBsAg particles into the medium in the exponential growth phase (Kuroda
et al., 1993). Glycosylation of the M protein occurs in yeast and the yeast-
produced M-containing particles differ from those of human sera in their very
high content of the glycosylated M protein (Imamura et aI., 1987). M proteins
produced in recombinant yeasts which were "wild-type" for glycosylation were
highly immunogenic, however a large proportion of hypermannosylated species
with extended mannose side-chains of up to several hundred thousand daltons
were found (Kniskern et a/., 1994). This hypermannosylation was eliminated by
expressing the preS2-S gene in a S. cerevisiae mnn9 mutant defective for
glycosylation (lp et aI., 1992). The M protein particles produced by this strain
are composed mainly of two major glycoproteins, GP37 and GP34 (Kobayashi
et aI., 1992). GP37 has an N-linked oligosaccharide bound to Asn 4 of the high-
mannose type (Man-Glcblac, or ManaGIcNac2) and an additional O-linked
oligosaccharide bound to the preS2 region. These oligosaccharides do not
have any effect on the ability of the HBsAg M protein vaccine to elicit anti-S and
anti-preS2 antibodies in experimental animals. In mice, the products of the
preS region were shown to be more immunogenic than the product of the S
gene (Katkov and Dienstag, 1995). However, studies carried out in humans
indicated that while the vaccine containing both the Sand preS2 determinants
is immunogenic in healthy, immunocompetent adults and that antibodies to
preS2 are detected, no dramatic advantage of preS2 vaccines over S-only
vaccines was shown. The potential of preS vaccines in non-responders to S-
only vaccines is promising, but still remains to be evaluated systematically.
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2.6.3.2. The L protein
Further development to improve vaccine efficacy included the incorporation of
the large (L) protein, coded by the preS1-preS2-S gene, which also plays a role
in viral attachment and host range determination (Imamura et al., 1987;
Ishikawa and Ganem, 1995). The preS1 region has been shown to be a
particularly efficient immunogen with a dominant T cell recognition site in the N-
terminal residues (21-28) and B cell determinants at residues 12-32, 32-35 and
94-117 of serotype adw (Prange et al., 1995b; Sulowska et al., 1995). Thus the
L protein was also expressed in S. cerevisiae and, like the M protein, was
produced both in N-linked glycosylated and non-glycosylated forms (Dehoux
et al., 1986; Jacobs et al., 1989). In addition to N- and O-linked glycoslyation,
the L protein was also N-myristoylated at the N-terminal glycine, further
confirming the entry into the endoplasmic reticulum (ER) (Biemans et al., 1991).
In contrast to the M protein, the L protein molecules did not readily assemble
into the well-ordered structure that is typical of the major S polypeptides.
Rather it is retained in the ER, provoking the proliferation of the ER resulting in
the accumulation of membranous structures connected with the perinuclear
cisternae.
2.6.3.3. Simultaneous expression of different HBV proteins
Subsequently, the simultaneous synthesis of various hepatitis B surface
proteins in S. cerevisiae has been performed (Jacobs et al., 1989). In yeast,
transcription is directed by the yeast promoter and viral transcription initiation
signals within the HBV genes are not functional. Simultaneous expression of S,
Mand L proteins in S. cerevisiae was therefore accomplished by the
introduction of expression cassettes encoding the different proteins into the
yeast genome. Mixed lipoprotein structures were found in yeast extracts from
this transformant, with the different proteins undergoing coassembly into a
single lipoprotein structure. Another S. cerevisiae strain was also constructed
co-expressing the S, M, L and core proteins under control of the yeast GPO
promoter (Shiosaki et al., 1991). Cell Iysates from this recombinant strain
contained spherical particles with a diameter of 40 nm which were found to
consist of core particle surrounded by envelope, thus resembling the hepatitis B
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virion without DNA. While vaccines incorporating preS regions do exist, they
are not in widespread use and further research is required to determine the
optimal system to produce such vaccines.
2.6.4. Alternative hosts for expression of hepatitis Bantigens
Already, alternative hosts for expression of hepatitis B antigens have been
explored. These include the methylotrophic yeasts, Pichia pastoris and
Hansenula polymorpha, the yeast Kluyveromyces lactis, as well as plant hosts
(Barr et al., 1989; Gellissen, 2000; Gellissen and Hollenberg, 1997; Gellissen
and Veenhuis, 2001; Hadfield et al., 1993; Hollenberg and Gellissen, 1997;
Martinez et aI., 1992; Thanavala, 1996). For P. pastoris it has been shown in
several examples that the addition of terminal mannoses occurs by a1,2
linkages instead of the a1 ,3 linkages frequently observed in S. cere visia e, which
are considered to be allergenic (Gellissen, 2000). The methylotrophic yeasts
proved to be very effective in producing HBsAg, with P. pastoris initially
producing high levels of protein (2% to 3% of the soluble protein of the cell)
(Cregg et al., 1987). The surface antigen also self-assembled intracellularly into
22-nm lipoprotein particles composed of approximately 100 units of a non-
glycoslyated S protein and yeast lipids (Tleugabulova et al., 1999). Industrial
scale production of HBsAg in P. pastoris under control of the alcohol oxidase I
(AOX) promoter has yielded levels of 1.3 ± 0.2 giL (Hardy et aI., 2000). In this
case the expression cassette was integrated into the genome of P. pastoris and
yielded a non-glycosylated, biologically active product. This P. pastoris-derived
HBsAg has since been employed as a safe, efficacious vaccine
(HEBERBIOVAC HB, Heberbiotec S. A, Cuba). Recently, a recombinant
P. pastoris strain has been constructed expressing the S gene under control of
the constitutive P. pastoris glyceraldehyde-3-phosphate dehydrogenase
promoter, obviating the need for methanol induction thereby reducing the
fermentation time for peak production levels (Vassileva et al., 2001). In-frame
fusion of the S. cerevisiae a-factor secretion signal to the S gene resulted in the
secretion of 20 nm particles into the medium. However, the levels of secreted
HBsAg particles were very low, presumably due to the inherent hydrophobicity
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of the HBsAg molecule and the consequent propensity for membrane
association.
H. polymorph a also produced high levels of antigen (5% to 8% of total cell
protein) containing both Sand L surface antigens and has also been shown to
successfully express M protein (Gellissen, 2000; Janowicz et al., 1991; Shen
et al., 1989). The proteins were also found to be glycosylated far less than in
S. cerevisiae, making this an attractive alternative host (Janowicz et al., 1991).
A production strain was generated by introducing a plasmid with the S gene
fused to the H. polymorpha methanol oxidase (MOX) promoter (Gellissen,
2000). The transformed strain is able to grow on glycerol and methanol as
carbon sources. Currently, two H. polymorpha-derived hepatitis B vaccines are
commercially available: Hepavax-Gene, produced by KGCC (Korea) and AgB,
produced by LPC (Argentina).
In recent years, plants have gained in importance as hosts for heterologous
protein production. The HBsAg has been expressed in tobacco plants (the leaf
cells produce the recombinant protein) and potato plants (Domansky et al.,
1995; Thanavala, 1996). The transgenic tobacco-derived HBsAg was shown to
retain the immunological characteristics needed to generate HBsAg-specific B
and T cell responses, however the maximal level of HBsAg obtained was not
sufficient to use the plants for production of a vaccine (Domansky et al., 1995).
Nevertheless, this technology could potentially make vaccines more readily
available to countries lacking refrigeration and an elaborate infrastructure for
health care, in that "edible vaccines" could be developed.
Most recently, we have evaluated the filamentous fungus A. niger as a
heterologous host for the expression of the HBV S gene (Paper 1, this thesis).
The fungus was shown to produce 22 nm pseudoviral particles similar to those
isolated from human serum and yeast hosts expressing the S gene. In shake
flasks, initial production levels of the pseudoviral particles were 0.4 mg/L, which
compares favourably with those obtained from the yeast hosts (Cregg et al.,
1987; Hitzeman et aI., 1983; Valenzuela et aI., 1982). Fermentation can
generate up to 20 times more dry weight of mycelium per litre than shake-flask
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yields and well optimised fermentation should give yields at least five to ten
times greater than shake-flask yields, indicating the potential of the Aspergillus
system (Davies, 1994). The advantages of the Aspergillus system already
discussed, particularly the ease of fermentation and production levels, make
this host an attractive alternative for the production of hepatitis B vaccines.
Research into the development of vaccines to combat the spread of hepatitis B
is still an ongoing process despite the availability of effective products. The
continued necessity for cheap, effective and, particularly, convenient vaccines
for the widespread use in underdeveloped countries primarily drive this quest,
as vaccination provides for the only means to combat the unacceptably high
prevalence of this disease world-wide.
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3. EVALUATION OF ASPERGILLUS NIGER AS HOST FOR
VIRUS-LIKE PARTICLE PRODUCTION USING THE
HEPATITIS B SURFACE ANTIGEN AS A MODEL
Annette PlUddemann and Willem H. van Zyl*
Department ofMicrobiology, University of Stellenbosch, Stellenbosch 7600, South Africa
3.1. Abstract
The filamentous fungus Aspergillus niger was transformed with the hepatitis B
virus S gene encoding the major viral envelope protein under control of the
constitutive Aspergillus nidulans glyceraldehyde-3-phosphate dehydrogenase
(gpdA) promoter. Southern analysis revealed the integration of approximately
seven copies of the expression cassette on the genome, resulting in high level
transcription of the S gene. Production of the 24 kDa S protein, as well as a 48
kDa Sprotein dimer, in the membrane-associated protein fraction of the
recombinant A. niger strain was shown through Western analysis.
Recombinant S protein was purified from extracts of the A. niger strain by
sucrose gradient centrifugation and electron microscopy revealed the formation
of spherical pseudoviral particles with a diameter of 22 nm. The yield of
hepatitis B pseudoviral particles from mycelium of the recombinant Aspergillus
strain was estimated to be 0.4 mg per litre of culture, which compares
favourably with the reported levels initially obtained in yeast, indicating the
potential of the Aspergillus expression system as an alternative cost-effective
vaccine production system.
3.2. Introduction
Saccharomyces cerevisiae has traditionally been used as heterologous host for
the production of pharmaceutical (viral) proteins, but has manifested limitations
such as low product yields and hyperglycosylation of glycoproteins (Hadfield
et ai., 1993). Since the 1980's genetic engineering procedures have been
developed for the filamentous fungi, in particular aspergilli (Jeenes et al., 1991;
Kinghorn and Unkles, 1994; Van den Handel and Punt, 1991). Subsequently,
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various heterologous proteins of fungal and non-fungal origin have been
expressed in these fungi (reviewed by Kinghorn and Unkles, 1994; Van den
Hondel et al., 1991). Several characteristics of filamentous fungal expression
hosts give them potential advantages over S. cerevisiae, particularly their
efficient secretion of endogenous proteins. Hyperglycosylation is less of a
problem in filamentous fungi than in S. cerevisiae, as their glycosylation
patterns more closely resemble those found in mammalian cells. For example,
when produced in S. cerevisiae, human tissue plasminogen activator was
hyperglycosylated, but this was not the case when the protein was produced in
Aspergillus nidulans (Upshall et aI., 1987). Filamentous fungi are also rather
robust and can grow on many organic compounds (Jeenes et al., 1991; Van
den Hondel et al., 1991). They are known to produce and secrete enzymes in
large quantities and through their use in the food and food processing industry,
the species Aspergillus oryzae and Aspergillus niger have gained GRAS
(Generally Regarded 8,s§afe) status. Filamentous fungi have been extensively
used in industrial processes such as organic acid and enzyme production, and
therefore large-scale fermentation technology and downstream processing are
already well established (Bodie et al., 1994). Several proteins of
pharmaceutical importance have also been successfully produced in
Aspergillus, including tissue plasminogen activator (1 mgll) (Upshall et al.,
1987), human interleukin-6 (5-10 mg!l) (Gouka et al., 1997), human lactoferrin
(2 gil) <:Nard et al., 1995), human interferon a-2 (1 mg!l) (Gwynne et al., 1987)
and an industrial process for human superoxide dismutase via intracellular
expression in A. nidulans has been developed (Davies, 1994). However, viral
protein production in filamentous fungi has not been evaluated to date and the
hepatitis B surface antigen provides the ideal basis for such an evaluation.
Hepatitis B is a widespread and serious liver disease and can be considered a
global health problem with an estimated 2000 million HBV carriers in the world
today (World Health Organisation). The problem is most prominent in
developing countries with 95% of chronic carriers residing in the developing
world (Ayoola, 1988). With regard to southern Africa specifically, in a study
performed in Swaziland in 1983 and in Namibia in 1985, the prevalence of HBV
amongst those tested was already 82.6% and 98.9%, respectively, and a high
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endemicity exists in rural areas such as Kwazulu/Natal (>60%) and Kangwane
(>70%) within South Africa (Ayoola, 1988; Manyike et a/., 1992). No effective
treatment for this disease currently exists and an extensive programme of
vaccination presents the only solution to curb the spread of the disease
(Kassianides et a/., 1988). Routine infant or adolescent vaccination has been
recommended by the WHO since 1991 (Vryheid et a/., 2001). In order to make
a mass vaccination strategy feasible, large amounts of safe, affordable vaccine
must be available. The hepatitis B Virus (HBV) is a small DNA virus which has
a double-walled structure consisting of two concentric protein coats (Ganem
and Varmus, 1987; Huovila et a/., 1992). The envelope, or outer coat, contains
three proteins, designated the major (S) (24 kDa), middle (M) (33 kDa) and
large (L) (39 kDa) protein. These proteins are encoded by the S gene, preS2S
gene and preS1 preS2S gene, respectively. All three envelope components are
glycosylated, type II transmembrane proteins that form multimers stabilised by
disulphide bridges formed by cysteine residues present in the S domain
(Seeger and Mason, 2000). One virion contains 300 to 400 major (S) protein
molecules and 40 to 80 middle and large protein molecules (Tiollais et a/.,
1985), which together with the capsid form the 43-nm-diameter infectious viral
particle (virion), referred to as the Dane particle (Ganem and Varmus, 1987).
The S protein by itself and together with the larger envelope proteins
spontaneously assembles into filamentous and spherical particles 20 to 22 nm
in diameter, that are secreted from infected cells in 103- to 106-fold excess over
virions. These pseudoviral particles, termed the hepatitis B surface antigen
(HBsAg), are devoid of viral DNA and playa role in neutralising virus-eliminating
immune reaction (Peterson, 1987). Hepatitis B surface antigen proteins have
important functions in the viral life cycle, such as attachment and penetration,
envelopment and virus maturation (Gerlich, 1991). Thus, these proteins have
been targeted for heterologous expression to produce recombinant vaccines.
Recombinant DNA methods have provided an alternative to the blood-origin
vaccine obtained from plasma of chronic carriers and to date, yeasts (Dehoux
et a/., 1986; Hardy et a/., 2000; Valenzuela et a/., 1982), plants (Domansky
et a/., 1995; Mason et a/., 1992) and mammalian cells (Michel et a/., 1984)
transformed with appropriate expression vectors are able to synthesise hepatitis
B surface antigen (HBsAg) for immunisation purposes. The first yeast-derived
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hepatitis B vaccine was produced in S. cerevisiae and licensed in 1986 (Barr
et al., 1989; Hilleman, 1987), representing the first licensed vaccine of any kind
produced by recombinant technology and thus established the precedent for
new vaccines to be made using this methodology.
In this paper we describe the transformation of A. niger with the S gene of a
South African isolate of the hepatitis B virus subtype adw2, and the intracellular
production of 22 nm pseudoviral particles.
3.3. Materials and Methods
3.3.1. Strains and media
Recombinant plasmids were constructed and amplified in Escherichia coli
XL1Blue (Stratagene) cultivated at 3rC in Luria-Bertani liquid medium or on
Luria-Bertani agar (Sambrook et al., 1989). Ampicillin for selection and
propagation of resistant bacteria was added to a final concentration of 100
IJg/ml. A. niger 015, the recipient strain for transformation, is a uridine
auxotrophic (pyrG), protease-deficient (prtT), nonacidifying (phmA) mutant
(Gordon et al., 2000). All strains used in this study are summarised in Table 1.
A. niger 015 was cultured in Aspergillus minimal growth medium (Bennett and
Lasure, 1991) containing 1% glucose and supplemented with 0.2% casamino
acids (Difco), 0.5% yeast extract and 10 mM uridine (Sigma) in 1-liter
Erlenmeyer flasks containing 250 ml medium at 30°C on a rotary shaker at 150
rpm. Transformants were selected on minimal medium without uridine
containing 1.2 M sorbitol as osmotic stabiliser, 1.5% agar (Oxoid) and 10 mM
acetamide as sole nitrogen source. Transformants were selected for multicopy
integration of the expression cassettes on acrylamide plates (Verdoes et al.,
1993). Minimal medium without uridine, supplemented with 0.5% yeast extract,
0.1% casamino acids and 1% glucose, was used to culture transformants.
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Table 1. Microbial strains and plasmids.
Strain/Plasmid Genotype Source/Reference
Bacterial strain:
Escherichia coli XL 1-
Blue
Fungal strain s:
Aspergillus niger 015
A. niger 015
(pêluescript-pyrrêarndê)"
OAHB11#2
OAHB11#3
OAHB11#8
Plasmids:
pBluescript-py rGamdS
pCOR105
pAN52-1
pAN52-1-S
pAHB11
StratagenerecA1 endA1 gyrA96 thi-1hsdR17 supE44
relA1lac[F' proAB lacfz,1M15 Tn10 (Tet')t
pyrG prtT phmA
pyrG+ prtT phmA amdS+
pyrG+ prtT phmA emas' gpdAp-S-trpCr
pyrG+ prtT phmA emas' gpdAp-S-trpCr
pyrG+ prtT phmA emciS" gpdAp-S-trpCr
Gordon et al., 2000
This work
This work
This work
This work
bla pyrG amdS
bla S
bla gpdAp-trpCr
bla gpdAp-S-trpCr
bla pyrG amdS gpdAp-S-trpCr
This work
vs.s. de Wet
Punt et al., 1991
This work
This work
aA. niger 015 (pBluescript-pyrGamdS) was designated A. niger (control)
3.3.2. Plasmid construction and transformation of A. niger
Standard protocols were followed for DNA manipulations (Sambrook et a/.,
1989). Restriction endonuclease-digested DNA was eluted from agarose gels
by the method of Tautz and Renz (1983). Restriction endonucleases and T4
DNA ligase were purchased from Roche Molecular Biochemicals and used as
recommended by the manufacturer. The open reading frame of the hepatitis B
virus S gene was amplified from plasmid pCOR105 (donated by Prof. W.J. de
Wet, Potchefstroom University, South Africa) with the aid of primers S-LEFT (5'_
CTAGCCATGGAGAACATCACATCAGGATTCC-3') and S-RIGHT (5'_
GATCAGATCTCCAACAGGAAGTTTTCT AAAAC-3') which contained the
restriction sites Ncol and Bg/II, respectively. The resulting 814-bp PCR product
was digested with Ncol and Bg/II and cloned into the Ncol and BamH1 sites of
plasmid pAN52-1 (Punt et a/., 1991), resulting in plasmid pAN52-1-S. In this
vector the S gene is under the trancriptional control of the A. nidu/ans gpdA
promoter and trpC terminator. Finally, the A. nidu/ans amdS and A. niger pyrG
selection markers (provided by Prof. C.A.M.J.J. van den Handel, TNO, Zeist,
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The Netherlands) were introduced into pAN52-1-S at a unique Not1 site to
generate plasmid pAHB11. A schematic representation of plasmid pAHB11 is
given in Figure 1. The A. nidulans amdS and A. niger pyrG selection markers
were also introduced into pBluescript (Stratagene) at the unique Not1 site,
creating pBluescript-pyrGamdS. Fungal transformation was carried out by the
protoplasting method of Punt and Van den Hondel (1992), using Novozym 234
(Sigma).
Ncot
Nott pAHB11
Nott
Figure 1. Schematic representation of the Aspergillus expression vector pAHB11 constructed
in this study. The E. coli p-Iactamase (bla), A. nidulans acetamidase (amdS) and A. niger
orotidine-5'-decarboxylase (pyrG) genes were used as selectable markers and are indicated by
the hatched boxes. GpdAp and trpCt, indicated by open boxes, represent the A. nidulans
glyceraldehyde-3-phosphate dehydrogenase gene promoter and trpC (a trifunctional gene in
tryptophan biosynthesis) gene terminator, respectively. The hepatitis B virus S gene is
indicated by the cross-hatched box.
3.3.3. Isolation of RNA and Northern analysis
Total RNA was isolated from A. niger D15 transformants cultured for 40 h at
30°C as follows: Mycelium was harvested through Miracloth (Calbiochem),
frozen under liquid nitrogen, ground to a fine powder with a mortar and pestle
and resuspended in cold STE buffer (0.25 M Tris-HCI [pH7.2], 0.1 M NaCl,
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0.01 M EOTA [pH8]). One volume phenol/chloroform/isoamylalcohol (PCI) and
0.05% sodium dodecyl-sulphate (SOS) was added and the mycelial debris was
collected by centrifugation. The aqueous upper phase was collected, subjected
to PCI extraction and precipitated to yield total RNA. The total RNA was used
for conventional Northern blot analysis as described by Sambrook et al. (1989).
The probes were prepared by labelling the 814-bp hepatitis B virus S gene and
a 1350-bp fragment of the A. nidulans glyceraldehyde-3-phosphate
dehydrogenase (gpdA) gene with [a-32P]dATP, using a random primed DNA
labelling kit (Roche Molecular Biochemicals) as recommended by the
manufacturer.
3.3.4. Isolation of genomic DNA from A. niger and Southern blotting
The genomic DNA was isolated from A. niger transformants according to La
Grange et al. (1996), digested overnight with EcoRI at 3rC, separated on a
0.6% agarose gel and blotted to a Hybond-N membrane (Amersham).
Southern blot analysis was carried out according to Sambrook et al. (1989)
using the radioactively labelled 814-bp S gene as probe.
3.3.5. 50S-PAGE and Western blotting
Total intracellular and membrane-bound proteins were isolated from the
transformants cultured for 72 h in minimal medium. Protein extraction was
performed as follows: Mycelium was harvested and ground as before. Ground
mycelium was suspended in protein extraction buffer (50 mM phosphate buffer
[pH7.0], 1 mM MgCI2,20 ~M phenylmethylsulfonyl flouride) with or without 0.1%
Triton X-100, and the mycelial debris was removed by centrifugation.
S. cerevisiae-derived Engerix-B hepatitis B virus vaccine (20~g/ml) (SmithKline
Beecham Pharmaceuticals) was purchased from a local pharmacy to act as
reference protein. Proteins were separated on a 12% SOS polyacrylamide
gelelectrophoresis (PAGE) gel and visualised by staining with silver nitrate
(Blum et aI., 1987). For Western blotting, proteins were transferred to a
polyvinylidine difluoride (PVOF) membrane (Hybond-P; Amersham Pharmacia
Biotech) in transfer buffer (25 mM Tris-HCI [pH 7.5], 192 mM glycine, 15%
[vol/vol] methanol) using a semidry transfer apparatus (Hoefer). The
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Chemiluminescence Western Blotting Kit (Roche Molecular Biochemicals) was
used as recommended by the manufacturer. The primary antibodies were
polyclonal goat anti-hepatitis B surface antigen (1:5000 dilution) (Dako) and
secondary antibodies were anti-goat immunoglobulins conjugated to
horseraddish peroxidase (1:10 000 dilution) (Dako). HBsAg was assayed with
the Auszyme MC Dynamic kit (Abbott), using HBsAg derived from human
serum as a standard. HBsAg was diluted to give levels of 0.09-1.86 ng/ml, and
the absorbance at 492 nm after colour development gave a linear relationship in
this range. This method is dependent on the conformational epitopes of HBsAg
particles and will not detect free unassembled HBsAg proteins.
3.3.6. Dry cell weight determination
Dry weight was determined gravimetrically using nitrocellulose filters (0.45 urn,
Gelman Sciences). The filters were predried in a microwave oven for 10 min
and weighed. A known volume of culture was filtered and washed with an equal
volume of double-distilled water. The filters were dried in a microwave oven for
10 min and weighed. Dry cell weight was determined in triplicate.
3.3.7. Purification of hepatitis B Sprotein
Protein extracts from mycelium were made as described above and 1 ml of the
protein extract from the transformant was layered on a linear 36-ml 5-30%
sucrose gradient made in 10 mM sodium phosphate (pH7.0)/0.15 M NaCI. The
sucrose gradient was centrifuged in a Beckman SW28 rotor with a Beckman L7
Ultracentrifuge at 19 000 rpm for 20 h at 5°C. The gradient was subsequently
fractionated into 2-ml fractions while monitoring the absorbance at 280 nm.
Fractions were run on a 12% SDS-PAGE gel to determine which fractions
contained the HBsAg.
3.3.8. Electron microscopy
Sucrose fractions containing HBsAg were dialysed against 50 mM sodium
phosphate (pH7.0), stained with 2% uranyl acetate and visualised under 110
OOOxmagnification by transmission electron microscopy.
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3.4. Results
3.4.1. Recombinant A. niger expressing the hepatitis B S gene
The recombinant plasmid pAHB11 containing the hepatitis B S gene, encoding
the major (S) protein of the envelope of the hepatitis B virus (subtype adw2)
under control of the constitutive glyceraldehyde-3-phosphate dehydrogenase
(gpdA) promoter, was constructed and transformed to A. niger D15. The vector
pBluescript-pyrGamdS was also transformed to A. niger D15. Several uridine
prototrophic, acetamide utilising transformants were obtained for both vectors.
Transformants were purified twice on selective medium and plated on
acrylamide plates. Efficient growth and sporulation on acrylamide plates
reflects multicopy integration of the transforming vector (Verdoes et aI., 1993).
3.4.2. Gene copy number and expression
Three isolates of A. niger D15 transformed with pAHB11 (designated
DAHB11#2, DAHB11#3 and DAHB11#8) and showing growth and sporulation
on acrylamide plates were selected and cultured in minimal medium containing
glucose for 40 h and analysed for S gene transcription by Northern blotting
(Figure 2A). One A. niger D15 transformant containing pBluescript-pyrGamdS
was also cultured as reference strain. Transformant DAHB11#8 (lane 3)
showed the highest levels of S gene mRNA and was selected for further
analysis. To determine the copy number of the integrated plasmid in this
transformant genomic DNA was isolated, digested with EcoRI (which has only
one recognition site in pAHB11) and subjected to Southern analysis using the
[a-32p]dATP-labelied S gene as probe (Figure 2B). Results indicated that about
seven copies of the expression cassette integrated into the A. niger genome.
3.4.3. Viral protein production by A. niger
Transformant DAHB11#8 was cultured in glucose-containing minimal medium
for 72 h. Total intracellular proteins were isolated, separated on a 12% SDS-
PAGE gel and Western analysis was carried out with HBsAg-specific
antibodies. A 24-kDa and a 48-kDa protein species was highlighted, which did
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Figure 2. (A) Northern analysis of S gene mRNA transcripts from isolates of A. niger D15
transformed with plasmid pAHB11. Lane 1, transformant DAHB11#2; lane 2, transformant
DAHB11#3; lane 3, transformant DAHB11#8; lane 4, A. niger (control). (B) Southern blot
analysis to determine the number of S gene copies integrated into the recombinant Aspergillus
genome. Lane 1, molecular weight marker; lane 2, DNA isolated from A. niger (control)
digested with EcoRI; lane 3, DNA isolated from DAHB11#8 digested with EcoRI. The 814-bp S
gene was used as an [a-32P-dATPj-labelied probe in (A) and (B) and in the northern analysis a
1350-bp fragment of the A. nidulans glyceraldehyde-3-phosphate dehydrogenase (gpdA) gene
was used as internal standard.
not appear in the reference strain (Figure 3A). These proteins also appeared in
the Engerix vaccine positive control, confirming that the 24 kOa protein
corresponds to the S protein and the 48-kOa protein species represents a dimer
of the S protein. It has been shown previously that complete reduction of
HBsAg, to obtain a single band in SOS-PAGE, can only be achieved through
very harsh reducing conditions [1.3 M dithiothreitol (OTT), 4% (w/v) SOS and
65% (v/v) 2-mercaptoethanol] or through the repeated reductive treatment with
simultaneous lipid removal (O'Keefe and Paiva, 1995; Tleugabulova, 1998).
Subsequently, cytoplasmic proteins were isolated using extraction buffer without
the non-ionic detergent Triton X-100, and membrane-associated proteins were
isolated by the addition of Triton X-100 to the extraction buffer. Western
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analysis of these protein fractions could detect the S protein in the fraction
containing the membrane-associated proteins, but not in the cytoplasmic
fraction (Figure 3B).
A B
24kDa-+
48kDa-+48kDa-+
24kDa-+
Figure 3. Detection of viral protein production by Western blot analysis. (A) Lane 1, A. niger
(control); lane 2, DAHB11#8 total intracellular proteins; lane 3, yeast-derived Engerix-B hepatitis
B virus vaccine. (B) Lane 1, A. niger (control); lane 2, DAHB11#8 cytoplasmic protein fraction;
lane 3, DAHB11#8 membrane-associated protein fraction. Immunoblotting was done with a
polyclonal goat-a-HBsAg antibody. A protein species of 24 kDa is visible in transformant
DAHB11#8 corresponding to the size of the hepatitis B S protein, as well as an Sprotein dimer
of48 kDa.
3.4.4. Electron microscopy
The HBsAg in the fungal protein extract was subjected to sucrose gradient
centrifugation for purification and removal of detergent, which is essential for the
reassociation of the peptides into the immunogenic particle form (Howard et al.,
1986). The active fractions were dialysed, negatively stained with uranyl
acetate and examined by electron microscopy (Figure 4). Aggregates of 22 nm
spherical particles with a dense core were observed which did not appear in
control samples. The particles have a spherical structure similar to that of
HBsAg isolated from human serum and the dense core represents the
characteristic central pore found on both yeast and human HBsAg particles
(Yamaguchi et ai., 1998). Therefore, HBsAg produced by Aspergillus seemed
to be assembled into particles similar in size and shape to the spherical
pseudoviral particles found in HBV-infected patients' sera and those produced
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by recombinant S-protein producing S. cerevisiae strains (Yamaguchi et al.,
1998).
A
1 2
24 kDa
B
Figure 4. Protein purification and electron microscopy of pseudoviral particles. (A) SDS-PAGE
of purified S protein. Membrane-associated protein fractions were subjected to sucrose
gradient centrifugation, fractionated and dialysed. Lane 1, sucrose gradient fraction of
membrane-associated proteins from transformant DAHB11#8; lane 2, corresponding sucrose
gradient fraction of membrane-associated proteins from A. niger (control). (B) Electron
microscopy of Aspergillus-derived HBsAg particles. Samples were negatively stained with 2%
uranyl acetate. The bar represents 100 nm.
3.4.5. Quantification of protein production
Total intracellular protein extract including the membrane fraction was isolated
from the recombinant A. niger strain (DAHB11#8) to determine the yield of
HBsAg pseudoviral particles. The extraction was repeated six times to collect
total protein and samples were assayed, using HBsAg derived from human
serum as a standard. This enzyme immunoassay detects HBsAg with the aid of
monoclonal antibodies against the conformational epitapes of HBsAg particles
and will not detect free unassembled HBsAg proteins. The HBsAg levels in the
samples were determined from the standard curve. The yield of hepatitis B
pseudoviral particles from mycelium of the recombinant A. niger strain
DAHB11#8 was determined to be 0.2 mg per gram dry mycelium, giving an
estimated 0.4 mg HBsAg per litre of culture.
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3.5. Discussion
Several microbial systems have been established for the heterologous
production of viral proteins, specifically hepatitis B surface antigen. The
hepatitis B viral genome was first cloned in E. coli, resulting in the deduction of
the complete primary structure of the HBsAg (the main antigenic component of
the viral envelope) from the DNA sequence (Valenzuela et aI., 1979). High
level production of HBsAg-related immunogenic material was however not
achieved (Valenzuela et al., 1982) and, despite many efforts, production of
vaccines in E. coli has not succeeded because the HBsAg gene product seems
to be either unstable or deleterious to the host, or both (Miyanohara et al.,
1983). Subsequently, the yeast S. cerevisiae was successfully employed as an
alternative host system and the hepatitis B S protein was successfully
synthesised in yeast and spontaneously assembled with yeast lipids and
carbohydrates into particles having properties similar to the 22 nm particles
secreted by human cells (Janowicz et al., 1991; McAleer et al., 1984;
Miyanohara et al., 1983; Sato et al., 1995; Valenzuela et al., 1982). Other
successful alternative hosts for expression of hepatitis B antigens include the
methylotrophic yeasts, Pichia pastoris and Hansenula polymorph a, the yeast
Kluyveromyces lactis, as well as plant hosts (Barr et al., 1989; Hadfield et al.,
1993; Martinez et aI., 1992; Mason et aI., 1992; Thanavala et aI., 1995). The
inherent advantages of the Aspergillus expression system such as ease of
cultivation, the properties of expressed proteins and high-level protein
production could prove advantageous in the production of vaccines.
In this study the hepatitis B virus S protein has been successfully expressed
intracellularly in the filamentous fungus A. niger. The S gene encoding the
major envelope protein was placed under control of the constitutive
glyceraldehyde-3-phosphate dehydrogenase promoter of A. nidulans (Punt
et al., 1991) and transformed to a protease deficient, non-acidifying A. niger
strain. This strain has been previously shown to effectively produce
heterologous proteins (Gordon et aI., 2000; Wiebe et aI., 2001). Various
transformants were generated and evaluated on plates containing acrylamide
as sole nitrogen source. Selection on acrylamide therefore allowed for the
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identification of transformants containing multiple copies of integrated vector
(Verdoes et a/., 1993). One of these transformants (designated DAHB11#8)
that showed the highest level of S gene transcription was studied further.
Analysis of genomic DNA from this transformant revealed about seven copies of
integrated vector, indicating that the high copy number of integrated vector may
contribute to the level of transcription, as well as the level of protein production.
Previous studies have shown that transcription and protein production levels in
Aspergillus can be determined by the site of integration and/or vector copy
number (Christensen et a/., 1988; Davies, 1991; Ward et a/., 1990). Western
analysis of the total intracellular proteins with HBsAg-specific antibodies
showed the presence of the 24 kDa S protein in this transformant. The HBsAg-
specific antibodies also highlighted a 48-kDa protein. This protein species is
also present in the yeast-derived Engerix-B vaccine sample, indicating that this
is an Sprotein dimer.
To determine the cellular location of recombinant S protein, cell extracts were
separated into the cytoplasmic protein fraction and the membrane-associated
proteins. The S protein could only be detected in the membrane-associated
protein fraction, which is consistent with the transmembrane characteristic of
the protein (Seeger and Mason, 2000). The presence of the S protein in the
membrane-associated protein fraction suggested spontaneous aggregation of S
protein monomers with host membrane molecules into pseudoviral particles.
The S protein was subsequently purified by sucrose gradient centrifugation.
This process further indicated that the S protein was present in the extract as
part of a pseudoviral particle, as the banding in a sucrose gradient is
characteristic of HBsAg particles (Janowicz et a/., 1991). The presence of
HBsAg particles was verified by electron microscopy. These Aspergillus-
derived recombinant pseudoviral particles have a diameter of about 22 nm and
are similar to the HBsAg particles observed in HBV positive human serum
(Ganem and Varmus, 1987), and those obtained from yeast expressing the S
gene which occur in a range of sizes with a mean diameter of 17 nm
(Valenzuela et a/., 1982). We conclude that the particles made in Aspergillus
retain the capacity for self-association and thus have the physical properties of
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serum-derived HBsAg and recombinant yeast HBsAg, both of which are highly
immunogenic in the particle form.
The yield of hepatitis B pseudoviral particles from mycelium of the recombinant
Aspergillus strain DAHB11#8 was determined to be 0.2 mg per gram dry
mycelium, giving an estimated 0.4 mg HBsAg per litre of culture. This value
compares favourably with the reported levels initially obtained in S. cerevisiae
which were respectively 10 to 25 I..IgHBsAgll cells (Valenzuela et al., 1982) and
50 I..IgHBsAg/1cells (Hitzeman et ai., 1983), and in wild-type Pichia pastoris,
where levels of 0.14 mg/I were initially reported (Cregg etai., 1987). This
shows the potential of the Aspergillus expression system, as production levels
can be expected to improve upon optimisation of the system. To the authors'
knowledge this is the first report of a viral protein expressed in A. niger with
concomitant pseudoviral particle formation. Given the emerging versatility of
filamentous fungi for the production of proteins of pharmaceutical interest, this
work paves the way for the evaluation of Aspergillus as an effective host for the
expression of other viral proteins for the production of subunit vaccines to
address the increasing threat of diseases caused by viruses such as HIVand
rotavirus in Africa.
3.6. Acknowledgements
We would like to thank Prof. C.A.M.J.J. van den Handel (TNO, Zeist, The
Netherlands) for the generous donation of plasmid pAN52-1, the pyrG and
amdS marker genes and the A. niger 015 strain, as well as Dr. J.G.M. Hessing
(TNO, Zeist, The Netherlands) for assistance with the Aspergillus
transformation procedure. Our sincere gratitude also goes to Dr. J.T. Burger
(Department of Genetics, University of Stellenbosch, South Africa) for valuable
discussions, F. Tiedt (Department of Medical Microbiology, University of Cape
Town, South Africa) for the electron microscopy work and R den Haan for
critical reading of the manuscript.
Stellenbosch University http://scholar.sun.ac.za
141
3.7. References
Ayoola, E.A. 1988. Viral hepatitis in Africa, p. 161-169. In A.J. Zuckerman (ed.), Viral Hepatitis
and Liver Disease. Alan R. Liss, Inc., New York.
Barr, P.J., H.L. Gibson, l.C. Bathurst, E.A. Sabin, A. Medina-Selby, D. Coit, and P.
Valenzuela. 1989. Recombinant subunit vaccines from yeast, p. 319-335. In P.J. Barr, A.J.
Brake, and P. Valenzuela (eds.), Yeast genetic enginering. Butterworths, Boston.
Bennett, J. W., and L. L. Lasure. 1991. Growth media. p. 441-457. In J. W. Bennett and L. L.
Lasure (ed.), More gene manipulations in fungi, Academic Press Inc., San Diego, California.
Blum, H., H. Beier, and H.J. Gross. 1987. Improved silver staining of plant proteins, RNA and
DNA in polyacrylamide gels. Electrophoresis 8:93-99.
Bodie, E.A., B. Bower, R.M. Berka, and N.S. Dunn-Coleman. 1994. Economically important
organic acid and enzyme products, p. 561-602. In S.D. Martinelli and J.R. Kinghorn (eds.),
Aspergillus: 50 years on. Elsevier, Amsterdam.
Christensen, T., H. Woeldike, E. Boel, S.B. Mortensen, K. Hjortshoej, L. Thim, and M.T.
Hansen. 1988. High level expression of recombinant genes in Aspergillus oryzae.
Bio/Technology 6:1419-1422.
Cregg, J.M., J.F. Tschopp, C. Stillman, R. Siegel, M. Akong, W.S. Craig, R.G. Buckholz,
K.R. Madden, P.A. Kellaris, G.R. Davis, B.L. Smiley, J. Cruze, R. Torregrossa, G.
Velicelebi, and G.P. Thill. 1987. High-level expression and efficient assembly of hepatitis B
surface antigen in the methylotrophic yeast, Pichia pastoris. BiolTechnology 5 :479-485.
Davies, R.W. 1991. Molecular biology of a high-level recombinant protein production system in
Aspergillus, p. 45-81. In SA Leong and R.M. Berka (eds.), Molecular Industrial Mycology:
Systems and Applications for Filamentous Fungi. Marcel Dekker Inc., New York.
Davies, R.W. 1994. Heterologous gene expression and protein secretion in Aspergillus, p. 527-
559. In S.D. Martinelli and J.R. Kinghorn (eds.), Aspergillus: 50 years on. Elsevier, Amsterdam.
Dehoux, P., V. Ribes, E. Sobczak, and R.E. Streeck. 1986. Expression of the hepatitis B large
envelope protein in Saccharomyces cerevisiae. Gene 48:155-163.
Domansky, N., P. Ehsani, A.-H. Salmanian, and T. Medvedeva. 1995. Organ-specific
expression of hepatitis B surface antigen in potato. Biotechnol.Lett. 17:863-866.
Ganem, D., and H.E. Varmus. 1987. The molecular biology of the hepatitis B viruses.
Annu.Rev.Biochem. 56:651-693.
Gerlich, W. 1991. Hepatitis B surface proteins. J.Hepatol. 13{Suppl. 4):S90-S92
Gordon, C.L., V. Khalaj, A.F.J. Ram, O.B. Archer, J.L. Brookman, A.P.J. Trinci, D.J.
Jeenes, J.H. Doonan, B. Wells, P.J. Punt, C.A.M.J.J. van den Hondel, and G.O. Robson.
2000. Glucoamylase::green fluorescent protein fusions to monitor protein secretion in
Aspergillus niger. Microbiology 146:415-426.
Gouka, R.J., P.J. Punt, and C.A.M.J.J. van den Hondel. 1997. Glucoamylase gene fusions
alleviate limitations for protein production in Aspergillus awamori at the transcriptional and (post)
translational levels. AppI.Environ.Microbiol.63:488-497.
Gwynne, D.I., F.P. Buxton, S.A. Williams, S. Garven, and R.W. Davies. 1987. Genetically
engineered secretion of active human interferon and a bacterial endoglucanase from
Aspergillus nidulans. BiolTechnology 5:713-719.
Stellenbosch University http://scholar.sun.ac.za
142
Hadfield, C., K.K. Raina, K. Shashi-Menon, and R.C. Mount. 1993. The expression and
performance of cloned genes in yeasts. MycoI.Res.97:897-944.
Hardy, E., E. Martinez, D. Diago, R. Diaz, D. Gonzalez, and L. Herrera. 2000. Large-scale
production of recombinant hepatitis B surface antigen from Pichia pastoris. J.Biotechnol.
77:157-167.
Hilleman, M.R. 1987. Yeast recombinant hepatitis B vaccine. Infection 15:3-7.
Hitzeman, R.A., C.Y. Chen, F.E. Hagie, E.J. Patzer, C.-C. Liu, O.A. Estell, J.V. Miller, A.
Yaffe, O.G. Kleid, A.D. Levinson, and H. Oppermann. 1983. Expression of hepatitis B virus
surface antigen in yeast. Nucleic Acids Res. 11:2745-2763.
Howard, C.R., P.R. Young, S. Lee, J. Dixon, A.J. Zuckerman, W.J. McAleer, and E.D.
Lehman. 1986. Hepatitis B surface antigen polypeptide micelles from antigen expressed in
Saccharomyces cerevisiae. .LVirol.Methods 14:25-35.
Huovila, A.-P.J., A.M. Eder, and S.D. Fuller. 1992. Hepatitis B surface antigen assembles in a
post-ER, pre-Golgi compartment. J.Cell BioI. 118:1305-1320.
Janowicz, Z.A., K. Melber, A. Merckelbach, E. Jacobs, N. Harford, M. Comberbach, and
C.P. Hollenberg. 1991. Simultaneous expression of the Sand L surface antigens of hepatitis B,
and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha. Yeast
7:431-443.
Jeenes, D.J., O.A. MacKenzie, I.N. Roberts, and O.B. Archer. 1991. Heterologous protein
production by filamentous fungi. BiotechnoI.Genet.Eng.Rev.9:327-367.
Kassianides, C., A.M. Di Bisceglie, J.H. Hoofnagle, K. Mullen, M. Peters, V. Rustgi, B.
Jones, M. Lisker-Melman, Y. Park, J.G. Waggoner, and E.A. Jones. 1988. Alpha-interferon
therapy in patients with decompensated chronic type B hepatitis, p. 840-843. In A.J. Zuckerman
(ed.), Viral Hepatitis and Liver Disease. Alan R. Liss, Inc., New York.
Kinghorn, J.R., and S.E. Unkles. 1994. Molecular genetics and expression of foreign proteins
in the genus Aspergillus, p. 65-100. In J.E. Smith (ed.), Aspergillus. Plenum Press, New York.
La Grange, D.C., l.S. Pretorius, and W.H. van Zyl. 1996. Expression of a Trichoderma reesei
D-xylanase gene (XYN2) in Saccharomyces cerevisiae. Appl.Environ.Microbiol. 62:1036-1044.
Manyike, P.T., S. Aspinall, and R.S. Summers. 1992. Immunogenicity of recombinant
hepatitis B vaccine in urban black children from Ga-Rankuwa, Bophuthatswana, South Africa.
Pediatr.lnfect.Dis.J.11:726-730.
Martinez, E., J. Morales, J. Aguiar, Y. Pineda, M. Izquierdo, and G. Ferbeyre. 1992. Cloning
and expression of hepatitis B surface antigen in the yeast Kluyveromyces lactis.
Biotechnol.Lett. 14:83-86.
Mason, H.S., D.M.K. Lam, and J. Arntzen. 1992. Expression of hepatitis B surface antigen in
transgenic plants. Proc.Natl.Acad .Sci.USA 89:11745-11749.
McAleer, W.J., E.B. Buynak, R.Z. Maigetter, D.E. Wampler, W.J. Miller, and M.R. Hilleman.
1984. Human hepatitis B vaccine from recombinant yeast. Nature 307:178-180.
Michel, M.-L., P. Pontisso, E. Sobczak, Y. Malpiêce, R.E. Streeck, and P. Tiollais. 1984.
Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for
polymerized human serum albumin. Proc.NatI.Acad.Sci.USA 81:7708-7712.
Miyanohara, A., A. Toh-e, C. Nozaki, F. Hamada, N. Ohtomo, and K. Matsubara. 1983.
Expression of hepatitis B surface antigen gene in yeast. Proc.NatI.Acad.Sci.USA 80:1-5.
Stellenbosch University http://scholar.sun.ac.za
143
O'Keefe, D.O. and A.M. Paiva. 1995. Assay for recombinant hepatitis B surface antigen using
reversed-phase high-performance liquid chromatography. Anal.Biochem. 230:48-54.
Peterson, D.L. 1987. The structure of the hepatitis B surface antigen and its antigenic sites.
BioEssays 6:258-262.
Punt, P. J., and e. A. M. J. J. van den Hondel. 1992. Transformation of filamentous fungi
based on hygromycin Band phleomycin resistance markers. Methods Enzymol. 216:447-457.
Punt, P.J., N.O. Zegers, M. Busscher, P.H. Pouwels, and e.A.M.J.J. van den Hendel. 1991.
Intracellular and extracellular production of proteins in Aspergillus under the control of
expression signals of the highly expressed Aspergillus nidulans gpdA gene. J.Biotechnol.
17:19-34.
Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual.
Cold Spring Harbor Laboratory, New York.
Sato, M., Y. Sato-Miyamoto, K. Kameyama, N. Ishikawa, M. Imai, Y. Ito, and T. Takagi.
1995. Peripherally biased distribution of antigen proteins on the recombinant yeast-derived
human hepatitis B virus surface antigen vaccine particle: structural characteristics revealed by
small-angle neutron scattering using the contrast variation method. J.Biochem.118:1297-1302.
Seeger, C., and W.S. Mason. 2000. Hepatitis B virology. Microbiol.Mol BioI.Rev. 64:51-68.
Tautz, D., and N. Renz. 1983. An optimized freeze squeeze method for the recovery of DNA
fragments from agarose gels. AnaI.Biochem.132:503-517.
Thanavala, Y., Y.-F. Yang, P. Lyons, H.S. Mason, and e. Arntzen. 1995. Immunogenicity of
transgenic plant-derived hepatitis B surface antigen. Proc.NatI.Acad.Sci.USA 92:3358-3361.
Tiollais, P., e. Pourcel, and A. Dejean. 1985. The hepatitis B virus. Nature 317:489-495.
Tleugabulova, D. 1998. Size-exclusion chromatograhic study of the reduction of recombinant
hepatitis B surface antigen. J.Chromatogr.B 713:401-407.
Upshall, A., A.A. Kumar, M.e. Bailey, M.D. Parker, M.A. Favreau, K.P. Lewison, M.L.
Joseph, J.M. Maraganore, and G.L. McKnight. 1987. Secretion of active human tissue
plasminogen activator from the filamentous fungus Aspergillus nidulans. Bio/Technology
5:1301-1304.
Valenzuela, P., A. Medina, W.J. Rutter, G. Ammerer, and B.D. Hall. 1982. Synthesis and
assembly of hepatitis B virus surface antigen particles in yeast. Nature 298:347-350.
Valenzuela, P., P. Gray, M. Quiroga, J. Zaldivar, H.M. Goodman, and W.J. Rutter. 1979.
Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface
antigen. Nature 280:815-819.
Van den Hondel, e.A.M.J.J., and P.J. Punt. 1991. Gene transfer systems and vector
development for filamentous fungi, p. 1-28. In J.F. Peberdy, C.E. Caten, J.E. Ogden, and J.W.
Bennett (eds.), Applied molecular genetics of fungi. Cambridge University Press, Cambridge.
Van den Hondel, e.A.M.J.J., P.J. Punt, and R.F.M. Van Gorcom. 1991. Heterologous gene
expression in filamentous fungi, p. 397-428. In J.W. Bennett and L.L. Lasure (eds.), More gene
manipulations in fungi. Academic Press Inc., San Diego.
Verdoes, J.C., P.J. Punt, J.M. Schrickx, H.W. van Verseveld, A.H. Stouthamer, and
e.A.M.J.J. van den Hendel. 1993. Glucoamylase overexpression in Aspergillus niger.
molecular genetic analysis of strains containing multiple copies of the glaA gene. Transgenic
Res. 2:84-92.
Stellenbosch University http://scholar.sun.ac.za
144
Vryheid, R.E., M.A. Kane, N. Muller, G.C. Schatz, and S. Bezabeh. 2001. Infant and
adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 19 :1026-1037.
Ward, P.P., C.S. Piddington, G.A. Cunningham, X. Zhou, R.D. Wyatt, and O.M. Conneely.
1995. A system for production of commercial quantities of human lactoferrin: a broad spectrum
natural antibiotic. BiofTechnology 13:498-502.
Ward, M., L.J. Wilson, K.H. Kodama, M.W. Rey, and R.M. Berka. 1990. Improved production
of chymosin in Aspergillus by expression as a glucoamylase-chymosin fusion. Bio/Technology
8:435-440.
Wiebe, M.G., A. Karandikar, G.O. Robson, A.P.J. Trinci, J.-L. Flores Candia, S. Trappe,
G.L.F. Wallis, U. Rinas, P.M.F. Oerkx, S.M. Madrid, H. Sisniega, I. Faus, R. Montijn,
C.A.M.J.J. van den Hondel, and P.J. Punt. 2001. Production of tissue plasminogen activator
(t-PA) in Aspergillus niger. BiotechnoI.Bioeng.76:164-174.
World Health Organisation Hepatitis B vaccine - making global progress. EPI update 31,
October 1996. Geneva: World Health Organisation.
Yamaguchi, M., K. Sugahara, K. Shiosaki, H. Mizokami, and K. Takeo. 1998. Fine structure
of hepatitis B virus surface antigen produced by recombinant yeast: comparison with HBsAg of
human origin. FEMS.MicrobioI.Lett. 165:363-367.
Stellenbosch University http://scholar.sun.ac.za
Chapter 4
Paper 2
Expression of the hepatitis B virus Sand
preS1preS2S genes in Aspergillus: problems and
prospects
Stellenbosch University http://scholar.sun.ac.za
145
4. EXPRESSION OF THE HEPATITIS B VIRUS SAND
PRES1PRES2S GENES IN ASPERGILLUS: PROBLEMS AND
PROSPECTS
Annette Pluddemann and Willem H. van Zyl
Department of Microbiology, University of Stellenbosch, Stellenbosch 7600, South Africa
4.1. Abstract
The hepatitis B virus Sand preS1preS2S genes encoding the major (8) and
large (L) envelop proteins, respectively, were cloned into Aspergillus expression
vectors for intracellular and extracellular expression. Both the viral genes were
placed under control of the constitutive Aspergillus nidulans glyceraldehyde-3-
phosphate dehydrogenase (gpdA) and inducible Aspergillus niger glucoamylase
(glaA) promoters. Fusion constructs between the respective viral genes and the
catalytic domain of the A. niger glucoamylase (glaA2) were also made to
explore secretion of the viral protein. The various constructs were transformed
to laboratory strains of A. niger and Aspergillus awamori. The majority of
transformants carried single integrated copies of the respective expression
vectors, and both the gpdA and glaA promoters directed S gene transcription.
Two transformants showed transcription of the glaA2-S fusion gene. No full-
length preS1preS2S gene transcripts were obtained in any of the recombinant
strains transformed with this viral gene. One A. niger transformant carrying the
S gene under control of the gpdA promoter, which had the highest vector copy
number and the highest levels of transcription, revealed intracellular production
of heterologous 8 protein and pseudoviral particle formation (detailed in
Paper 1, this thesis). None of the other transformants tested showed
production of heterologous viral protein and no secretion of 8 protein could be
obtained. This work clearly indicates that factors such as the choice of strain
and promoter, as well as the composition of the expression construct, influence
the success of each new attempt at heterologous protein expression in
Aspergillus. The most important insight that emerged from this study was that
the glaA2 fusion strategy was ineffectual in promoting or enhancing secretion
due to the inherent spontaneous aggregation properties of the viral proteins.
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4.2. Introduction
Since the 1980s, the filamentous fungus Aspergillus has been developed as an
alternative host to the commonly employed yeasts such as Saccharomyces
cerevisiae and Pichia pastoris, for the production of heterologous proteins
(Kinghorn and Unkles, 1994; Romanos et al., 1992). Efficient transformation
protocols and various expression vectors have been developed for Aspergillus
(Turner, 1994; Van den Hondel and Punt, 1991). Transformation generally
occurs by random integration into the chromosome (Ballance and Turner, 1985;
Tilburn et ai., 1983). Two of the promoters most commonly employed are the
constitutive Aspergillus nidulans glyceraldehyde-3-phosphate (gpdA) promoter
and the strong inducible Aspergillus niger glucoamylase (glaA) promoter
(Fowler et ai., 1990; Punt et ai., 1988). To identify transformants, the A. niger
orotidine-5'-phosphate decarboxylase (pyrG) gene is commonly used to
complement the corresponding mutation in pyrG- auxotrophic host strains
(Goosen et ai., 1987). In addition, the A. nidulans acetamidase-encoding amdS
gene has been used as a dominant marker and also to identify transformants
carrying multiple copies of the expression vector (Wemars et al., 1985). One
copy of the amdS gene is sufficient to allow the fungus to grow on acetamide as
sole carbon and/or nitrogen source, however growth on acrylamide is only
possible if several copies of the gene are present (Van den Hondel et aI., 1992).
These tools have since been employed for the heterologous production of
various fungal and non-fungal proteins in Aspergillus (Timberlake and Marshall,
1989; Van den Hondel et ai., 1991; Van den Hondel et ai., 1992).
Several proteins of pharmaceutical interest have been expressed in Aspergillus
with varying degrees of success (Gouka et ai., 1997b; Kinghorn and Unkles,
1994; Verdoes et ai., 1995). Biologically active proteins successfully produced
in this host include human interleukin-6 (15 mg/I) (Broekhuijsen et al., 1993),
human interferon a2 (1 mg/I) (Gwynne et ai., 1987), human lactoferrin (2 g/I)
(Ward et ai., 1995), antibody fragments (200 mg/I) (Frenken et ai., 1998),
human tissue plasminogen activator (1 mg/I) (Upshall et ai., 1987) and human
mucus proteinase inhibitor (3 mg/I) (Mikosch et ai., 1996). Various
heterologous expression experiments consistently show that, in general, the
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yields of most heterologous proteins are low compared to homologous proteins
and in most cases do not exceed levels of a few milligrams per litre. Some of
the factors affecting heterologous gene expression include the site of vector
integration and copy number (Verdoes et al., 1994), transcriptional control (i.e.
the promoter used) (Hanegraaf et al., 1991; Verdoes et al., 1993), codon bias
(Ballance, 1986; Gouka et al., 1996), secretion efficiency (Punt et al., 1994; Van
den Handel et al., 1992), molecular chaperone availability (Punt et al., 1998),
glycosylation processes (Sorensen et al., 1996; Wang et al., 1996) and the
presence of proteases (Archer and Peberdy, 1997; Van den Hombergh et al.,
1997). Proteolytic degradation has been shown to be one of the major factors
influencing the yield of these heterologous proteins, since Aspergillus strains
produce a number of aspartic proteases, alkaline and semi-alkaline serine
proteases and serine carboxypeptidases (Van den Hombergh et al., 1997).
Some of the problems experienced with the heterologous expression of non-
fungal proteins have been addressed with a variety of strategies. Some of
these strategies include codon optimisation (Gouka et al., 1996), the generation
of fusion constructs to improve secretion (Gouka et al., 1997b; Jeenes et al.,
1993; Spencer et al., 1998), overexpression of chaperone proteins (Ngiam
et al., 2000; Punt et al., 1998) and the isolation of protease deficient mutants
(Archer and Peberdy, 1997). While some of the problems encountered with the
expression of pharmaceutical proteins have been addressed, for each new
protein the optimal expression strategy needs to be evaluated.
This paper addresses some of the challenges encountered in the heterologous
production of the hepatitis B virus Sand preS1preS2S genes in A. niger and
A. awamori.
4.3. Materials and Methods
4.3.1. Strains and media
Recombinant plasmids were constructed and amplified in Escherichia coli
XL1Blue (Stratagene) cultivated at 3rC in Luria-Bertani liquid medium or on
Luria-Bertani agar (Sambraak et al., 1989). Ampicillin for selection and
propagation of resistant bacteria was added to a final concentration of
Stellenbosch University http://scholar.sun.ac.za
148
100 !-lg/ml. A. niger D15, the recipient strain for transformation, is a uridine
auxotrophic (pyrG), protease-deficient (prtT), nonacidifying (phmA) mutant
(Gordon et ai., 2000). The A. awamori T3 strain is a uridine auxotroph (pyrG)
derived from A. awamori eBS115.52 (Gouka etai., 1995). Aspergillus strains
were cultured in minimal growth medium (Bennett and Lasure, 1991) containing
1% glucose and supplemented with 0.2% casamino acids (Difco), 0.5% yeast
extract and 10 mM uridine (Sigma) in 1-liter Erlenmeyer flasks containing 250
ml medium at 30ae on a rotary shaker at 150 rpm. Transformants were
selected on minimal medium without uridine containing 1.2 M sorbitol as
osmotic stabiliser, 1.5% agar (Oxoid) and 10 mM acetamide as sole nitrogen
source. Transformants were selected for multicopy integration of the
expression cassettes on acrylamide plates (Verdoes et ai., 1993). Minimal
medium without uridine, supplemented with 0.5% yeast extract, 0.1% casamino
acids and 1% glucose, was used to culture transformants. For induction of the
glucoamylase promoter, minimal medium containing 5% maltodextrin was used.
4.3.2. Plasmid construction and transformation of A. niger and
A. awamori
Standard protocols were followed for DNA manipulations (Sambrook et al.,
1989). Restriction endonuclease-digested DNA was eluted from agarose gels
by the method of Tautz and Renz (1983). Restriction endonucleases and T4
DNA ligase were purchased from Roche Molecular Biochemicals and used as
recommended by the manufacturer. Vectors peOR 105 and peOR 103 (donated
by Prof. W.J. de Wet, Potchefstroom University, South Africa) served as
template for the peR amplification of the hepatitis B virus Sand preS1preS2S
genes, respectively. Primers were designed to include pentaHis tag sequences
and the dibasic "Lys-Arg" proteolytic cleavage site where required. The
sequences of the primers designed for the amplification of the 814-bp S gene
and the 1433-bp preS1preS2S gene are summarised in Table 1.
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Table 1. Primers used in this study.
Primer Sequence
S-Nco-LEFT
S-Kex2-LEFT
S-Blg2-RIGHT
S-Hind-RIGHT
S-BgI2-His-RIGHT
S-Hind-His-RIGHT
S1S2S-Nco-LEFT
S1S2S-Kex2-LEFT
5'-CT AGCCATGGAGAACATCACA TCAGGA TTCC-3'
5'-ATGTGAT ATCCAAGCGCATGGAGAACATCACATCAGG-3'
5'-GATCAGATCTCCAACAGGAAGTTTTCT AAAAC-3'
5'-GATCAAGCTTGGGCTGCAGGTCGACT -3'
5'-GATCAGATCTT AA TGGTGA TGGTGATGAA TGT ATTCCCAGAGACAAAAG-3'
5'-GATCAAGCTT AA TGGTGATGGTGA TGAA TGT ATTACCCAGAGACAAAAG-3'
5'-CTAGCCATGGGAGGTTGGTCATCAAAACC-3'
5'-ATGTGAT ATCCAAGCGCATGGGAGGTT GGTCATCA-3'
Restriction enzyme sites are underlined and the proteolytic cleavage site is highlighted.
Construction of the expression vectors was carried out as follows: three
Aspergillus vectors were used as basis for all the constructions, namely
pAN52-1, pAN52-10 and pAN56-8 (kindly provided by Prof. C.A.M.J.J. van den
Hondel, TNO, Zeist, The Netherlands). Vector pAN52-1 carries the constitutive
A. nidulans glyceraldehyde-3-phosphate dehydrogenase (gpdA) promoter,
pAN52-10 carries the inducible A. niger glucoamylase (glaA) promoter and
pAN56-8 contains the A. niger glaA promoter and secretion signal fused to a
sequence encoding truncated A. niger glucoamylase (GLA G2, the catalytic
domain) (Figure 1). All the vectors contain the trpC terminator. The Sand
preS1preS2S genes were PCR-amplified using the appropriate primers with or
without the pentaHis tag, digested with Ncol and Bglli and cloned into the
unique Ncol, BamH1 sites in pAN52-1. Similarly, the viral genes were
amplified, digested with Ncol and HindiII and cloned into the corresponding
unique sites in pAN52-10. To fuse the Sand preS1preS2S genes to the
truncated A. niger GLA G2 form (514 aa) lacking the starch-binding domain
(Broekhuijsen et aI., 1993), the viral genes were amplified using primer S-Kex2-
LEFT and S1S2S-Kex2-LEFT, respectively, in combination with primer S-Hind-
RIGHT and cloned into the unique EcoRV and HindIII sites in plasmid pAN56-8.
The GLA G2 and hepatitis B sequences were thus separated by the dibasic
proteolytic cleavage site "Lys-Arg", which results in cleavage of the fusion
protein into both separate proteins by a Kex2-like protease (Broekhuijsen et aI.,
1993). Finally, the A. nidulans amdS and A. niger pyrG selection markers
(provided by Prof. C.A.M.J.J. van den Hondel, TNO, Zeist, The Netherlands)
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were introduced into all the expression vectors at the unique Not! site. The
resulting vectors are summarised in Table 2. A schematic representation of the
cloning procedure and the various plasmid constructs is given in Figure 1. The
A. nidulans amdS and A. niger pyrG selection markers were also introduced
into pBluescript (Stratagene) at the unique Notl site, creating pBluescript-
pyrGamdS. Fungal transformation of A. niger and A. awamori was carried out
by the protoplasting method of Punt and Van den Hondel (1992), using
Novozym 234 (Sigma).
4.3.3. Isolation of RNA and Northern analysis
Total RNA was isolated from A. niger and A. awamori transformants cultured for
40 h at 30°C as follows: Mycelium was harvested through Miracloth
(Calbiochem), frozen under liquid nitrogen, ground to a fine powder with a
mortar and pestle and resuspended in cold STE buffer (0.25 M Tris-HCI [pH7.2],
0.1 M NaCI, 0.01 M EDTA [pH8]). One volume phenol/chloroform/
isoamylalcohol (PCI) and 0.05% sodium dodecyl-sulphate (SOS) was added
and the mycelial debris was collected by centrifugation. The aqueous upper
phase was recovered, subjected to PCI extraction and precipitated to yield total
RNA. The total RNA was used for conventional Northern blot analysis as
described by Sambrook et al. (1989). The probes were prepared by labelling
the 814-bp hepatitis B virus S gene and a 1350-bp fragment of the A. nidulans
glyceraldehyde-3-phosphate dehydrogenase (gpdA) gene with [a-32P]dATP,
using a random primed DNA labelling kit (Roche Molecular Biochemicals) as
recommended by the manufacturer.
4.3.4. Isolation of genomic DNA from A. niger and Southern blotting
The genomic DNA was isolated from Aspergillus transformants according to La
Grange et al. (1996), digested overnight with EcoRI at 3rC, separated on a
0.6% agarose gel and blotted to a Hybond-N membrane (Amersham).
Southern blot analysis was carried out according to Sambrook et al. (1989)
using the radioactively labelled 814-bp S gene as probe.
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StrainlPlasmid SourcelReferenceGenotype
Bacterial strain:
Escherichia coli XL1-Blue Stratagene
Fungal strains:
Aspergillus niger 015
A. niger 015 (pBluescript-
pyrGamdS)a
OAHB11
OAHB14
OAHB15
OAHB17
OAHB18
OAHB19
OAHB20
Aspergillus awamori T3
AWAHB11
AWAHB15
AWAHB17
AWAHB20
Plasmids:
pBluescript-pyrGamdS
pCOR103
pCOR105
pAN52-1
pAN52-10
pAN56-8
pAHB11
pAHB12
pAHB13
pAHB14
pAHB15
pAHB16
pAHB17
pAHB18
pAHB19
pAHB20
recA1 endA1 gyrA96 thi-1hsdR17 supE44
relA1lac[F' proAB lacfZ,1M15 Tn10 (Tet')]c
pyrG prtT phmA
pyrG+ prtT phmA amdS+
pyrG+ prtT phmA amdS+ gpdAp-S-trpCr
pyrG+ prtT phmA amdS+ gpdAp-
preS1preS2S-His-trpCr
pyrG+ prtT phmA emas' glaAp-S-trpCr
pyrG+ prtT phmA amdS+ glaAp-S-His-trpCr
pyrG+ prtT phmA amdS+ glaAp-
preS1preS2S-His-trpCr
pyrG+ prtT phmA amdS+ glaAp-glaAss-
glaAGrS-trpCr
pyrG+ prtT phmA amdS+ glaAp-glaAss-
glaAG2-preS 1preS2 S-trpCr
pyrG
pyrG+ emas' gpdAp-S-trpCr
pyrG+ amdS+ glaAp-S-trp Cr
pyrG+ amdS+ glaAp-S-His-trpCr
pyrG+ amdS+ glaAp-glaAss-glaAG2_
preS1 preS2S-trpCr
bla pyrG amdS
bla preS1preS2S
bla S
bla gpdAp-trpCr
bla glaAp-trpCr
bla glaAp-glaAss-glaAGrtrpCr
bla pyrG amdS gpdAp-S-trpCr
bla pyrG amdS gpdAp-preS1preS2S-trpCr
bla pyrG amdS gpdAp-S-His-trpCr
bla pyrG amdS gpdAp-preS1preS2S-His-
trpCr
bla pyrG amdS glaAp-S-trpCr
bla pyrG amdS glaAp-preS1preS2S-trpCr
bla pyrG amdS glaAp-S-His -trpCr
bla pyrG amdS glaAp-preS1preS2S-His-
trpCr
bla pyrG amdS glaAp-gla Ass-glaAG2-S-trpCr
bla pyrG amdS glaAp-gla Ass-glaAG2-
preS 1preS2S-trpCr
Gordon et al., 2000
This work
This work
This work
This work
This work
This work
This work
This work
Gouka et al., 1995
This work
This work
This work
This work
This work
vs.s. de Wet
w.s. de Wet
Punt et al., 1991
CAM.J.J. van den
Hondel
CAM.J.J. van den
Hondel
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
aA. niger 015 (pBluescript-pyrGamdS) was designated A. niger (control)
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A
pAN56-8
EcoRV EcoRV
pAHB19 pAHB20
Figure 1. Schematic representation of the Aspergillus expression vectors constructed in this
study. pAN56-8 (A), pAN52-1 (B) and pAN52-10 (C) are the initial Aspergillus expression
vectors into which the viral genes and fungal marker genes were cloned. The viral gene
expression vectors constructed are grouped below the respective Aspergillus expression vector
from which they were derived. The E. coli (3-lactamase (bla), A. nidulans acetamidase (amdS)
and A. niger orotidine-5'-decarboxylase (pyrG) genes were used as selectable markers. gpdAp,
glaAp, glaA2 and trpCt, represent the A. nidulans glyceraldehyde-3-phosphate dehydrogenase
gene promoter, the A. niger glucoamylase gene promoter, the catalytic domain of the A. niger
glucoamylase and the trpC (a trifunctional gene in tryptophan biosynthesis) gene terminator,
respectively. The hepatitis B virus Sand preS1 preS2S genes are indicated in red.
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B
pAN52-1
Neal Neal
trpCr
(A. nidulans)
pAHBll
trpCr
(A. nidulans)
pAHB12
Neal Neal
trpCr
(A. nidulans)
pAHB13
Figure 1. Schematic representation of the Aspergillus expression vectors constructed in this
study (continued).
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Nco Ic
pAN52-10
Nco I Nco I
Nco I Neol
Figure 1. Schematic representation of the Aspergillus expression vectors constructed in this
study (continued).
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4.3.5. 50S-PAGE and Western blotting
Total intracellular proteins were isolated from the transformants cultured for
72 h in minimal medium containing 1% glucose or 5% maltodextrin as before.
Extracellular proteins were recovered from the growth medium after filtering of
the mycelium by filtration and concentration of the medium by a Diaflo Ultrafilter
PM10 concentrator (Amicon Division of W.R. Grace and Co., Danvers, Mass.).
Intracellular protein extraction was performed as follows: Mycelium was
harvested and ground as before. Ground mycelium was suspended in protein
extraction buffer (50 mM phosphate buffer [pH7.0), 1 mM MgCI2, 20 !JM
phenylmethylsulfonyl flouride) with or without 0.1% Triton X-100, and the
mycelial debris was removed by centrifugation. S. cerevisiae-derived Engerix-B
hepatitis B virus vaccine (20 !Jg/ml) (SmithKline Beecham Pharmaceuticals)
was purchased from a local pharmacy to act as reference protein. Proteins
were separated in a 12% SOS polyacrylamide gelelectrophoresis (PAGE) gel
and visualised by staining with silver nitrate (Blum et aI., 1987). For Western
blotting, proteins were transferred to a polyvinylidine difluoride (PVDF)
membrane (Hybond-P; Amersham Pharmacia Biotech) in transfer buffer (25
mM Tris-HCI [pH 7.5], 192 mM glycine, 15% [vol/vol] methanol) using a semi-
dry transfer apparatus (Hoefer). The Chemiluminescence Western Blotting Kit
(Roche Molecular Biochemicals) was used as recommended by the
manufacturer. The primary antibodies were polyclonal goat anti-hepatitis B
surface antigen (1:5000 dilution) (Dako) and secondary antibodies were anti-
goat immunoglobulins conjugated to horseradish peroxidase (1:10 000 dilution)
(Dako). Primary antibodies raised against glucoamylase were provided by
P. Punt (TNO, Zeist, The Netherlands) and used at a dilution of 1:20 000. Anti-
mouse antibodies conjugated to alkaline phosphatase served as secondary
antibodies and detection was performed with 5-bromo-4-chloro-3-indolyl-
phosphate/nitro blue tetrazolium (BCIP/NBT) (Promega). For Western analysis
with penta-His antibodies (Qiagen) the primary antibody was used at a dilution
of 1:1000 as recommended by the manufacturer and anti-mouse horseraddish
peroxidase conjugated antibodies served as secondary antibodies at a final
concentration of 40 mU (Roche Molecular Biochemicals).
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4.3.6. Protease susceptibility assay
Samples of the intracellular fraction from OAHB11#8 containing recombinant
hepatitis B S protein were incubated in 5% maltodextrin medium in which A.
niger 015 had been cultivated for 48 h. Incubation times at 3rC were 1 h, 2 h,
3 h and overnight. Samples from the various time points were run on a 12%
SOS-PAGE gel and subjected to Western analysis as described previously
using the goat anti-hepatitis B surface antigen primary antibodies.
4.4. Results
4.4.1. Recombinant Aspergillus strains expressing the hepatitis B
genes.
All ten different expression vectors (pAHB11 to pAHB20) were transformed to
A. niger 015 and A. awamori T3. However, not all transformation experiments
yielded transformants and a summary of the number of uridine prototrophic,
acetamide utilising transformants obtained for each expression vector in both
Aspergillus strains is given in Table 3. The vector pBluescript-pyrGamdS was
also transformed to A. niger 015 and this strain served as a prototrophic
reference strain. More transformants were obtained for the hepatitis B S gene,
encoding the major (S) protein of the envelope of the hepatitis B virus (subtype
adw2), than for the preS1preS2S gene, encoding the large (L) protein. In total,
33 A. niger 015 transformants were obtained carrying the S gene under the
transcriptional control of either the constitutive gpdA promoter or the inducible
glaA promoter, and 6 transformants were obtained carrying the S gene fused to
the 3' end encoding region of the catalytic domain of the highly expressed
A. niger glucoamylase. In contrast, only nine transformants were obtained
carrying the peS1preS2S gene, of which only one was under the control of the
gpdA promoter. Six transformants were also obtained for the glaA-
preS2preS2S fusion construct. The A. awamori T3 transformation frequency
was much lower and only 18 transformants carrying hepatitis B viral genes were
obtained for this strain. All the transformants were purified twice on selective
medium and subsequently plated on acrylamide plates. Efficient growth and
sporulation on acrylamide plates reflects multicopy integration of the
transforming vector (Verdoes et aI., 1993).
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Table 3. Number of transformants obtained.
Plasmid Plasmid Components Strain Number of Transformants
Transformed Transformants Analysed Further
Obtained Number Desl9_nation
pAHB11 bla pyrG amdS gpdAp-S-trpCr A. niger 015 10 3 OAHB11#2
OAHB11#3
OAHB11#8
A. awamori T3 6 3 AWAHB11#1
AWAHB11#4
AWAHB11#5
pAHB12 bla pyrG amdS gpdAp- A. niger 015 0 0 -
preS1preS2S-trpCr A. awamori T3 0 0 -
pAHB13 bla pyrG amdS gpdAp-S-His- A. niger 015 0 0 -
trpCr A. awamori T3 0 0 -
pAHB14 bla pyrG amdS gpdAp- A. niger 015 1 1 OAHB14#1
preS1preS2S-His-trpCr A. awamori T3 0 0 -
pAHB15 bla pyrG amdS glaAp-S-trpCr A. niger 015 10 4 OAHB15#1
OAHB15#3
OAHB15#4
OAHB15#8
A. awamori T3 5 3 AWAHB15#1
AWAHB15#3
AWAHB15#4
pAHB16 bla pyrG amdS glaAp- A. nig_er01 5 0 0 -
preS 1preS2S-trpCr A. awamori T3 0 0 -
pAHB17 bla pyrG amdS glaAp-S-His- A. niger 015 13 4 OAHB17#2
trtiC, OAHB17#6
OAHB17#7
OAHB17#13
A. awamori T3 4 0 -
pAHB18 bla pyrG amdS glaAp- A. niger 015 8 5 DAHB18#1
preS 1preS2S-His-trpCr OAHB18#6
OAHB18#7
OAHB18#8
OAHB18#9
A. awamori T3 0 0 -
pAHB19 bla pyrG amdS glaAp-glaAss- A. niger 015 6 2 OAHB19#1
glaAG2-S-trpCr OAHB19#2
A. awamori T3 0 0 -
pAHB20 bla pyrG amdS glaAp-glaAss- A. niger015 6 4 OAHB20#1
glaAGrpreS 1preS2S-trpCr OAHB20#2
OAHB20#5
OAHB20#6
A. awamori T3 3 0 -
4.4.2. Gene copy number and expression
With regard to A. niger D15, three isolates transformed with pAHB11, 1 isolate
transformed with pAHB14, 4 isolates transformed with pAHB15, 4 isolates
transformed with pAHB17, 5 isolates transformed with pAHB18, 2 isolates
transformed with pAHB19 and 4 isolates transformed with pAHB20 that showed
growth and sporulation on acrylamide plates were selected (Refer to Table 3).
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These transformants were cultured in minimal medium containing glucose (in
the case of the gpdA promoter) or maltodextrin (in the case of the glaA
promoter) for 40 h and analysed for Sand preS1preS2S gene transcription by
Northern blotting (Figure 2A,B). One A. niger D15 transformant containing
pBluescript-pyrGamdS was also cultured to act as reference strain. With regard
to A. awamori T3, three isolates transformed with pAHB11 (designated
AWAHB11#1, AWAHB11#4 and AWAHB11#5) and three isolates transformed
with pAHB15 (designated AWAHB15#1, AWAHB15#3 and AWAHB15#4) were
selected and cultured in the same manner and analysed for S gene
transcription by Northern blotting (Figure 2B). The untransformed parental
strain acted as reference strain in this case.
Transcription levels varied significantly between the different transformants, with
some showing no S gene transcripts. Some of the transformants carrying the
preS1preS2S gene showed an 814-bp transcript similar to that of the
transformants carrying the S gene, but no full-length 1433-bp preS1preS2S
transcripts could be detected. Both transformants (DAHB19#1 and DAHB19#2)
carrying the truncated glucoamylase-S protein fusion showed transcripts of the
expected size for the fusion protein (2814 bp). In strain DAHB19#1 a second
transcript of 814 bp was also detected. No hepatitis B viral gene transcript
could be detected in any of the transformants carrying the truncated
glucoamylase-preS1 preS2S protein fusion (DAHB20) (data not shown).
Transformant DAHB11#8 (Figure 2A, lane 3) showed the highest levels of S
gene mRNA transcripts and was selected for further analysis, which is detailed
in Paper 1 (this thesis).
To determine the copy number of the integrated plasmid in some of the A. niger
D15 transformants genomic DNA was isolated, digested with EcoRI (which has
only one recognition site in the expression vectors) and subjected to Southern
analysis using the [a-32P]dATP-labelied S gene as probe (Figure 3). Results
indicated that most of the transformants contained single copies of the
expression cassette integrated into the A. niger genome, but DAHB11#8,
DAHB15#1, DAHB15#3 and DAHB15#4 contained multiple copies.
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Subsequent Southern analysis of DAHB11#8 revealed the integration of
approximately seven copies (refer to Paper 1, this thesis).
0.814 kb __.
A
B
0.814 kb__.
1.35 kb__.
Figure 2. (A) Northern blot analysis of S gene mRNA transcripts from isolates of A. niger 015
transformed with plasmids pAHB11, pAHB15 and pAHB19. (B) Northern blot analysis of Sand
preS1 preS2S gene transcripts from isolates of A. niger 015 transformed with plasmids pAHB14,
pAHB17 and pAHB18 and A. awamori T3 transformed with plasm ids pAHB11 and pAHB15.
Refer to Table 2 for the genotypes of the various strains. The 814-bp S gene was used as an
[a-32p-dATP]-labelied probe in (A) and (B) and a 1350-bp fragment of the A. nidulans
glyceraldehyde-3-phosphate dehydrogenase (gpdA) gene was used as internal standard
(bottom panel of A and B).
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5.1 kb
3.5 kb
21.2 kb
2.0 kb
1.6 kb
14 kb
0.95 kb
0.83 kb
0.56 kb
Figure 3. Southern blot analysis to determine the number of S gene copies integrated into the
recombinant A. niger 015 genome. Refer to Table 2 for the genotypes of the various strains.
DNA isolated from the transformants was digested with EcoRI. Plasmid pAHB11 served as
reference DNA. The 814-bp S gene was used as an [a- 32p_dATP]-Iabeled probe. The sizes of
the lambda marker DNA fragments are indicated.
4.4.3. Protein production analysis
Transformants carrying the viral gene under control of the gpdA promoter were
cultured in glucose-containing minimal medium and transformants carrying the
viral gene under control of the glaA promoter were cultured in maltodextrin
medium for induction of the glucoamylase promoter. Total intracellular proteins
were isolated, separated on 12% SOS-PAGE gels and Western analysis was
carried out with HBsAg-specific antibodies. In the intracellular protein fraction of
OAHB11#8 a 24-kOa protein species was highlighted, which did not appear in
the reference strain (Figure 4). This protein also appeared in the Engerix
vaccine HBsAg protein, confirming that the 24 kOa protein corresponds to the S
protein. However, none of the other transformants showed any production of
recombinant hepatitis B S or L protein in the intracellular fraction (Figure 4 and
additional data not shown). Additional Western analysis of samples from the
constructs carrying a penta-His tag (OAHB14, OAHB17 and OAHB18) with anti-
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penta-His antibodies also did not reveal the presence of recombinant S or L
protein (data not shown).
24kDa .....
48kDa .....
Figure 4. Detection of intracellular viral protein production by Western blot analysis. Engerix-B
is a sample of commercially available hepatitis B virus vaccine which acted as reference protein.
Immunoblotting was done with a polyclonal goat-a-HBsAg antibody. A protein species of
24 kDa is visible in transformant DAHB11#8 corresponding to the size of the hepatitis B S
protein.
Transformant OAHB19#2 carrying the truncated glucoamylase-S protein fusion
was further analysed for extracellular S protein production. Extracellular
fractions of OAHB19#2 were obtained by culturing the strain for 65 hand 112 h,
filtering the mycelium and subsequently concentrating the growth medium ten
times. These samples were then subjected to SOS-PAGE and Western
analysis as was performed for intracellular fractions. No extracellular Sprotein
production could be detected (Figure 5). Western analysis of the OAHB19
transformants with antibodies specific for glucoamylase revealed the presence
of the two forms (the larger G1 form and the smaller G2 form lacking the starch
binding domain) (Boel et al., 1984a; Boel et aI., 1984b) of the enzyme in the
medium, indicating that the promoter was induced (Figure 6A). In the
intracellular fraction, several breakdown products that did not appear in the
reference strain, were observed (Figure 6B). This result may indicate that in the
transformants carrying the truncated glucoamylase-S protein fusion, passage
through the secretory pathway may be impaired, resulting in the degradation of
Stellenbosch University http://scholar.sun.ac.za
162
glucoamylase and/or the fusion protein. A protease susceptibility assay was
also performed with recombinant hepatitis B virus S protein from transformant
DAHB11#8 and this revealed that the S protein levels diminished somewhat
after one hour, and that the protein was completely degraded after overnight
incubation in the medium in which A. niger D15 had been previously cultured
(Figure 7).
With regard to the A. awamori T3 transformants, even though some of the
transformants showed S gene transcription, none of them produced any
detectable recombinant S protein (Figure 8).
65h 112h 65h 112h
Unconcentrated Unconcentrated Concentrated Concentrated
48 kDa _.
24 kDa _.
Figure 5. Western blot analysis of concentrated and unconcentrated extracellular fractions of
transformant DAHB19#2. Samples were taken from the transformant and the prototrophic
reference strain (D15-pyrGamdS) after 65 hand 112 h and part of the sample was concentrated
ten times. Engerix vaccine served as HBsAg reference protein. Immunoblotting was done with
a polyclonal goat-a-HBsAg antibody.
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Figure 6. Western blot analysis of extracellular (A) and intracellular (B) protein fractions of
three OAHB19 transformants and one OAHB20 transformant. Immunoblotting was done with a
mouse-a-glucoamylase antibody.
o Ih 2h 3h 24h
24kDa .....
Figure 7. Protease susceptibility assay. Protein samples from the recombinant hepatitis B S
protein-producing A. niger 015 (OAHB11#8) were incubated for 1 h, 2 h, 3 hand 24 h in
medium samples in which A. niger 015 had been previously cultured. Subsequently the
samples were subjected to Western analysis using a polyclonal goat-a-HBsAg antibody.
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Figure 8. Western blot analysis of total intracellular proteins from A. awamori transformants.
Intracellular proteins from the S protein-producing strain DAHB11#8 served as positive control.
Immunoblotting was done with a polyclonal goat-a-HBsAg antibody.
4.5. Discussion
In recent years, A. niger and A. awamori have been extensively studied for their
ability to produce several proteins of pharmaceutical interest, with varying
degrees of success. Some success stories include the high level production of
biologically active human lactoferrin in A. awamori (2 g/I) (Ward et al., 1995), as
well as the secretion of active human interleukin-6 by A. niger and A. awamori
(Broekhuijsen et ai., 1993; Gouka et ai., 1997a). However, many problems
have also been encountered in the expression of heterologous proteins by
Aspergillus. Proteolytic degradation has been shown to be one of the major
factors influencing the production of heterologous proteins (Van den Hombergh
et al., 1997). A. niger produces various extracellular proteases, four of which
have acid pH optima, and the major extracellular protease of A. awamori is also
an acid protease (Berka et ai., 1990; Van den Hombergh et ai., 1997). Other
factors strongly influencing expression levels include site of vector integration,
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mRNA stability and secretion efficiency (Gouka et aI., 1997a; Verdoes et aI.,
1994).
In this study, various gene constructs were made to explore the intracellular and
extracellular expression of the hepatitis B Sand preS1preS2S genes in
Aspergillus. The two promoters employed have both been shown to be strong
promoters that have previously been successfully used for the overproduction of
various heterologous proteins (e.g. Archer et aI., 1990; Broekhuijsen et aI.,
1993; Carrez et aI., 1990; Ward et aI., 1990). The A. nidulans gpdA promoter
directs the constitutive production of a key enzyme in glycolysis and
gluconeogenesis and expression signals from this promoter have been shown
to be very strong (Punt et aI., 1990). The A. niger glaA promoter is induced to
high levels when the fungus is grown on starch, maltose or maltodextrin, but is
repressed in the presence of xylose, making this an ideal inducible promoter
(Santerre Henriksen et aI., 1999). Northern analysis showed that both
promoters were effective in directing transcription of the S gene, but
transcription levels varied significantly between the different transformants
(Figure 2A, B). In some transformants no S gene transcript could be detected
and the highest levels were obtained for transformant DAHB11#8, carrying the
S gene under transcriptional control of the gpdA promoter. The various
transformants analysed carrying the S gene under control of the glaA promoter
consistently showed lower transcript levels. Two factors generally determine
transcription levels in recombinant aspergilli, namely the copy number of the
integrated plasmid and the site of integration (Christensen et a/., 1988; Davies,
1991; Ward et aI., 1990). The position of integration of a foreign gene in the
chromosome can influence expression levels as heterochromatic DNA affects
transcriptional activity (Thompson and Gasson, 2001). The complex regulatory
mechanisms found in eukaryotes also results in a greater variation in promoter
strengths, which could influence a downstream heterologous gene.
Transformant DAHB11#8 was previously shown to contain approximately seven
integrated vector copies, which probably contributed to the high levels of gene
expression (Paper 1, this thesis). However, three transformants carrying the S
gene under control of the glaA promoter (namely DAHB15#1, DAHB15#3 and
DAHB15#4) also contained multiple copies of integrated vector, but transcript
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levels from these transformants never reached those of OAHB11#8. This could
be attributed to the site of integration, particularly since it has been shown that
vector copies generally integrate in only one chromosome (Verdoes et aI.,
1993), but the reason for lower transcript levels was more likely the combination
of strain and promoter choice. The activity of the glaA promoter is pH
dependent and appears to be activated by acidification of the medium (Withers
et aI., 1998). As the A. niger strain employed in this study is a non-acidifying
mutant, this could account for the rather low levels of S gene transcription
obtained from this promoter. This hypothesis is further underscored by the
observation that no glucoamylase could be detected in the culture supernatant
of A. niger 015 on a Coomassie Brilliant Blue stained SOS-PAGE gel (data not
shown) and was only detectable at low levels with Western analysis. A. niger
N402, the parent strain of A. niger 015, has been shown to secrete 50 mg!1of
glucoamylase, which is easily visible on a Coomassie Brilliant Blue stained
SOS-PAGE gel (Verdoes et aI., 1993). Thus it is possible that the lack of
detectable S protein in the intracellular fractions of the transformants carrying
the S gene under control of the glaA promoter was due to the lower transcript
levels resulting from a weakly induced promoter.
Regarding transcription of the preS1preS2S gene, none of the transformants
carrying any of the constructs with this gene showed transcripts of the expected
size of 1433 bp. Some transformants showed low levels of transcript
corresponding to the size of the S gene. The reasons for this are unclear, but
the presence of the smaller transcript may possibly be attributed to splicing of
the mRNA transcript. Although hepatitis B viral transcripts in infected cells
generally remain unspliced, a few spliced transcripts (generated by the removal
of one or two introns) have been described in transfected cells and in the livers
of infected individuals (Fallows and Goff, 1996; GOnther et aI., 1997; Obert
et aI., 1996). An example of alternative mRNA splicing has been identified in
the phoA gene of A. nidulans which encodes two cyclin-dependent kinases
(Bussink and Osmani, 1998). However, this kind of alternative pre-mRNA
splicing (splicing or non-splicing of an intron containing one of two alternative in-
frame translation initiation codons) has not been well documented in fungi.
Whatever the reason for the absence of transcripts, the lack of recombinant L
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protein production by Aspergillus transformants can be directly attributed to the
lack of mature preS1preS2S transcripts.
Regarding extracellular protein production, one of the most promising strategies
that has been widely employed to facilitate the secretion of heterologous non-
fungal proteins involves the construction of gene fusions to genomic sequences
encompassing the complete or partial coding region of a highly expressed
fungal gene such as glucoamylase (Ward et aI., 1990). The object of these
fusion constructs is to facilitate the passage of the target protein through the
secretory pathway and this strategy has been proven to be effective in many
cases (Contreras et al., 1991; Mikosch et al., 1996; Spencer et al., 1998;
Tsuchiya et al., 1994; Ward et aI., 1990). Therefore an in-frame fusion was
made between the S gene and the catalytic domain of glucoamylase to explore
the possible secretion of hepatitis B S protein by Aspergillus. The ubiquitous
KEX2 protease cleavage site was introduced between the S gene and the
glucoamylase domain to facilitate the release of mature S protein (Contreras
et al., 1991). However, despite relatively high transcription levels, no
extracellular S protein could be detected in the transformants carrying this
construct. This lack of secreted heterologous S protein could be attributed to
the presence of extracellular proteases, which is further indicated by the
protease susceptibility assay which showed that heterologous Sprotein
produced intracellularly by strain DAHB11#8 was completely degraded after
overnight incubation in A. niger D15 culture medium.
In anticipation of the common problem of proteolytic degradation, strains
deficient in extracellular protease activity are commonly employed, and thus in
this study the A. niger strain was a protease mutant which also does not acidify
the medium upon culturing, thereby reducing the induction of the acid proteases
(Gordon et al., 2000). However, although acid proteases predominate in
A. niger, the fungus also produces an alkaline protease (PEPD) which may play
a role in the degradation of the heterologous viral protein (Jarai et aI., 1994).
Furthermore, the total protease activity in A. niger D15 was reduced by
mutagenesis, not by specific protease gene deletions (Mattern et al., 1992).
Therefore, although protease activity in this strain is strongly reduced, it is not
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absent. Aberrant processing through the secretory pathway may also
contribute to the lack of secreted S protein. This was indicated by the presence
of various breakdown products in the intracellular fraction of DAHB19
transformants when they were analysed with antibodies specific for the
glucoamylase moiety. In the viral life cycle, the hepatitis B S protein is inserted
into the ER membrane and subsequently translocated to the ER lumen where
disulphide-linked dimers are rapidly formed (Huovila et a/., 1992). These
dimers are transported to a post-ER/pre-Golgi compartment where the
formation of oligomer erosslinks occurs, resulting in the formation of pseudoviral
particles, which are then exported from the cell via vesicular transport (Huovila
et a/., 1992; Prange and Streeck, 1995). In Aspergillus transformants carrying
the glucoamylase-S protein fusion construct, this process is probably impaired,
since dibasic cleavage by the Kex2p is known to occur in the Golgi complex
(Brigance et a/., 2000) and the presence of the glucoamylase moiety will
prevent assembly of the viral proteins in the ER. Therefore passage of these
proteins through the secretory pathway is most likely blocked, resulting in the
intracellular degradation of the heterologous Sprotein.
The food-grade industrial host A. awamori was also transformed with vectors
carrying the Sand preS1preS2S genes, but none of the transformants
produced heterologous viral protein. This can most likely be attributed to the
generally low transcription levels obtained from these transformants. The host
is also not a protease-deficient strain and thus proteolysis may also contribute
to the lack of heterologous protein production. When the sweet-tasting protein
thaumatin was expressed in A. awamori it was degraded by host proteases
during secretion and folding (Moralejo et al., 1999). However, expression in a
protease-deficient mutant of A. awamori resulted in high-level production of this
protein (Moralejo et al., 2000). Overall, far less transformants were obtained in
A. awamori than in A. niger. In this study, only one of the 54 A. niger
transformants obtained could be shown to produce heterologous viral Sprotein.
In contrast, only 18 A. awamori transformants were obtained. Since the level of
heterologous protein production is determined by various factors including the
vector copy number and site of integration (Davies, 1991; Ward et al., 1990), it
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is possible that if more transformants were generated, one of them may
successfully produce heterologous Sprotein
This work clearly indicates that when evaluating the expression of a new protein
in a recombinant host such as Aspergillus it is imperative to employ a variety of
approaches, specifically regarding choice of promoter and host strain.
Furthermore it is essential to obtain various transformants for each construct to
screen for an efficient heterologous protein producing strain.
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5. GENERAL DISCUSSION AND CONCLUSIONS
Since the filamentous fungus Aspergillus was first used for the production of
heterologous proteins in the 1980s, there have been numerous impressive
successes (e.g. commercial production of chymosin by Aspergillus awamori
[Ward, 1989]), but also some less successful attempts. This work details the
evaluation of Aspergillus for the expression of hepatitis B virus surface antigens
and encompasses both successful and unsuccessful approaches for
heterologous production, which have also furthered our understanding of the
utilisation of Aspergillus as a heterologous host. From the extensive body of
literature available it is evident that filamentous fungi, particularly aspergilli,
have emerged as viable, interesting and, in some cases, preferred hosts for the
production of heterologous proteins.
The heterologous expression of hepatitis B virus surface antigens in yeast has
been proven to be an effective method of producing safe, affordable,
immunogenic vaccines which are now routinely used world-wide (Fu et al.,
1996; Gellissen, 2000; Hardy et al., 2000). Hepatitis B is a wide-spread and
serious, potentially fatal liver disease which has a high endemicity in southern
Africa (Vryheid et al., 2001). South Africa implemented the routine infant HBV
immunisation programme recommended by the World Health Organisation in
1995 (Hino et al., 2001; Tsebe et al., 2001) and as more countries implement
this programme, the need for a cheap and effective vaccine will increase. As
industrial fermentation systems have been established for the filamentous
fungus Aspergillus, it may be the ideal organism for the production of an
alternative cost-effective vaccine. With only one published report of the
expression of hepatitis B major (S) protein in Aspergillus foetidus in Chinese
(Liu et al., 1990), limited information was available on the use of filamentous
fungi for the expression of viral proteins. We therefore further investigated the
potential of Aspergillus, particularly the GRAS status organism Aspergillus
niger, as a host for the production of the hepatitis B major (S) and large (L)
proteins.
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5.1. Expression of the hepatitis B S gene
The hepatitis B virus S gene encodes the major viral envelope protein which is
24 kDa in size and spontaneously assembles with other viral envelope proteins
into pseudoviral particles devoid of DNA (Ganem and Varmus, 1987). This
particle assembly also occurs in the heterologous expression of the S gene in
various yeast hosts (Cregg et a/., 1987; Janowicz et a/., 1991; Valenzuela et a/.,
1982). To investigate the intracellular and extracellular expression of the
hepatitis B virus S gene in Aspergillus, numerous vector constructs were made.
These included placing the gene under the transcriptional control of two
different promoters, including a pentaHis tag to aid purification and detection
and adding a carrier moiety to possibly enhance secretion. These vectors were
transformed to laboratory strains of A. niger and A. awamori. A. niger, which is
routinely used in the industrial production of citric acid, has been afforded
GRAS (Generally Regarded 8s .s_afe)status and many non-fungal heterologous
proteins have been successfully expressed in this host. Numerous
transformation experiments were undertaken, generating a total of 39 A. niger
and 15 A. awamori transformants carrying the hepatitis B S gene. One of these
A. niger transformants showed the intracellular high-level production of
recombinant S protein that was similar in size (24 kDa) to the native protein.
Furthermore, 22 nm hepatitis B pseudoviral particles were isolated from this
transformant at levels of 0.4 mg!1culture.
Various factors have been shown to affect heterologous protein expression in
Aspergillus. These may include transcriptional control, site of DNA integration,
intron splicing, codon bias, secretion efficiency, proteases, glycosylation and the
availability of chaperones. Some of these factors and their possible effects in
the expression of the S gene can be summarised as follows:
5.1.1. Choice of promoter
One of the first aspects to consider during the construction of an expression
vector is the choice of promoter. The two main types of promoters are
constitutive and inducible promoters and in this work we placed the viral gene
under control of the constitutive Aspergillus nidu/ans glyceraldehyde-3-
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phosphate dehydrogenase (gpdA) promoter and the inducible A. niger
glucoamylase (glaA) promoter. These promoters have been used extensively in
the production of various proteins with the A. nidulans promoter directing high
level transcription in various Aspergillus hosts and the glaA promoter showing
high levels of induction in the presence of starch, maltose or maltodextrin (Punt
et al., 1988; Fowler et al., 1990). Both promoters effectively directed
transcription of the hepatitis B S gene in the numerous A. niger and A. awamori
transformants obtained. Transcript levels obtained from the glaA promoter
constructs were generally lower than those obtained from the gpdA promoter in
both hosts. The generation of heterologous transcript can however not be
equated with successful protein expression and this was evident in this work.
Although many of the transformants generated showed the presence of S gene
transcripts, only one with the S gene under control of the gpdA promoter
(designated DAHB11#8), exhibiting high levels of transcription, and was finally
shown to produce appreciable levels of recombinant viral protein. Therefore, in
this case, the constitutive gpdA promoter was more effective.
5.1.2. Site of vector integration and copy number
In this work, the stable recombinant Aspergillus strains were generated by the
random integration of the circular vector into the chromosome. This is a
common feature of Aspergillus transformation where integration shows no
dependence on extensive homology between the transforming DNA and the
host chromosomal sequences (Ballance and Turner, 1985). The site of
integration may influence the levels of heterologous gene transcription as
different regions on the chromosome are transcribed with different efficiencies
(Verdoes et al., 1994). Southern analysis also revealed that the number of
integrated copies of S gene carrying vector differed significantly between the
various transformants, ranging from a single copy to as many as seven.
Transformant DAHB11#8 had the highest vector copy number, suggesting the
conclusion that vector copy number determined the higher transcription levels,
which in turn led to the production of heterologous S protein. However, a
combination of promoter choice, site of integration and copy number may have
determined the higher levels of transcription.
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Of the 54 Aspergillus transformants obtained, only one produced appreciable
levels of heterologous S protein, highlighting the importance of the generation
and screening of numerous transformants.
5.1.3. Secretion
The extracellular production of heterologous protein is frequently desirable as
this simplifies purification procedures. In the yeast hosts, heterologous
production of S-protein containing pseudoviral particles has generally been
achieved intracellularly (Fu et ai., 1996; Gellissen, 2000; Hardy et ai., 2000). To
investigate the secretion of hepatitis B S protein by Aspergillus, the S gene was
fused to the catalytic domain of the highly expressed and efficiently secreted
glucoamylase (glaA) gene. The two regions were separated by the dibasic
KEX2 proteolytic cleavage site (Lys-Arg), which is recognised in Aspergillus by
a KEX2-like protease. This fusion strategy was previously shown to be very
effective in the enhanced secretion of proteins such as chymosin (Ward et al.,
1990), human interleukin (Contreras et al., 1991) and human lactoferrin (Ward
et al., 1992). However, no secretion of S protein could be detected in any of the
A. niger transformants carrying this construct. Intracellular degradation
products were detected, suggesting that secretion of the protein was somehow
blocked. The most probable explanation for this can be found in the assembly
and secretion process of the S protein in infected mammalian liver cells. In the
viral life cycle, the hepatitis B S protein is co-translationally inserted into the
endoplasmic reticulum (ER) membrane and then translocated to the ER lumen
where disulphide-linked Sprotein dimers are rapidly generated (Huovila et ai.,
1992). The dimers are subsequently assembled into pseudoviral particles in a
post-ER/pre-Golgi compartment and are then exported out of the cell via
vesicular transport. Since the Kex2p is located in the Golgi complex, dibasic
cleavage of the glucoamylase moiety from the S protein would not occur in the
ER, thereby probably preventing the formation of the Sprotein dimers and thus
inhibiting pseudoviral particle assembly. This would lead to the accumulation of
glucoamylase-S fusion protein in the ER, which can then be targeted for
degradation by the cell. Therefore, although the fusion protein strategy has
been proven to be very effective for many heterologous proteins, it is clear that
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in the case of this viral protein, which spontaneously assembles into dimers and
oligomers, the presence of a foreign protein moiety impedes rather than
enhances protein production. This result has highlighted the necessity of
evaluating effective expression strategies for each individual heterologous
protein to be expressed, taking into particular consideration the inherent
properties of the protein.
5.1.4. Proteases
One of the disadvantages of Aspergillus as a host for the production of
heterologous proteins has been the presence of various (secreted) proteases
(Mattern et al., 1992; Van den Hombergh et aI., 1997). To overcome this
problem, protease-deficient host strains have been developed, which have been
effective in alleviating the problem of extracellular degradation (Mattern et al.,
1992; Van den Hombergh et al., 1997). In this study, a protease-deficient
A. niger strain was employed which does not acidify its culture medium (Gordon
et aI., 2000). In this strain, proteolytic activity is virtually absent at non-acidic pH
and it has been previously effectively employed for the production of human
interleukin-6 (Punt et aI., 2002). However, an in vitro proteolytic degradation
assay involving the overnight incubation of S protein in A. niger culture medium
revealed that the protein was degraded by residual proteolytic activity.
Therefore, although the primary stumbling block in the secretion of Sprotein
was the aberrant assembly in the ER, proteolysis may have contributed to the
lack of heterologous extracellular S protein. This problem could potentially be
addressed by fermentation strategies, which have shown that fungal
morphology plays a role in the production of extracellular proteases (Xu et al.,
2000). The extracellular protease activity of A. niger varies with pellet size and
decreases dramatically when the morphology changes from free mycelia to
pellets.
Fermentation conditions have been shown to play an important role in the levels
of heterologous protein production by Aspergillus. Factors such as the growth
medium composition (Archer et aI., 1995; Hellmuth et aI., 1995), pH
(Mainwaring et aI., 1999), temperature (MacKenzie et aI., 1994), aeration
(Wongwicharn et aI., 1999b), dilution rate (Wongwicharn et aI., 1999a) and
Stellenbosch University http://scholar.sun.ac.za
180
agitation (Amanullah et al., 1998) influence the morphology and productivity of
the fungal strain. One example where the manipulation of fermentation
conditions played a role in the levels of heterologous protein production is in the
expression of hen egg white lysozyme (HEWL) in A. niger. In standard
expression medium, the secreted levels were found to be maximal at 20-25°C
and markedly reduced at 30-3rC (MacKenzie et aI., 1994). However, in richer
medium generally higher levels were obtained and maximal levels were
achieved at 3rC. Formation of the heterologous enzyme also increased with
increasing O2 supply and by optimising levels of ammonium chloride and
sodium phosphate buffer in the medium (Wongwicharn et al., 1999b;
MacKenzie et aI., 1994). There was also a very clear distinction between
conditions and morphology that maximised protein secretion and those that
maximised HEWL synthesis (Wongwicharn et aI., 1999a). Fermentation
optimisation improved HEWL levels from an initial 12 mgll to production levels
of 1 gIl (Archer et aI., 1990; Archer et aI., 1995; Wongwicharn et aI., 1999b).
With regard to heterologous HBsAg production, optimising fermentation
conditions improved HBsAg yields by S. cerevisiae 1000-fold, from 10-25 IJg/I
(Valenzuela et aI., 1982) to 3-10 mg!1 (Hsieh et aI., 1988). Similarly, the
production levels of recombinant HBsAg by A. niger could potentially also be
improved by investigating the effect of the above-mentioned variables and
thereby optimising fermentation conditions.
5.2. Expression of the preS1 preS2S gene
The 1433-bp preS1preS2S gene encodes the 42 kDa large envelope protein of
the hepatitis B virus (Tiollais et aI., 1985). This protein contains additional
antigenic epitopes and has been successfully expressed in S. cerevisiae,
however without concomitant pseudoviral particle formation (Dehoux et. ai.,
1986). For expression in Aspergillus, this gene was also cloned into Aspergillus
expression vectors under control of the gpdA and glaA promoters, with or
without the addition of the glucoamylase catalytic domain or pentaHis tag.
These vectors were transformed to A. niger and A. awamori, but only 18
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transformants were obtained. Full-length preS1preS2S transcript could not be
detected in any of these transformants and no recombinant viral protein was
produced. A smaller transcript similar in size to the S gene transcript was
detected in some transformants, which may be the result of mRNA splicing.
Although viral transcripts in infected cells generally remain unspliced, a few
spliced transcripts have been described in liver cells (Fallows and Goff, 1996).
However, mRNA splicing has not been well documented in fungi.
5.3. Conclusions
The following can therefore be concluded from the data presented in this study:
1. The S gene of the hepatitis B virus subtype adw2 was successfully
expressed in A. niger under control of the constitutive gpdA promoter.
2. The recombinant fungal strain produced hepatitis B pseudoviral particles
22 nm in size which are very similar to those observed in human serum and
those obtained from recombinant yeast.
3. The particle production levels were somewhat higher (0.4 mg/I) than those
initially obtained in S. cerevisiae (0.05 mg/I) (Valenzuela et aI., 1982) and
P. pastoris (0.14 mg/I) (Cregg et aI., 1987).
4. The pseudoviral particles were located in the intracellular, membrane-
associated fraction. No secretion of viral particles was detected.
5. The commonly employed strategy of fusing the heterologous gene to a
highly expressed and secreted carrier (such as the catalytic domain of
glucoamylase) to enhance secretion was unsuccessful due to the inherent
aggregation properties of the major (S) protein.
6. Heterologous production of the hepatitis B large (L) protein could not be
obtained due to the absence of full-length preS1 peS2S gene transcript.
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7. A. awamori was not an effective host for the production of hepatitis B viral
proteins.
This study has clearly shown that the filamentous fungus Aspergillus is an
effective alternative host for the production of hepatitis B viral protein and has
the ability to produce pseudoviral particles. As the initial levels of viral particle
production were somewhat higher than those obtained in yeast, it is tempting to
speculate that upon optimisation of production, levels may exceed those
obtained from yeast, making for a potentially more cost effective vaccine. More
importantly, however, this work paves the way for the investigation of
Aspergillus as a potential host for the heterologous production of proteins from
viruses such as HIV-1 and rotavirus for the development of subunit vaccines to
address the increasing health risk posed by these viruses, especially in Africa.
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FIELD OF INVENTION
The present invention relates to a method of providing a recombinant fungus
strain.
More particularly the invention relates to a method of producing a fungus strain
with the capability of producing viral coat proteins and to a recombinant DNA
sequence for use in transforming a fungus strain to produce viral coat proteins.
BACKGROUND TO INVENTION
Hepatitis B is a serious, potentially lethal liver disease caused by the hepatitis B
virus (HBV), which affects 400 to 500 million people world-wide (Moradpour and
Wands, 1995). The disease is especially prevalent in underdeveloped areas of
the world, such as Africa, where 60% to 99% of healthy adults show evidence of
exposure to HBV (Moradpour and Wands, 1995; Ayoola, 1988). No effective
treatment for this disease currently exists and an extensive programme of
vaccination presents the only solution to curb the spread of the disease
(Kassianides et al., 1988; Dehoux et al., 1986). With the establishment of
mandatory childhood immunisation programmes against Hepatitis B, there is a
growing demand for a safe, affordable vaccine.
Hepatitis B surface antigen proteins have important functions in the viral life-
cycle, such as attachment and penetration of human liver cells, envelopment
and virus maturation from the liver cells. These proteins spontaneously
assemble into virus-like particles devoid of viral DNA. It has been postulated
that these "dummy particles", which also elicit an immune response, serve to
absorb virus-neutralising antisurface antibodies during progression of infection
as these non-infectious particles are produced in excessive amounts and are
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released into the blood (Ganem and Varmus, 1987). Thus these proteins have
been targeted for heterologous expression to produce recombinant vaccines.
Recombinant DNA methods have provided an alternative to the blood-origin
vaccine obtained from plasma of chronic carriers and to date, bacteria, yeasts
and mammalian cells, transformed with appropriate expression vectors
containing the hepatitis B virus S gene, are able to synthesise hepatitis B
surface antigen (HBsAg) for immunisation purposes (Dehoux et al., 1986;
Valenzuela et al., 1982; Michel et al., 1984). Currently, a commercial yeast-
derived hepatitis B vaccine has been licensed and is in general use (Hilleman,
1987; Barr et al., 1989).
Since the 1980's genetic engineering procedures have been developed for the
filamentous fungi, in particular aspergilli (Kinghorn and Unkles, 1994).
Subsequently, various heterologous proteins of fungal and non-fungal origin
have been expressed in these fungi (Gwynne, 1992). The use of
Saccharomyces cerevisiae as heterologous host for the production of
pharmaceutical (viral) proteins has already highlighted limitations, such as low
product yields and hyperglycosylation of glycoproteins.
Several characteristics of filamentous fungal expression hosts give them
potential advantages over Saccharomyces cerevisiae, particularly their efficient
secretion of endogenous proteins. Filamentous fungi are also rather robust and
can grow on many organic compounds (Jeenes et al., 1991; Van den Hondel et
at., 1991). They are known to produce and secrete enzymes in large quantities
and through their use in the food and food processing industry, the species
Aspergillus oryzae and Aspergillus niger have gained GRAS (Generally
Regarded As Safe) status. Hyperglycosylation is also less of a problem in
filamentous fungi than in Saccharomyces cerevisiae, as their glycosylation
patterns more closely resemble those found in mammalian cells. Filamentous
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fungi have been extensively used in industrial processes such as organic acid
and enzyme production, and therefore large-scale fermentation technology and
downstream processing are already well established (Bodie et al., 1994; Xu et
al., 1989). Viral protein production in filamentous fungi has not been evaluated
to date.
Traditionally, Aspergillus niger strains have been used for the production of
citric acid on an industrial scale using cheap sugar syrups as substrate (Xu et
al., 1989). An Aspergillus-derived hepatitis B vaccine could therefore provide a
cost-effective alternative to the yeast-derived vaccine.
A need therefore exists to produce a fungus strain with the capability of
producing viral coat proteins; to assemble the viral coat proteins into virus-like
particles (VLPs); and to provide a recombinant DNA sequence for use in
transforming a fungus strain to produce viral proteins.
SUMMARY OF INVENTION
According to a first embodiment of the invention, there is provided a method of
producing a fungus strain which is capable of producing viral coat proteins, the
method including the step of transforming a fungus strain with a DNA sequence
including a gene encoding a hepatitis B virus Sprotein.
The DNA sequence may include a suitable promoter for promoting expression
of the S protein gene in the transformed fungus. The promoter may be the
gpdA promoter DNA sequence from Aspergillus nidulans.
A terminator sequence may be the trpC DNA sequence from Aspergillus
nidulans.
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Fungus marker genes may also be inserted into the transformed fungus strain.
The marker genes may be selected from the Aspergillus niger pyrG gene and
the Aspergillus nidulans amdS gene.
The fungus strain may be an Aspergillus strain.
The gene encoding the viral coat protein may be the S gene from a virus such
as hepatitis B virus subtype adw2.
The gene encoding the hepatitis B virus S protein may be carried in a DNA
vector. The vector may be the Aspergillus / Escherichia coli vector pAHB11.
According to a second embodiment of the invention there is provided a viral
coat protein expressed by the fungus strain described above.
The viral coat protein may be the major S protein of hepatitis B virus subtype
adw2.
According to a third embodiment of the invention there is provided one or more
virus-like particles (VLPs) assembled from at least one viral coat protein
expressed by a fungus strain described above.
According to a further embodiment of the invention there is provided an
Aspergillus fungus transformed with vector pAHB11.
According to yet a further embodiment of the invention there is provided a
method for fungally producing a hepatitis B virus S protein which comprises:
Causing expression in an Aspergillus fungus of DNA containing the
coding sequence for the hepatitis B S protein preceded by a translation start
signal codon and followed by a translation stop signal codon; and
Recovering the resulting hepatitis B virus S protein produced within the
fungus.
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The expression may result in the formation of virus-like particles.
BRIEF DESCRIPTION OF THE FIGURES
The invention will now be described by way of example with reference to the
accompanying schematic drawings, diagrams and representations.
The drawings, diagrams and representations illustrate the method according to
the invention for transforming an Aspergillus strain so that it is capable of
producing hepatitis B virus S protein and virus-like particles.
Figure 1 shows the construction of the Aspergillus expression vector,
plasmid pAHB11;
Figure 2A shows the presence of multiple copies of the HBV Sprotein
expression cassette integrated into the Aspergillus genome;
Figure 2B shows the presence of S gene mRNA transcript in the Aspergillus
transformant carrying integrated HBV S protein expression
cassettes;
Figure 2C shows the presence of S protein in intracellular protein extract of
the Aspergillus transformant carrying integrated HBV Sprotein
expression cassettes;
Figure 3 shows the presence of HBV virus-like particles in intracellular
extracts of the Aspergillus transformant carrying integrated HBV S
protein expression cassettes.
Figure 4 shows the standard curve compiled to determine the levels of
HBsAg production by the Aspergillus transformant.
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DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Definitions
The term "a fungal expression cassette" is used to denote a recombinant DNA
molecule according to the invention which includes the fungal gpdA promoter
and trpC terminator DNA sequences, preferably a gpdA promoter DNA
sequence of Aspergillus nidulans FGSC4 (Glasgow wild-type: Clutterbuck,
1986; Punt et aI., 1988) and a trpC terminator DNA sequence of Aspergillus
nidulans (Punt et al., 1987).
The term "HBV S protein expression cassette" is used to denote a recombinant
DNA molecule according to the invention which includes a S gene, preferably
the S gene from hepatitis B virus (HBV) subtype adw2 (donated by prof. W.J. de
Wet, Potchefstroom University, South Africa), and fungal gpdA promoter and
trpC terminator DNA sequences, preferably a gpdA promoter DNA sequence of
Aspergillus nidulans and a trpC terminator DNA sequence of Aspergillus
nidulans resident on the Aspergillus / Escherichia coli integrative vector
pAHB11.
The term "fungal marker fragment" is used to denote a recombinant DNA
molecule according to the invention which includes a pyrG gene of Aspergillus
niger and a amdS gene of Aspergillus nidulans (donated by Prof. C.A.M.J.J. van
den Hondel, Department of Molecular Genetics and Gene Technology, TNO
Nutrition and Food Research Institute, Zeist, The Netherlands).
STEP 1
The construction of a fungus expression vector containing the Aspergillus
nidulans gpdA promoter and trpC terminator DNA regions, the pyrG and amdS
Stellenbosch University http://scholar.sun.ac.za
196
fungal marker fragment and the hepatitis B virus S gene, called plasmid
pAHB11, is shown in Figure 1. The plasmid pAN52-1 carrying the Aspergillus
nidulans gpdA promoter and trpC terminator (Genbank Accession Number
Z32697, donated by Prof. C.A.M.J.J. van den Handel) was digested with
restriction enzymes Nco1 and BamH1 to linearise the vector. The hepatitis B
virus S gene was amplified from plasmid pCOR105 (donated by Prof. W.J. de
Wet, Potchefstroom University, South Africa) using the PCR technique with the
aid of oligodeoxyribonucleotide DNA primers designed by conventional
techniques, which contained the restriction sites Nco1 and BglIl, and cloned as
a 814-bp Nco1-BamHlIBg/li DNA fragment into the Nco1-BamH1 restriction
enzyme sites of plasmid pAN52-1, generating plasmid pAN52-1-S. The two
following synthetic oligodeoxyribonucleotides were used for the amplification of
the hepatitis B virus S gene:
S-Ieft 5'-CTAGCCATGGAGAACATCACATCAGGATTCC-3'
S-right 5'-GATCAGATCTCCAACAGGAAGTTTTCT AAAAC-3'
Plasmid pAN52-1-S was subsequently digested with the restriction enzyme
Not1 and the fungal marker fragment containing the pyrG and amdS genes
(donated by Prof. C.A.M.J.J. van den Handel) was ligated into the Not1 site to
generate plasmid pAHB11.
STEP 2
Plasmid pAHB11 was introduced into Aspergillus niger 015 (donated by Prof.
C.A.M.J.J. van den Handel) by the protoplasting method of Punt and Van den
Handel (1992), using Novozyme 234 (Sigma Chemical Co. St. Louis, USA).
Selection for successful transformants was performed on medium without
uridine and containing acetamide as sole nitrogen source. The amdS gene
enables Aspergillus niger to utilise acetamide as sole nitrogen source (on
minimal media without nitrate containing 1% glucose, 10 mM acetamide, 15 mM
CsCI and trace elements). Aspergillus niger 015 is also a pyrG- strain and can
therefore not grow in the absence of uridine. Transformants carrying the pyrG
gene however are able to grow in the absence of uridine.
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The presence of the S gene in the Aspergillus genome was determined by
isolating chromosomal DNA from a stable S gene transformant. The genomic
DNA was isolated according to La Grange et al. (1996) and digested overnight
with the restriction enzymes EcoRI and Nru1 (which only cut once in pAHB11)
and used for conventional Southern blot analysis with the 814-bp S gene as
probe (Sambrook et aI., 1989). The copy number of the S gene in the
recombinant Aspergillus strain was determined to be at least 6 copies (Figure
2A).
The presence of the 814-bp S gene mRNA transcripts was confirmed by
isolating total RNA from the recombinant Aspergillus strain cultured for 40 h at
30°C in minimal medium with nitrate, 0.5% yeast extract, 0.1% casamino acids
,1% glucose and trace elements.
Total RNA was isolated as follows: mycelium was harvested through Miracloth
(Calbiochem, USA), frozen under liquid nitrogen, ground to a fine powder with a
mortar and pestle and resuspended in cold STE buffer (0.25M Tris-HCI pH7.2 /
0.1M NaCI / 0.01M EDTA). One volume phenol/chloroform/isoamylalcohol
(PCI; 24:24:1) as well as 0.05% sodium dodecyl-sulphate (SOS) was added and
the mycelial debris was collected by centrifugation. The aqueous upper phase
was collected, subjected to PCI extraction and precipitated to yield total RNA.
The total RNA was used for conventional Northern blot analysis using the
radioactively-labelled 814-bp S gene as probe (Figure 2B). The Aspergillus
nidulans 1350-bp glyceraldehyde-3-phosphate dehydrogenase gene (donated
by Prof. C.A.M.J.J. van den Hondel) was used as an internal standard to verify
RNA integrity.
The presence of hepatitis B virus S protein was determined by extracting total
intracellular and membrane-bound proteins from the recombinant Aspergillus
niger strain cultured for 72 h in minimal medium as before.
Protein extraction was performed as follows: mycelium was harvested and
ground as before. Ground mycelium was suspended in protein extraction buffer
(50 mM phosphate buffer pH7.0 / 1 mM MgCI2/ 20 ~M PMSF / 0.1% TritonX-
100) and the mycelial debris was removed by centrifugation. Proteins were
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separated on a 12% SDS polyacrylamide gelelectrophoresis (PAGE) gel,
transferred to a PVDF membrane (Hybond-P; Amersham Pharmacia Biotech,
UK) and subjected to standard Western blotting using the Chemiluminescence
Western Blotting Kit (Roche Diagnostics, Germany) as recommended by the
manufacturer. The primary antibodies were polyclonal goat anti-Hepatitis B
surface antigen (Dako, USA) which were used at a 1:5000 dilution and the
secondary antibodies were goat immunoglobulins coupled to horseraddish
peroxidase (Dako, USA) which were employed at a dilution of 1:10 000 (Figure
2C).
STEP 3
To determine whether the hepatitis B S protein monomers spontaneously
aggregate into virus-like particles (VLPs), the total intracellular protein extract
including the membrane fraction of the recombinant Aspergillus strain was
subjected to sucrose gradient centrifugation as described by Mason et al.
(1992). The gradient was fractionated and fractions were run on a 12% SDS-
PAGE gel to identify fractions containing the hepatitis B S protein. The fraction
containing the highest concentration of hepatitis B S protein was dialysed
against 50 mM sodium phosphate buffer over night, negatively stained with
uranyl acetate and visualised by transmission electron microscopy (Figure 3).
Particles of 22 nm in size were observed which resemble hepatitis B virus virus-
like particles isolated from human serum of infected individuals (Yamaguchi et
al., 1998).
STEP4
To determine the yield of hepatitis B virus-like particles from the recombinant
Aspergillus strain the total intracellular protein extract including the membrane
fraction was isolated as before. The extraction was repeated six times to yield
total protein, and samples were assayed with the Auszyme MC Dynamic kit
(Abbott Diagnostics, USA), using the positive control provided (HBsAg derived
from human serum) as a standard.
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This enzyme immunoassay detects HBsAg with the aid of monoclonal
antibodies. Beads coated with mouse monoclonal antibody to Hepatitis B
Surface Antigen (Anti-HBs) are incubated with the samples, appropriate
controls and mouse monoclonal Anti-HBs Peroxidase (horseraddish) Conjugate
(Anti-HBs:HRPO). During the incubation period, any HBsAg present is bound
to the solid phase antibody and simultaneously bound by the Anti-HBs:HRPO.
Unbound material is aspirated and washed and o-Phenylenediamine (OPD)
solution containing hydrogen peroxide is added to the bead, which develops a
yellow-orange colour in proportion to the amount of HBsAg which is bound to
the bead. Absorbance of the samples and controls is then determined at a
wavelength of 492 nm. The positive control was diluted to give HBsAg levels of
0.09-1.86 ng/ml, and the absorbance at 492 nm after colour development gave
a linear relationship in this range (Figure 4). The HBsAg levels in the samples
were determined from this standard curve. This method is dependent on the
conformational epitopes of HBsAg particles and will not detect free
unassembled HBsAg proteins.
Mycelium dry weight was determined gravimetrically using nitrocellulose filters
(0.45 urn, Gelman Sciences). The filters were predried in a microwave oven for
10 min and weighed. A known volume of culture was filtered and washed with
an equal volume of double-distilled water. The filters were dried in a microwave
oven for 10 min and weighed. Dry cell weight was determined in triplicate.
The yield of hepatitis B VLPs from mycelium of the recombinant Aspergillus
strain was determined to be 0.2 mg per gram dry mycelium, giving an estimated
0.4 mg HBsAg per litre of culture. This value compares favourably with the
reported levels initially obtained in Saccharomyces cerevisiae which were
respectively 10 to 25 !Jg HBsAg/L cells (Valenzuela et al., 1982) and 50 !Jg
HBsAg/L cells (Hitzeman et al., 1983), and in wild-type Pichia pastoris, where
levels of 0.14 mg/L were reported (Cregg et al., 1987). This indicates the
potential of the Aspergillus expression system, as production levels can be
expected to improve upon optimisation of the system.
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The method of the invention has been found to be particularly effective for
transforming an Aspergillus fungal strain into a microorganism capable of
producing hepatitis B virus S protein and assembly of virus-like particles.
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Figure 1: Construction of the Aspergillus expression vector pAHB11.
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Figure 2A: Southern blot analysis to determine the number of S gene copies
integrated into the Aspergillus genome. Lane 1: DNA isolated from the negative
control (Aspergillus niger 015), digested with EcoR1, lane 2: DNA isolated form
Aspergillus niger 015 transformed with pAHB11, digested with EcoR1, lane 3:
DNA isolated from the negative control, digested with Nru1, lane 4: DNA
isolated from Aspergillus niger 015 transformed with pAHB11, digested with
Nru1 and lane 5: plasmid pAHB11 digested with Nru1. The S gene was
detected with 32P-labelledS DNA probe.
1 2
~ 814-bp S gene
~ 1350-bp gpd gene
Figure 28: Northern analysis of S gene mRNA transcrpts of Aspergillus niger
015 transformed with pAHB11. The 814 bp S gene was used as an [a_32p_
dATP]-labelied probe and the Aspergillus nidulans glyceraldehyde-3-phosphate
dehydrogenase (gpd) gene was used as internal standard. Lane 1: Aspergillus
niger 015 negative control. Lane 2: Transformant with pAHB11.
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Figure 2C: Western blot analysis of total intracellular proteins isolated after
culturing transformants for 72 h at 30°C. Intracellular proteins were separated
in a 12% SOS-PAGE gel and transferred to a PVOF membrane by
electroblotting. Lane 1: Aspergillus niger 015 negative control. Lane 2 :
Aspergillus niger 015 transformed with pAHB11. Immunoblotting was done
with a polyclonal goat-a-HBsAg antibody. A protein species of about 22 kOa is
visible in the pAHB11 transformant (lane 2) corresponding to the size of the
hepatitis B S protein, as well as a Sprotein dimer of 44 kOa.
.'........
........
Figure 3. Transmission electron microscopy (magnification: x135 000) of
purified Hepatitis B S protein to show presence of virus-like particles.
Stellenbosch University http://scholar.sun.ac.za
207
0.35
0.3
E 0.25
r::
('ol 0.2en
"'It- 0.15cac
0 0.1
0.05
0
0 0.5 1.5 2
y = 0.1696x
R2 = 0.9996
Concentration of HBsAg (ng/ml)
Figure 4. Standard curve of the correlation between Absorbance at 492 nm
and the concentration of purified HBsAg (Subtype ad) in the detection of HBsAg
by the Auszyme Me Dynamic assay.
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